var title_f17_29_17872="Richardson retractor";
var content_f17_29_17872=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54817&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Richardson retractor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 319px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17872=[""].join("\n");
var outline_f17_29_17872=null;
var title_f17_29_17873="Patient information: Hydrocele (The Basics)";
var content_f17_29_17873=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17163\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/61/17360\">",
"         Hydrocele",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?16/52/17217\">",
"         Patient information: Varicocele (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Hydrocele (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/hydrocele-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15868391\">",
"      <span class=\"h1\">",
"       What is a hydrocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hydrocele is a buildup of fluid inside the scrotum. The scrotum is the skin sac that holds the testicles, the 2 ball-shaped organs that hang between a man&rsquo;s legs (",
"      <a class=\"graphic graphic_figure graphicRef55941 \" href=\"UTD.htm?16/61/17360\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      Hydroceles are common in newborn baby boys. They usually go away by the time the baby is 1 year old. Older boys and adult men can also get hydroceles.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868408\">",
"      <span class=\"h1\">",
"       What are the symptoms of a hydrocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A hydrocele usually does not cause symptoms, except when it gets very large. When it does, the symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain or discomfort in the scrotum &nbsp;",
"       </li>",
"       <li>",
"        Feeling as though the scrotum is heavy or full",
"       </li>",
"       <li>",
"        Swelling or irritation in the skin around the scrotum",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868423\">",
"      <span class=\"h1\">",
"       Is there a test for a hydrocele?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Tests include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Light test &ndash; Your doctor can shine a powerful light on the area of your scrotum where there is a swelling. If the light passes through, it means nothing solid is blocking the light. The fluid in a hydrocele does not block the light, so if the light goes through that, it is good proof that the swelling is a hydrocele.",
"       </li>",
"       <li>",
"        Ultrasound &ndash; This test uses sound waves to create pictures of the inside of the body. An ultrasound can tell the doctor if you have a hydrocele or a different condition.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868440\">",
"      <span class=\"h1\">",
"       How is a hydrocele treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on what caused the hydrocele and what symptoms it causes. Treatment is not always necessary. Some hydroceles go away on their own. Depending on your age, symptoms, and type of hydrocele, you might not need treatment.",
"     </p>",
"     <p>",
"      If a baby has a hydrocele that does not go away by age 1, he will probably need surgery to remove the fluid or the sac that holds it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868455\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=see_link\">",
"       Patient information: Varicocele (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/29/17873?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17163 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3A8E13EC2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17873=[""].join("\n");
var outline_f17_29_17873=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868391\">",
"      What is a hydrocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868408\">",
"      What are the symptoms of a hydrocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868423\">",
"      Is there a test for a hydrocele?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868440\">",
"      How is a hydrocele treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868455\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/61/17360\">",
"      Hydrocele",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/52/17217?source=related_link\">",
"      Patient information: Varicocele (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17874="Calculator: Epworth Sleepiness Scale (ESS)";
var content_f17_29_17874=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"EpworthSleepScale_form\" name=\"EpworthSleepScale_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Epworth Sleepiness Scale (ESS)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Rate situations associated with sleepiness:",
"         <br/>",
"         &nbsp;",
"         <br/>",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting and reading",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc1\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Watching television",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc2\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting inactive in a public place",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc3\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting for an hour as a passenger in a car",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc4\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Lying down in the afternoon to rest",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc5\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting and talking to another person",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc6\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting quietly after a lunch (no alcohol at lunch)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc7\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <span class=\"medCalcFontCCTabBold\">",
"         Sitting in a car, stopped for a few minutes due to traffic",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc8\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         No chance of dozing (0 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc8\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Slight chance of dozing (1 point)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc8\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         Moderate chance of dozing (2 points)",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td width=\"20\">",
"        <br/>",
"       </td>",
"       <td align=\"right\">",
"        <input name=\"cc8\" onclick=\"EpworthSleepScale_fx();\" type=\"radio\"/>",
"       </td>",
"       <td align=\"left\">",
"        <span class=\"medCalcFontCCTab\">",
"         High chance of dozing (3 points)",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <span class=\"medCalcFontCCTabBold\">",
"     Total Criteria Point Count:",
"    </span>",
"    <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"    </center>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        ESS Interpretation",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <center>",
"     <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"      <tr id=\"rr1_1\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         1-6 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Normal sleep",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_2\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         7-8 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Average sleepiness",
"        </span>",
"       </td>",
"      </tr>",
"      <tr id=\"rr1_3\">",
"       <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"        <span class=\"medCalcFontOneBold\">",
"         9-24 points:",
"        </span>",
"       </td>",
"       <td align=\"left\" style=\"border-left: 0px;\">",
"        <span class=\"medCalcFontOne\">",
"         Abnormal (possibly pathologic) sleepiness",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"    </center>",
"   </form>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <span class=\"medCalcFontRef\">",
"    <b>",
"     References",
"    </b>",
"   </span>",
"   <ol>",
"    <li>",
"     <span class=\"medCalcFontRef\">",
"      Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.",
"      <i>",
"       Sleep",
"      </i>",
"      . 1991;14:540-5.",
"     </span>",
"    </li>",
"   </ol>",
"   <br/>",
"   &nbsp;",
"   <br/>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    /* &lt;![CDATA[ */",
"",
";",
"EpworthSleepScale_fx();",
"/* ]]&gt; */",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17874=[" /* <![CDATA[ */",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function EpworthSleepScale_fx() {",
"with(document.EpworthSleepScale_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1[0].checked){",
"Score = Score + 0;",
"}",
"if (cc1[1].checked){",
"Score = Score + 1;",
"}",
"if (cc1[2].checked){",
"Score = Score + 2;",
"}",
"if (cc1[3].checked){",
"Score = Score + 3;",
"}",
"if (cc2[0].checked){",
"Score = Score + 0;",
"}",
"if (cc2[1].checked){",
"Score = Score + 1;",
"}",
"if (cc2[2].checked){",
"Score = Score + 2;",
"}",
"if (cc2[3].checked){",
"Score = Score + 3;",
"}",
"if (cc3[0].checked){",
"Score = Score + 0;",
"}",
"if (cc3[1].checked){",
"Score = Score + 1;",
"}",
"if (cc3[2].checked){",
"Score = Score + 2;",
"}",
"if (cc3[3].checked){",
"Score = Score + 3;",
"}",
"if (cc4[0].checked){",
"Score = Score + 0;",
"}",
"if (cc4[1].checked){",
"Score = Score + 1;",
"}",
"if (cc4[2].checked){",
"Score = Score + 2;",
"}",
"if (cc4[3].checked){",
"Score = Score + 3;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 1;",
"}",
"if (cc5[2].checked){",
"Score = Score + 2;",
"}",
"if (cc5[3].checked){",
"Score = Score + 3;",
"}",
"if (cc6[0].checked){",
"Score = Score + 0;",
"}",
"if (cc6[1].checked){",
"Score = Score + 1;",
"}",
"if (cc6[2].checked){",
"Score = Score + 2;",
"}",
"if (cc6[3].checked){",
"Score = Score + 3;",
"}",
"if (cc7[0].checked){",
"Score = Score + 0;",
"}",
"if (cc7[1].checked){",
"Score = Score + 1;",
"}",
"if (cc7[2].checked){",
"Score = Score + 2;",
"}",
"if (cc7[3].checked){",
"Score = Score + 3;",
"}",
"if (cc8[0].checked){",
"Score = Score + 0;",
"}",
"if (cc8[1].checked){",
"Score = Score + 1;",
"}",
"if (cc8[2].checked){",
"Score = Score + 2;",
"}",
"if (cc8[3].checked){",
"Score = Score + 3;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"",
"rrclr();",
"if ((Score >= 1) && (Score <= 6)){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 7) && (Score <= 8)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if ((Score >= 9) && (Score <= 24)){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"}",
"",
"",
"/* ]]> */"].join("\n");
var outline_f17_29_17874=null;
var title_f17_29_17875="Chapter 9A: Water balance and regulation of plasma osmolality";
var content_f17_29_17875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 9A: Water balance and regulation of plasma osmolality",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17875/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/29/17875/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoosmolality and hyperosmolality can produce serious neurologic symptoms and death, primarily due to water movement into and out of the brain, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17875/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=see_link\">",
"     \"Manifestations of hyponatremia and hypernatremia\"",
"    </a>",
"    .) To prevent this, the plasma osmolality (Posm ), which is primarily determined by the plasma Na+ concentration, is normally maintained within narrow limits by appropriate variations in",
"    <strong>",
"     water intake",
"    </strong>",
"    and",
"    <strong>",
"     water excretion",
"    </strong>",
"    . This regulatory system is governed by osmoreceptors in the hypothalamus that influence both thirst and the secretion of antidiuretic hormone (ADH).",
"   </p>",
"   <p>",
"    Although it may seem that regulation of the plasma Na+ concentration must have something to do with Na+ balance, osmoregulation is almost entirely mediated by changes in",
"    <strong>",
"     water balance",
"    </strong>",
"    . Thus, the effectors for osmoregulation (ADH and thirst, affecting water excretion and water intake) are very different from those involved in volume regulation (renin-angiotensin-aldosterone system and atrial natriuretic peptide, affecting Na+ excretion) (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). This chapter will describe the sources of water intake, the sites of water loss from the body, and the roles of ADH, thirst, and renal water excretion in the maintenance of the Posm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WATER BALANCE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Obligatory water output",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the steady state, water intake (including that generated from endogenous metabolism) must equal water output (",
"    <a class=\"graphic graphic_figure graphicRef75632 \" href=\"UTD.htm?22/6/22639\">",
"     figure 1",
"    </a>",
"    ). Much of the water output involves obligatory losses in the urine, stool, and, by evaporation, from the moist surfaces of the skin and respiratory tract. The evaporative losses play an important role in",
"    <strong>",
"     thermoregulation",
"    </strong>",
"    ; the heat required for evaporation, 0.58",
"    <span class=\"nowrap\">",
"     kcal/1.0",
"    </span>",
"    mL of water, normally accounts for 20 to 25 percent of the heat lost from the body, with the remainder occurring by radiation and convection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17875/abstract/6\">",
"     6",
"    </a>",
"    ]. The net effect is the elimination of the heat produced by body metabolism, thereby preventing the development of hyperthermia.",
"   </p>",
"   <p>",
"    In contrast to these insensible losses, sweat can be called a sensible loss. Sweat is a hypotonic fluid (Na+ concentration equals 30 to 65",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    secreted by the sweat glands in the skin. It also contributes to thermoregulation, as the secretion and subsequent evaporation of sweat result in the loss of heat from the body. In the basal state, sweat production is low, but it can increase markedly in the presence of high external temperatures or when endogenous heat production is enhanced, as with exercise, fever, or hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17875/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, a subject exercising in a hot, dry climate can lose as much as 1500",
"    <span class=\"nowrap\">",
"     mL/h",
"    </span>",
"    as sweat [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17875/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The obligatory renal water loss is directly related to solute excretion. If a subject has to excrete 800 mosmol of solute per day (mostly Na+ and K+ salts and urea) to remain in the steady state, and the maximum Uosm &nbsp;is 1200",
"    <span class=\"nowrap\">",
"     mosmol/kg,",
"    </span>",
"    then the excretion of the 800 mosmol will require a minimum urine volume of 670",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"   </p>",
"   <p>",
"    Only small amounts of water are normally lost in the stool, averaging 100 to 200",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"    However, gastrointestinal losses are increased to a variable degree in patients with vomiting or diarrhea. The effect of these losses on the plasma Na+ concentration depends on the sum of the Na+ and K+ concentrations in the fluid that is lost. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=see_link&amp;anchor=H2#H2\">",
"     \"Chapter 9B: Renal water excretion and reabsorption\", section on 'Measurement of Renal Water Excretion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Water intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;To maintain water balance, water must be taken in (or generated) to replace these losses (",
"    <a class=\"graphic graphic_table graphicRef51153 \" href=\"UTD.htm?22/41/23195\">",
"     table 1",
"    </a>",
"    ). Net water intake is derived from three sources: (1) ingested water; (2) water contained in foods, e.g., meat is roughly 70 percent water and certain fruits and vegetables are almost 100 percent water; and (3) water produced from the oxidation of carbohydrates, proteins, and fats. If the latter two sources account for 1200",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    and the obligatory water loss (from the skin, gastrointestinal tract, and in the urine) is 1600",
"    <span class=\"nowrap\">",
"     mL/day,",
"    </span>",
"    then at least 400 mL must be ingested by drinking to maintain balance. Humans drink more than this minimum requirement for social and cultural reasons, and the extra water is excreted in the urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REGULATION OF PLASMA OSMOLALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal plasma osmolality (Posm ) is 275 to 290",
"    <span class=\"nowrap\">",
"     mosmol/kg.",
"    </span>",
"    It usually is held within narrow limits as variations of only 1 to 2 percent initiate mechanisms to return the Posm &nbsp;to normal. These alterations in osmolality are sensed by receptor cells in the hypothalamus which affect water intake (via thirst) and water excretion (via ADH, which increases water reabsorption in the collecting tubules)&dagger;.",
"   </p>",
"   <p>",
"    &dagger; The physiology of the release and actions of ADH are discussed in detail in Chap. 8.",
"   </p>",
"   <p>",
"    In terms of water balance, a water load decreases the Posm , and &nbsp;water loss (as with exercise on a hot day) increases the Posm . In both of these settings, there is a parallel change in the plasma Na+ concentration. These alterations in water balance must be differentiated from conditions of isosmotic fluid loss (such as bleeding or some cases of diarrhea), in which solute and water may be lost proportionately, producing no direct change in the Posm or the plasma Na+ concentration.",
"   </p>",
"   <p>",
"    The body responds to a water load by suppressing ADH secretion, resulting in decreased collecting tubule water reabsorption and excretion of the excess water. The peak diuresis is delayed for 90 to 120 min, the time necessary for the metabolism of previously circulating ADH. As will be seen, the kidneys can excrete up to 10 to 20 liters of water per day, well above any normal level of water intake. Therefore, water retention resulting in hypoosmolality and hyponatremia occurs, with rare exceptions, only in patients with an impairment in renal water excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The correction of a water deficit (hyperosmolality) requires the intake and retention of exogenous water. This is achieved by increases in thirst and ADH release, which are induced by the elevation in the Posm. In contrast to the response to hypoosmolality, in which renal water excretion is of primary importance, increased thirst is the major defense against hyperosmolality and hypernatremia. Although the kidney can minimize water excretion via the effect of ADH, a water deficit can be corrected only by increased dietary intake.",
"   </p>",
"   <p>",
"    An example of the efficiency of the thirst mechanism occurs in patients with complete central diabetes insipidus who, because they secrete little or no ADH, may excrete more than 10 liters of urine per day. Despite this, the Posm &nbsp;remains near normal because the thirst mechanism augments water intake to match output. Thus, symptomatic hypernatremia generally will not occur in a patient with a normal thirst mechanism and access to water. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=see_link\">",
"     \"Etiology and evaluation of hypernatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Excretion of a water load generally occurs so rapidly that there is little change in volume and no activation of the volume regulatory pathways. There are, however, settings in which both the volume and osmoregulatory systems come into play. As an example, the intake of NaCl without water (as with a large quantity of potato chips) results in an elevation in the Posm and, due to the rise in extracellular Na+ stores, expansion of the effective circulating volume. The latter change promotes the renal excretion of the excess Na+, via a response that is mediated at least in part by a reduction in the release of aldosterone and an increase in that of atrial natriuretic peptide. ADH secretion and thirst also are stimulated (by the rise in Posm); the ensuing increment in water intake both lowers the Posm &nbsp;toward normal and further expands the volume, thereby enhancing the stimulus to renal Na+ excretion. The end result is that the urine has a high osmolality and a relatively high concentration of Na+, a composition that is similar to net intake.",
"   </p>",
"   <p>",
"    In comparison, an infusion of isotonic saline causes volume expansion, but does not change the Posm. Consequently, ADH release and thirst are not directly affected, and the steady state is restored by the volume regulatory pathways.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=see_link\">",
"     \"Chapter 9B: Renal water excretion and reabsorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/1\">",
"      Pollock AS, Arieff AI. Abnormalities of cell volume regulation and their functional consequences. Am J Physiol 1980; 239:F195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/2\">",
"      Arieff AI, Llach F, Massry SG. Neurological manifestations and morbidity of hyponatremia: correlation with brain water and electrolytes. Medicine (Baltimore) 1976; 55:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/3\">",
"      Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992; 117:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/4\">",
"      Laureno R, Karp BI. Myelinolysis after correction of hyponatremia. Ann Intern Med 1997; 126:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/5\">",
"      Ellis SJ. Severe hyponatraemia: complications and treatment. QJM 1995; 88:905.",
"     </a>",
"    </li>",
"    <li>",
"     Guyton AC. Textbook of Medical Physiology, 7th ed., Saunders, Philadelphia, 1986, chap. 30.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17875/abstract/7\">",
"      Knochel JP, Dotin LN, Hamburger RJ. Pathophysiology of intense physical conditioning in a hot climate. I. Mechanisms of potassium depletion. J Clin Invest 1972; 51:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7258 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-AC55A795B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17875=[""].join("\n");
var outline_f17_29_17875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WATER BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Obligatory water output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Water intake",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REGULATION OF PLASMA OSMOLALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7258|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/6/22639\" title=\"figure 1\">",
"      Normal water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/41/23195\" title=\"table 1\">",
"      Osmoregulation v volume reg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/52/2886?source=related_link\">",
"      Chapter 9B: Renal water excretion and reabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36857?source=related_link\">",
"      Etiology and evaluation of hypernatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/58/23464?source=related_link\">",
"      Manifestations of hyponatremia and hypernatremia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17876="Acetaminophen, isometheptene, and dichloralphenazone: Patient drug information";
var content_f17_29_17876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen, isometheptene, and dichloralphenazone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/32/23045?source=see_link\">",
"     see \"Acetaminophen, isometheptene, and dichloralphenazone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, isometheptene, dichloralphenazone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703576",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, heart disease, high blood pressure, liver disease, or poor kidney function.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than 5 capsules a day for a migraine or 8 capsules a day for a tension headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12395 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17876=[""].join("\n");
var outline_f17_29_17876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026376\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026378\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026377\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026382\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026383\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026385\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026380\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026381\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026386\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026387\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/32/23045?source=related_link\">",
"      Acetaminophen, isometheptene, and dichloralphenazone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17877="Loratadine and pseudoephedrine: Pediatric drug information";
var content_f17_29_17877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loratadine and pseudoephedrine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41653?source=see_link\">",
"    see \"Loratadine and pseudoephedrine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19349?source=see_link\">",
"    see \"Loratadine and pseudoephedrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&trade; Allergy and Sinus [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 12 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Claritin-D&reg; 24 Hour Allergy &amp; Congestion [OTC];",
"     </li>",
"     <li>",
"      Loratadine-D 12 Hour [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chlor-Tripolon ND&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Extra;",
"     </li>",
"     <li>",
"      Claritin&reg; Liberator",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine/Decongestant Combination",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41653?source=see_link\">",
"      see \"Loratadine and pseudoephedrine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alavert&trade; Allergy and Sinus, Claritin-D&reg; 12-Hour, Loratadine-D 12 Hour: 1 tablet every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Claritin-D&reg; 24-Hour: 1 tablet every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&trade; Allergy and Sinus, Claritin-D&reg; 12-Hour, Loratadine-D 12 Hour: 1 tablet every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin-D&reg; 24-Hour: 1 tablet every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release: Loratadine 10 mg and pseudoephedrine sulfate 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&trade; Allergy and Sinus: Loratadine 5 mg and pseudoephedrine sulfate 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin-D&reg; 12 Hour Allergy &amp; Congestion: Loratadine 5 mg and pseudoephedrine sulfate 120 mg [contains calcium 30 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin-D&reg; 24 Hour Allergy &amp; Congestion: Loratadine 10 mg and pseudoephedrine sulfate 240 mg [contains calcium 25 mg/tablet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loratadine-D 12 Hour: Loratadine 5 mg and pseudoephedrine sulfate 120 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer on an empty stomach or before meals; swallow extended release tablets whole, do not chew or crush",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of symptoms of seasonal allergic rhinitis and nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Claritin-D&reg; may be confused with Claritin-D&reg; 24",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Claritin-D&reg; 24 may be confused with Claritin-D&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F190123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loratadine, pseudoephedrine, or any component; MAO inhibitor therapy; severe hypertension; severe coronary artery disease; narrow-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution and adjust dosage in patients with renal impairment; use with caution in patients with hyperthyroidism, diabetes mellitus, prostatic hypertrophy, mild to moderate hypertension, arrhythmias; use cautiously in patients who are also taking ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, or other drugs which may impair loratadine's hepatic metabolism; although increased plasma levels of loratadine have been observed, no adverse effects with concomitant administration have been reported including QT interval prolongation which has occurred when similar antihistamines, terfenadine and astemizole, were combined with these agents; while less sedating than other antihistamines, loratadine may cause drowsiness and impair ability to perform hazardous activities requiring mental alertness, the CNS stimulant properties of pseudoephedrine may counteract this effect. Use cautiously in breast-feeding women as breast milk levels of loratadine are equivalent to serum levels.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1059916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administration with food increases loratadine's bioavailability by 40%",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in signs and symptoms of allergic rhinitis or nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic serum levels (not used clinically): Loratadine: 2.5-100 ng/mL; active metabolite: 0.5-100 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Loratadine is a long-acting tricyclic antihistamine with selective peripheral histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonistic properties. Pseudoephedrine directly stimulates alpha-adrenergic receptors of respiratory mucosa causing vasoconstriction and directly stimulates beta-adrenergic receptors causing bronchial relaxation, increased heart rate and contractility",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19349?source=see_link\">",
"      see \"Loratadine and pseudoephedrine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of water; may cause dry mouth; may color urine; notify physician if fainting episode occurs; avoid alcohol. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13400 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17877=[""].join("\n");
var outline_f17_29_17877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190101\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190102\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059907\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059900\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190092\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190081\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059912\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059911\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190123\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059915\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059899\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190088\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059916\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059906\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059910\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059898\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059914\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059905\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41653?source=related_link\">",
"      Loratadine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/57/19349?source=related_link\">",
"      Loratadine and pseudoephedrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17878="Fat emulsion: Drug information";
var content_f17_29_17878=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fat emulsion: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5668?source=see_link\">",
"    see \"Fat emulsion: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=see_link\">",
"    see \"Fat emulsion: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Intralipid&reg;;",
"     </li>",
"     <li>",
"      Liposyn&reg; II",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Caloric Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     At the onset of therapy, the patient should be observed for any immediate allergic reactions (eg, dyspnea, cyanosis, and fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caloric source:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Fat emulsion should not exceed 60% of the total daily calories.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose: 1 g/kg/day (not to exceed 500 mL 20% fat emulsion on the first day of therapy), increase by 1 g/kg/day to a maximum of 2.5 g/kg/day (ASPEN Guidelines, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Essential fatty acid deficiency (EFAD):",
"     </b>",
"     I.V.: Administer 8% to 10% of total caloric intake as fat emulsion; infuse 2-3 times weekly.  If EFAD occurs with stress, the dosage needed to correct EFAD may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Local anesthetic toxicity (unlabeled use):",
"     </b>",
"     20%: 1.5",
"     <b>",
"      mL",
"     </b>",
"     /kg administered over 1 minute, followed immediately by an infusion of 0.25",
"     <b>",
"      mL",
"     </b>",
"     /kg/minute. Continue chest compressions (lipid must circulate). Repeat the bolus 1-2 times as needed for persistent asystole, pulseless electrical activity, or re-emergence of hemodynamic instability. Increase the infusion rate to 0.5",
"     <b>",
"      mL",
"     </b>",
"     /kg/minute if hemodynamic instability persists or recurs. Continue the infusion for at least 10 minutes after hemodynamic stability is restored; discontinue within 1 hour, if possible (ACMT, 2010; Neal, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=see_link\">",
"      see \"Fat emulsion: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     At the onset of therapy, the patient should be observed for any immediate allergic reactions (eg, dyspnea, cyanosis, and fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Caloric source:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Fat emulsion should not exceed 60% of the total daily calories.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 3 g/kg/day depending on needs/nutritional goals; daily dose may be infused over 24 hours if possible (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-10 years: Initial dose: 1-2 g/kg/day, increase by 0.5-1 g/kg/day to a maximum of 2-3 g/kg/day depending on needs/nutritional goals; daily dose may be infused over 24 hours if possible (ASPEN Guidelines, 2002; ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Essential fatty acid deficiency (EFAD):",
"     </b>",
"     I.V: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, emulsion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intralipid&reg;: 20% (100 mL, 250 mL, 500 mL, 1000 mL); 30% (500 mL) [contains aluminum, egg yolk phospholipid, soybean oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liposyn&reg; III: 10% (250 mL, 500 mL); 20% (250 mL, 500 mL); 30% (500 mL) [contains aluminum, egg yolk phospholipid, soybean oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Can be administered in a peripheral line or by central venous infusion. At the onset of therapy, the patient should be observed for any immediate allergic reactions such as dyspnea, cyanosis, and fever. Change tubing after each infusion. May be simultaneously infused with amino acid dextrose mixtures by means of Y-connector located near infusion site or administered in total nutrient mixtures (3-in-1) with amino acids, dextrose, and other nutrients. Hang fat emulsion higher than other fluids (has low specific gravity and could run up into other lines). Infuse via a pump using either a peripheral or central venous line.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Intralipid&reg;: Do not use &lt;1.2 micron filter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Liposyn&reg; III: Do not use a filter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Caloric source/EFAD:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Children: Initiate infusions of 10% emulsions at &le;0.1 mL/minute for 10-15 minutes; if no untoward effects occur, the infusion rate may be increased to 1 mL/kg/hour. Initiate infusions of 20% emulsions at &le;0.05 mL/minute for 10-15 minutes; if no untoward effects occur, the infusion rate may be increased to 0.5 mL/kg/hour.",
"     <b>",
"      Note:",
"     </b>",
"     Premature and/or septic infants may require reduced infusion rates. Do not exceed 1 g fat/kg in 4 hours in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Adults: Initiate infusions of 10% emulsions at 1 mL/minute for 15-30 minutes; if no untoward effects occur, the infusion rate may be increased to 2 mL/minute. Initiate infusions of 20% emulsions at 0.5 mL/minute for 15-30 minutes; if no untoward effects occur, the infusion rate may be increased to 1 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Local anesthetic toxicity:",
"     </i>",
"     Administer initial bolus over 1 minute followed by a continuous infusion. Chest compressions should continue during administration if patient is in cardiac arrest. The infusion rate may be increased if hemodynamic instability persists or recurs. Continue the infusion for at least 10 minutes after hemodynamic stability is restored (ACMT, 2010; Neal, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Source of calories and essential fatty acids for patients requiring parenteral nutrition of extended duration; prevention and treatment of essential fatty acid deficiency (EFAD)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F5502208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of local anesthetic-induced cardiac arrest unresponsive to conventional resuscitation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14599185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Intralipid&reg; may be confused with ViperSlide&trade; (lubricant used during atherectomy procedures)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, brown pigment deposition in the reticuloendothelial system (&ldquo;intravenous fat pigment&rdquo;), cholestasis, cyanosis, hepatomegaly, hypercoagulability, hyperlipidemia, infusion site irritation, jaundice, leukopenia, liver function tests increased, pancreatitis, overloading syndrome (focal seizures, fever, leukocytosis, hepatomegaly, splenomegaly, shock), thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Disturbances of normal fat metabolism (eg, pathologic hyperlipidemia, lipoid nephrosis, acute pancreatitis associated with hyperlipemia)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170037\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anemia: Use with caution in patients with anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with bleeding disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat embolism: Use with caution in patients who may be at danger for fat embolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Local anesthetic toxicity: Cardiac arrest: Successful resuscitation following the administration of fat emulsion has been reported in animal studies and several human case reports in which cardiovascular toxicity was unresponsive to conventional resuscitation and antidotal measures. Successful resuscitation following the administration of fat emulsion in a pediatric patient experiencing local anesthetic cardiovascular toxicity has been reported (Ludot, 2008). Additional information is available at file://www.lipidrescue.org. Consider use when local anesthetic toxicity is likely and conventional methods are unsuccessful. Continue CPR throughout treatment with lipid emulsion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Use with caution in patients with pancreatitis without hyperlipidemia; ensure triglyceride levels remain &lt;400 mg/dL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Premature and small for gestational age infants clear intravenous fat emulsion poorly; serious and sometimes fatal reactions have occurred.",
"     <b>",
"      [U.S. Boxed Warning]: Deaths in preterm infants following administration of fat emulsion have been reported. Strict adherence to proper infusion rates, dosing, and monitoring are necessary; infusion rate should not exceed 1g fat/kg in 4 hours; strict monitoring of metabolic tolerance and elimination of infused fat from the circulation must occur.",
"     </b>",
"     To avoid hyperlipidemia and/or fat deposition, do not exceed recommended daily doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aluminum: Some formulations may contain aluminum which may accumulate following prolonged administration in renally-impaired patients. Due to immature renal function, premature neonates are at higher risk of accumulation/toxicity from aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Monitor triglyceride levels prior to next dose. Ensure clearance of lipid solution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Three-in-one mixtures: Lipid emulsion in a three-in-one mixture may obscure the presence of a precipitate; follow compounding guidelines, especially for calcium and phosphate additions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5062137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted. Indications for fat emulsion therapy in pregnant women are the same as in nonpregnant women. The ASPEN guidelines for parenteral and enteral nutrition state that intravenous fat emulsion may be used safely in pregnant women to provide calories and prevent essential fatty acid deficiency (ASPEN Guidelines, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13824136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The fatty acids found in fat emulsion (eg, linoleic acid, linolenic acid) are endogenous to human milk and concentrations are influenced by maternal diet (IOM, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5020936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Phosphorus: ~1.5 mMol /100 mL of emulsion",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Caloric content: 10% fat emulsion = 1.1 kcal/mL; 20% fat emulsion = 2 kcal/mL; 30% fat emulsion = 3 kcal/mL",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Fat emulsion should not exceed 60% of the total daily calories.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Intralipid Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (250 mL): $31.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (500 mL): $47.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Liposyn II Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (500 mL): $14.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (250 mL): $19.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Emulsion",
"     </b>",
"     (Liposyn III Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (250 mL): $18.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (250 mL): $17.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30% (500 mL): $39.03",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor line site for signs and symptoms of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monitor liver function tests periodically. Monitor triglycerides before initiation of lipid therapy and at least weekly during therapy (or until triglycerides are stable and when changes are made in the amount of fat administered; ASPEN Guidelines, 2002); monitor especially closely in premature infants, septic infants, and patients with pancreatitis or liver disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neonates: Frequent (some advise daily) platelet counts should be performed in neonatal patients receiving parenteral lipids.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Intrafat (TW);",
"     </li>",
"     <li>",
"      Intralipid (AE, AU, BG, BH, CH, CY, CZ, DK, EE, EG, FI, HK, ID, IL, IN, IQ, IR, JO, KW, LB, LY, MY, NO, NZ, OM, PH, QA, RU, SA, SE, SY, TH, TR, TW, YE);",
"     </li>",
"     <li>",
"      Intralipos (HK, KP, MY, TH, TW);",
"     </li>",
"     <li>",
"      Lipofundin-S (MY, TW);",
"     </li>",
"     <li>",
"      Liposyn II (MX, PE);",
"     </li>",
"     <li>",
"      Lipovenos (CL, PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fat emulsion is metabolized and utilized as an energy source; provides the essential fatty acids, linoleic acid, and alpha linolenic acid necessary for normal structure and function of cell membranes;  in local anesthetic toxicity, lipid emulsion probably extracts lipophilic local anesthesia from cardiac muscle",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     In local anesthetic toxicity, exogenous lipids provide an alternative source of binding of lipid-soluble local anesthetics (Rowlingson, 2008), commonly known as the \"lipid sink\" effect. This is more relevant to bupivacaine, levobupivacaine, and ropivacaine than mepivacaine and prilocaine. High lipid partition constant and large volumes of distribution are good predictors of success when using lipid therapy (French, 2011). Lipid administration may also affect the heart in a metabolically advantageous way by improving fatty acid transport (Weinberg, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes lipolysis to free fatty acids which are utilized by reticuloendothelial cells",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 0.5-1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Medical Toxicology (ACMT), \"Interim Guidance for the Use of Lipid Resuscitation Therapy,\" 2010. Available at file://www.acmt.net/cgi/page.cgi?aid=3384&amp;_id=52&amp;zine=show",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):1-138.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Carney LN, Nepa A, Cohen SS, et al, &ldquo;Parenteral and Enteral Nutrition Support: Determining the Best Way to Feed,&rdquo; In: Corkins MR, Balint J, Bobo E, et al, eds,",
"      <i>",
"       The A.S.P.E.N Pediatric Nutrition Support Core Curriculum",
"      </i>",
"      , Silver Spring: MD: American Society of Parenteral and Enteral Nutrition, 2010, 440.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corcoran W, Butterworth J, Weller RS, et al, &ldquo;Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2006, 103(5):1322-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/17056977/pubmed\" id=\"17056977\" target=\"_blank\">",
"        17056977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, &ldquo;Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French D, Smollin C, Ruan W, et al, &ldquo;Partition Constant and Volume of Distribution as Predictors of Clinical Efficacy of Lipid Rescue for Toxicological Emergencies,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 2011, 49(9):801-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/21981684/pubmed\" id=\"21981684\" target=\"_blank\">",
"        21981684",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Haumont D, Richelle M, Deckelbaum RJ, et al, &ldquo;Effect of Liposomal Content of Lipid Emulsions of Plasma Lipid Concentrations in Low Birth Weight Infants Receiving Parenteral Nutrition,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 121(5 Pt 1):759-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/1432430/pubmed\" id=\"1432430\" target=\"_blank\">",
"        1432430",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)",
"      </i>",
"      , Washington, DC: The National Academies Press, 2005.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ludot H, Tharin JY, Belouadah M, et al, \"Successful Resuscitation After Ropivacaine and Lidocaine-Induced Ventricular Arrhythmia Following Posterior Lumbar Plexus Block in a Child,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 106(5):1572-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/18420879/pubmed\" id=\"18420879\" target=\"_blank\">",
"        18420879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo J, Canada T, Johnson D, et al, &ldquo;Safe Practices for Parenteral Nutrition. Task Force for the Revision of Safe Practices for Parenteral Nutrition,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2004, 28(6):S39-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/15568296/pubmed\" id=\"15568296\" target=\"_blank\">",
"        15568296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neal JM, Mulroy MF, and Weinberg GL, &ldquo;American Society of Regional Anesthesia and Pain Medicine Checklist for Managing Local Anesthetic Systemic Toxicity: 2012 Version,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2012, 37(1):16-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/22189574/pubmed\" id=\"22189574\" target=\"_blank\">",
"        22189574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neuzil J, Darlow BA, Inder TE, et al, &ldquo;Oxidation of Parenteral Lipid Emulsion by Ambient and Phototherapy Lights: Potential Toxicity of Routine Parenteral Feeding,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(5 Pt 1):785-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/7752007/pubmed\" id=\"7752007\" target=\"_blank\">",
"        7752007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, &ldquo;Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rowlingson JC, \"Lipid Rescue: A Step Forward in Patient Safety? Likely So!\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2008, 106(5):1333-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/18420839/pubmed\" id=\"18420839\" target=\"_blank\">",
"        18420839",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinberg GL, Ripper R, Murphy P, et al, &ldquo;Lipid Infusion Accelerates Removal of Bupivacaine and Recovery From Bupivacaine Toxicity in the Isolated Rat Heart,&rdquo;",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2006, 31(4):296-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/29/17878/abstract-text/16857549/pubmed\" id=\"16857549\" target=\"_blank\">",
"        16857549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8437 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17878=[""].join("\n");
var outline_f17_29_17878=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708777\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170060\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170061\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170074\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170062\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170069\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170063\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170033\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170049\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170048\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5502208\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14599185\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170072\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170052\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170037\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5062137\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170067\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13824136\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5020936\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323146\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170045\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170036\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170051\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8437\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8437|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/34/5668?source=related_link\">",
"      Fat emulsion: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/9/19606?source=related_link\">",
"      Fat emulsion: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17879="Nasal foreign body positive pressure technique";
var content_f17_29_17879=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Nasal foreign body positive pressure technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 500px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH0AdYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDn0CIyEkcnBz3zUlxIqx5xgE4NY1xI7MCMkg7gfSla6dlbjpzzXyVna7PbT1NFXUkfPjHtUd8UzlsYBzn19axluWdzgnLHgelJNK5kOWJpqHRaIG0X7pVjiUjgBevfOaz0UMeGwT7064ZvLwegAFEB+b8Kb0WhGuw1rYsMjOfWnRgxBsAEk81MjqCTnjpg07yhs+XBJ5xT12EIGMoHBJPH4U+WMeQueCoOAD1p9pD8oBPPWpZbdmOSCPlyPQmpe49Wjnrl2ZiW5Pp61UbjoDgcCtW7jVS4PBB6Cq0NqzsAoyT15rpTSWpJT2kdRS4wMZP+FWpoHBwE3P7Ui2srKQcDHJBpqSaH1I413N6Z96eg5AyQeoyaeI/LkwO3OaEIwwY8k9fWluIlKBlY+g5ohxs5OMfKQO9ITjeR1b8abGeMMflPp1zU3Y2WUZQxDZGD+VTLsK7hjaeRjrVSJ8uATntk1OvLYYbSo6jpSvZiLi5LBcD5TxSPGjdxxniiEg5jOVOcbh60+NMgAkZBweeoqVq97iZSIKsHUAqAcipYwUUKpGCucnrU1ztjlVSFLVWVd+ACyqoIP+NCaQW1HDMvkh/lzjJ+hq6MbV4+XccVVgTa6Fgdm3OBVlmI8vYOpyc1XN/KKwpJU4HIzzU0A3Sx5688enFVyB5xznHbtip4m/exNzg5ziqvdX2GQlDgg8AHpQMb+MsRwadOcc5BX7p56CmOWaUmMgfKWH4Vlzt2ZSXKNjUMZWyFXAxTmbiUAj0FQSSHyz0GW9MU9eSCCOeTjtT1jqhXFjDtMvUbj+uKsLiNWDNhxhfrWdLdeVsC4LDjPpzVm1VSGeVw2eQSegrqoU01eWxlObWkdyaKRPOzgkZx06+1WPtBLZ2fjjrSJLDJ5ezAycnHSlnkijRXZtik4GfSrlOhF2grgo1Hq3Yd9pMUgPlMMgngVNZXuJ45G+VFOcn0qC3mVJWD4+bO0t2Pb8KsTMot2jfY+7gnHBpRgnL3oD5nbSRchuImDMz7VJY5PTP1qyMfYnCnqB055rmpFWNAYGdGOMgNkEfSnC8lhQeZg5OSV68eopSwjavHSw1W7nRRIJGYEY+bC/lV5eCzDqoJyO3bFc7Y6pCxGWwN/wAx9PwrbimDwsCwG5SQ4PB5rjq4eUdW9DaFRSJEdWcYz8uRg1XvgEIJzuAAzSqP3TyKfmT7w9RRc7ZoRJnazEH69q55Jo0Wg63YttbG1eaVMK475Jwe1QRkqhxnk7ePWnzgglucMdu0cc96JLW+3/Dh0uWpWLRsT128jNVtQTdFFngI4I+pHerEAbdjqMHnrVe5LfYlYgZBBYeozUQ+Jco+mpNqBHkrkhThcVSbD3yybDhIz+dWNRYSxRuQTtdfypkw/fTgDaQgI/E1rFtK3XUiw+BlW2CcY8xVz6ZqLUXBvLoY4GFP5VIqjzLVegaQZx3wKr3ODLdOvJ84g/Udqdot3Wv9IHoxIm8pCAAcAY+lRFsu20kYAJ+hqUDERJ4YjFQN/qJG6HIWjTdbltD3YshCY3EYz6jNQXrb9jMTlVx7VK48uIMFxhemaiuD5nAUhsZx/SoUfeRJTG7ypdzAFlwfx7VNI4BBY5AQKBjqKrbMQ3GOoAJB9TUsy+asOxlACjdnrt71vS10bIlqaUEibUBcAhF7UVXcbEGTwT8p74FFaOPN3+RjexlRRBGOTx2GKpXalZmAxjoPetVGARXGc5zVGeFpArqM5Gce9Zvbmf8AX9featameiGGQsuM4wKfbxvNJwODjmpLmIxuBnHHORyDUll8j8MfUA96XMrXBb2C5QbI8L1znPSq4wq9PvflVtJjIzqR8uPTvUF18rpjII/ShdgIkZlO5gCOvWpDNvG4DJ+tRSN8p24GaXYAgyMDuTV2bQEhmIPAz6HpipY71sbXOTnjuDVMjByWBGelGQEAH3uoyO9JaE3sbMttFOUc/iM1CIVilZUOADnOeo96rWtwYlOT909atJOu8MxG1hzn0pSbRSIfLCTb1Ocr+H1rMebD7mIyeOnFbDNHJII8/Ie/asy+hWONdp49+oog7u5LSKquzKxI755pqZeTOQPU4oXjvyf0p0X3v0GK2uDJmJG7cCecCmsPkfk9jinOFO4/xA45pSflG5m4HOKm2tkHUROMYGVA54xU6lAVxycc7qiBBK4JI6ijeRKxHbk029bAX0b5kKMAVOcEdakiKozEnjPT0qvBvddyEE8kg0qDcW2tgLisrDJL0CVwcBh0C4pwjG5SMc8H2qYxNsyWBXb1FUn/AHYUKwAbnnqDVRTsrEtMl3lVkCnkDAwO1Nt1zhdxOOTUKnL4Y9Mn61IZYraMGSQIDzgnn8K6aFCpiKijSTbfbUmTRcwYm+Y5B5/+vU8Dho8ggllI9RWUb/zyRGvyno54ApyzOV2lwgH90cV9bgeB8ZiUp12ofnYabLTM2CSAM8kGoQzqWK/Nk8fSrGmC1N/B9umaK38xd7gbioz1x6e1dj4+vfDN4rTaVFDDqJcbzajbG3YkDpg9fb869pcH4DD1IUpxnU5uq0S9TOVRqSXc8/a2vJAVVRnJ+82MfjUbWOqhi0HlN8uCCcVsLco0RjZ0AIwOKsJJGYtvmRHHUk8mvZ/1UyuKt7L8Zf5luPmcXJpeql2LIDzxhu/pTXtNVSKNLi3lVQGQsvPB+ld/CN4Jwrgeg/Wu0tPBS3HhX+0DfbbmaPz7baMoSpIaN+4J4wenNcGNyHKMPBOonFN20be/3mFXlgrts+fIptR08MPMlj2nbkjgfhV62vHmg23EjHac7t3B/CvQ/KWTyxIiugGSXGT9Pfmqdz4e0y4cuYEjZsnEXyg1yYnhCk3zUJ29Un+K/wAmP2clszmWvfN5lkBK9CtWFv0dgS+8Edj1puoeCpzGWsL7j+GOYY4+orlb+11XSZCLqB0VTjeg3L+YryK2QYvCK/LzLutf+D+BjOMt5HVyTgkYGFPr3qKV5jIWOP8A61cpBrbquWLyfj0qwniFh0iDD+6TxXmVKab03IT0sdIjKjAqrIT91geK1rK+uI43ilG5DyD3z3HtXDt4g2oAFGTzg9Kkh16VsYckZ6Vk05WTiVHTqeladfoIirMSp6HuK0IyGgjj4IUEj6e1ed2OtTDBKoQTgiuhsdVDqEB2nHQ15tfBwl70WdVOu46M6I5wAPvB/lB7+9TTkpE5xlh+lUIp43hwSOT16kehq7sEgG443fLx06V51Sk6TtL/AIPkdcZKWqZYgk2uoJHI4571HNHttrhTkggndUMTYIVmwR69uamlP7m4RRuGOmawleOqK8mMlDeTbBe5GfpTN7COWYjcrgYx+NSQvi0jVv4c7T/SqrHZanPILquBVa9RbluEbp7QgH5WPXtVKIl45HYYLSs315xV62VlmgJIJCMcfXvVJMLbWyN1JPP41cpJJpf1/VgSu0DcliT8pPWo5WBicY+Xfnj6VITy4IGcVWb5Y3wM5J/TFZuxTV9CQvkP6KAPpUZZvI3DOT071JOuIMqwyXDH/Cq8kjbhlenXHam/j1Jeq1K0vyCUuNxK8gj26UcbYpIwfnCkg+lTSr5kg5HIFOiJ4jlA8wJgDtnPWtKd29eliZF61/fzMTwqjHA70VJorrDatI4B3HvRWksQqb5bGPLc5mG4VomUHqQcU8yAKDg5BHHpUVnA28jaVLDFWDAdx5wSO/rUKN3ZI16D75EmA67uvHXOKpRKyx4Uk8f5xVybIiAwM7evemxoNjbT6Dms02m0ynqyvbQlzuYEjByTTbqIuxOfmGBn2q5CCisAu49cfjVa5kBmZUOff0qlf5ktaalHac4YDnjHpSAlDt6n1NSzLtHykDOTiqygZwpycZwa0WqEOV1HC4JB6460suHCnByO3TimkcccMDzR2IYHOPzo9Rbj2jOGIxyM4/rTXyo3Anb3HpVmOMtbCRWwU646moCTtfqccim3d6ASwSgg5yO4AqtqTELGCSME4GOoqeLLqEPCrzuqtqGTtzy2OvtSj8QPYr/eHbPp0p8Q/edAAO1Ki/ugD2Oc9atWUO9wXDZzwR61cnpqBCASNygcnBFNkDBAShx3q+6CMAAkHJJU03DSAJgYHTNSmIrRgGRMHaeCKaobc7ZX1GO9TGLZJjpjlaYqhVOec8j3FO2ugFiBSuzB5HAz3+tSwkOSF+XJwRUYVdvBxnmpo1QktjnPbvRPTd6i1JV5SREyFxgc9PaoJUDFQFxtGD7VctYnkkCxqWfnoOwHNVtbWG1niit7lbkNHv3LwR6g+4r28jySpmNVRbcYd7fl3IlNX5VuUZJWUn7OBuH8bdBSfYZY9k9xFK2/o7qdp9hU9i6W9xDPcQpcQowLwNwrr3Ge31rV8Q+LY7qD7HFmHTw++OFyGdfbIr9WwuXUcr5KeFpqz+JvcTumklfzMmOMk9AFFS+XGFBkfBJPWs8XzSEiG3lcdiBivSPhnqeh6d4f1V9esYrm4eZPNtJow5lhx8rxHswJIZfoa9TF4iWHpupGDk+3XVhVm4rmSucfGIF2qrISeoParccltHCMN/Fkjbx9Kra1apNq15caSiWWnvKTBFKCWRe3H+cVGul6gQ229iA4IzH1/wDrirhN1KanLS62f5dS07x5jUMlkyMQMEgbjs7UqW9hITs8gk4wAOmBmsz+zdUjTC3kTADkNHzUkdtqseCptHUgE5+XGfT3pPTZ/ihbF2SxtGYtCVG0AbVcirMUFzEjeTezxxEfdySPyrEc3gAEmnAlcYeFs4pWvEjDAtdWx6YkX5foaGm1a/6ieq1N0y3keFMEc6keuD0p/wBusyF89XtmBwRIvAPsazbXVZgM/urqPaBlGwRWqrgWUM95Z3FrbXL7UkmjIidsZ4bofX6VlKNt19z/AK/IG7dSZlEsYaJkdGGeD+VQNG7ZEkQ9NvUEelQNpUWA1hI8LDktA3B+o6Gka+vLNyl/b/abf/ntCMMB6lf8KlL+R3/MEZ0vgODxHfra2FoyX8wJi8nC8gEncOnY1wPiXwXrHh64dLm38xQAd0fPBGc4r2PRdWZJ4r7RrtFljIZGHVT6Ef0pmvalPfXazXkSOwGBsXAUZz/PNeXi8vjjKtqkUlbdaSv+T+ZjKm5S8vxPnR/mcgnaQMEd6WMtG4KnPuDXqOt+GrDWN7hRbTbtqyR9z1ORXner6JdaS+ZkLQngSr0P+FfNZhkOIwl5w96Pl09V/XyMJ0nDXoaOn6lHkLIoIJ5I4reheOZiyM3P3WHXNefCQ/StXTLy4THzZjPUda+dq0ZWbgwjPWzPRbC+eLiT5h7f1rprW9V0jCnLd1/wPrXn1nKCFJ6AcMDW1YXgb5WwT6dyP8964MRCNWPI1Z/1/W5rCTi7o7Lg3RkxkH2/pVgSBo5GxwVycfkRWFYXbSzbGPzqOv8Ae/8Ar1uIymPYo42HkV4laDpu0j0YSUldEflutlGFO0k+tUpGdvlwNom6Vb89jZ2yMcPtOT16VRZt0sJIK/OW47/WpvraW49DUU/6YoJwTE3XpgVnSOP9HZRwNw/XirSEfbpmHRYcjPas2J98w29NpOKi7XXb/ggty7kbQ2ACepqrLIPIJK8Biv61O+DCgJOWH5VANjQRlckbiOelU4xi3cq7kiS5fbbKRjeW6fhVWMswkxxtznNPuG4ROCxOeO1Q7mSElSSMksPUGs2nHbqJ+Y4HkKgxjkH3q6sf78F1wSuCPSqGnFmkUSEH045+lXr5mjdnUYY4AraELarQiTuG1za7VODv4weoAoot8fIhbHyliT0JJorTli9Zb/Ijna0SMVZwTlcgY4Aplxd+WQOcmqEQZeBgj3PFHzGbeeQDxS8ym+4+8uXJ+XgEdPpT7e8bYQPvHmqsg554JPal27UIGPbHWi3QTepfW7CRNxk/yqmsgLF+Cc8545poR9hHAwPzpVTEZPHA6nrRZRC7Yk0jYye/Y9KdDDlBg89fpUbAbTkHPvU6gKi7WIYD1703oLqJ5JTLBuWOBmo5cgZPJ7/4VPK+UYE49jSxbZ4SCP3g5FHM0tQa6EMUhC7AScj8/wAadCuSykfKe1TxRIByvPf2NSLCTuOcgYJHeny6oTGwInkuEwXGODxmlkgVtysmG6D6VI8Q81TGp5Gc9PpUYkDk7iQScVCs9UxtEcVmHmIUbYj1x1A9KtzokWdi4IOBge1KrbIyyNggdeuBWe0+5y5yxbg/SlrsGw3zCUTJwxPeopJSBkgg9s1KQDjoWPfuKYEQhRID64NXG2y2FbTUjUFkLEKGQ5/ClGBg8An1qUALINx5IOfcUyOMhwCobqeOhq9OgWZOQTGC3QcjbzipLcKAWLYX9BRGAShx+7A6dMUXUN1JYyXFpZSTQRHllHH416+T5Y8fUvLSmnq/0XmROfKRteS+b5sEjW8cZ3BlOD0rPN0GZhbL5rk/M3aoZIZJHSTUG2rjKwocgD3ourkw2qfZlWBT/Eecj8K/UpY7A5XSUG1G2llq/nYm0USm0mcZvLjYmcFFNBNjZ7m8veyjOcZJrHZvO+X7Q0kvv/Sm2M3l3CPESDu5B54zXiVuMFGVsND+vz19Acupov4jRU3QQnHYlsDNQHxPcZBQRLnjGTmrNxpu95FEKMmeCRg1LbaJAVVjFHkdeK5HxlVnqo2+en6BKbtoUT4kuH+UzRAA7eFzirMWvTFtrXQ54ICHmr0lvbiaSKOEMQeSFGK19N8OKQWFqNxHzEjlVop8YVntTVvVkObW5RsdQupzlb2EKpGWZSBj3rRe7kLBRNbSsTgHf8tR6ylpbQ+VHEGOPTr9a5uPRGvB9pdDDD1Em4r+A/xq4cXTlU/eQXKuza/X8BvmtdnXNcXcKZFrvXsYJA9EeqW0MjNfRz25Y/8ALWMgD3rmrPTYURxFeXDEjjJ5BHRh6n+dOa78R6erNE8d7Co27GwxI9cHqK9rD8U4OtpJOPn0/UXtLaM6lbTTrtg9r9m8zI2Mhxk9ef8ACvSPFni221fw1dafHblIpo0/0Z0G2CUYO6M+gI/WvD4vFGmO2zW9JaxmIwZYgUBH4V0Gn+ROqS6PriScYEd0A2fxr0pxwuY8sufm5dVr/l6eQnCFVp9iAPd6aWbyXaNv4rc78e+OtaVlr0FxtIlWVgOSvDA/7tI9xc2zf8TSwKqhGJYBvUD8KgmsNN1gPIgUyZGJIztcHucjr9DXpStLWS+ZqXprC3vHE0W6CbPEsXyuPqOh/Gq5nvtPb/Sk+2WuADJGMOPqv+FZjw6rpZ2Ryfb4DjK42yD29zVux1uG4Ujczuv3lYYkQ+49KXK7d0BpQfZb6FZ7ZwwOfun881Q1OygMLrJh+MHeM7uemKZNbRSz/aLG48i6PO5B8r8fxD/ClGpLK622qRCGbHDD7rj/AGT/AE61STi7p6CPPfEXhXaXudKBIHLQk8/8B9a5mBwDt+Zcce+a9gubblnRwFBBGepJ7Vx3ifSvMH2yCMCReX/2x6/Wvn84yGFaDxGFVpLVrv6ef5+phUo31iVNJutrLGQBnHU5NbSFUlZhgFQSQO4rmrHaYhKhACnPXlf/AK2a29PuBcKIyNs6NuQ/zX8f/rV+f1Ia3e/4mCZv20xfADDzYyGVifvr/wDWrpdMu1uYkV2IyGXB9c/zrgvNlinbyjlwN6Ke47rW1pd75bxvE58uXlcj7rehrysRRU1y9f6R1UanKdPJvby41++IifpVSJGNz5R4wvBHQGrcSiaFJ0cfNGMj+lQopW5DucFwBXk/DPz/AK0O691ctyEJDdE8BYsE1nR5BiPXKHnFTyPutL5ieSwjqK3b93CGABx+XNTNXV3sNbk7gcDPTg+lVBIdij+EM2SeMnNSSy4+XOeSfrVSR1UIATgZJA7kmoik9/61HLuSSKXETHaG3HGfSmKwKBlICkbsZqrcXJMSKuNwU4P1NQpveMRq3UAZI4z6VaS6E8xr6fiS5jLHAZu3oBU1wzyRoTyGzyOuM1maczxOruchOGzVua4KbEAG5FzjOcU0rQUX1IbuxJLvyYxJIMAttAPfHeiqt5IDFAjDLbdxH1orRx7P8ibX1M1yoAI6Y6ikVlC5NMclpNqk5Pep5UG0BepHHrQ1bQvYgX5mDY9sepo9MHkfe9qsiMbeQQfX3qJAoHXHf0pc10JEbP8ALtIwRzz60uCVAHTqcigZkkAwc9x1xUj5CEryemKe7SC5EPmcJnLdqnZV2jI4Azg0y3XcxcYznAyMZqZ8BfccZHYVMnrZAmVuGOOp6GrFnFtlHzAqTg+xqFQRuYkE9BxVm2Rtq5AKHjnsaqTtsKxd8oIzdAAcnNIJkiLbgDgVPgYII4Kg1DPZeY+QSOAcjuKVr6v+v+CNDJpgqh1PC88nrWbM21vmO5cg8Cpb1F6E89T6cdqoPJiUCJcq3I9hVRStotRaErznKY4xnnNMQ5+bc2SRjAqJPv5IIB6ematKpLZUdunqarlXUAUBmwcKSMHt78U5juUODxjGT60rFmLr1LClKYVf9rjGOp+lJc2yQtLjoB5kcnmYC4yAexp23M7RjgMgP0qdIcwKCOC3zADmmahthkmdc/KgXng5/wAa6aVBzmoy6bkSla7ZVv7xNqW1qMzkYkcdF461aF3cS2Fra2ai2jSER3EyOcXDZOHK9jjrik8N6BJcvIqh0To0nUsT/MV0WrWdraQ/Z0kS3SJeT1dzjsK92WYzoUvY0fdX9LY5rKW5wd9EIg4EhYL95z0NYk1w8zMsasExwCOmP8a1tckjjtNsSkM54Z+WrO0TTbm+vUBLtz/nNefFOq3Oe7/q5cpWRStYr2W4QQJuG4cgV1NlpbwP51yq5YkiPsa3fDWi/Zbd7+73Q2EOQGC/63HYZrofDWmJfLPqt2FECZEcR7D1P4VU5xSvtbfy/wCCZ3lcwrPSJ2PmSxknd8wHG8npj8KVdHmMrCTCBjwDnAH9a7OSWEESzSqicLFGnfiqCXZOojcqqBuUIeSvGaw5vaK3LoWvd3KqWVnpZLxJ5tw4HzNjjj07VJJcK9vMjSDKjGRwG9eax7tjJehC5UOAVI7ENjn9Pwq9d4S3jVsKB87nuD0x9KOW8VJ6u4762Mq8aK4VZPKd1RtqAcA+m72pt3Z3TzO06gkD5Youi/SntOixP5LCOUlkUNyF+vr16UWF29/FJHJ+6u7chQQeD/dx+PH4itFF316EuRQNpHI20Ha3dSe/1q3ZxBPlMilidoDcc+lBlgu5As2EmJ27mONx9D2yOlRXVvJFE+D5iDhkYcge9bQkm7x0Ik3buF/D5a+XewRvGefmX9K5fUNLhR/M095LKQcYT7rVvx6oY0VHYug4Abkr+PcfyqrdSQSMcb0Y9jyD9DXRTqTi1yPUzfkZmn+Lde0NSkxS8gxg7hyBXQ6drnh3xGwy507U24DKdhz/ACP41zd7ZmSNgpzjkgelc7qWizKolVODyCOtfQYLiLE0ZWn735/f/mmaqrJLXU9YnOpaUm+6jOoWQPMtuP3igdCV/qKgaPTNcQTwS7boD5ZVO119vf8AGvONC8YavoEoXzWntxwUkPb2NdxZX+ieLGD2Ttp2rHkY+XJ75HRhX12BzfD4z4HaXb+t/l9xtCpGew5vtWnTj7TgKG/16jCnt8w7fyr1C7+GMx8Cvqz3Md5Ikf2h7bbgGPGWIbruHUfSvMZNRurEtba9CDHINn2pBmNhnvW+viXxDbaFFaWGoeZapE0UcZPJRsgqGHbHrXXjViqkYvDSSaet+qIqqpKzg/Uw5JG0+RcSma1xtFwy8qD2b1HuKddKksG9SmGGACPyFQ2d/DeK0KhklXgwS/wj6d/wqKeMWbM8B32eclO8PuP9n27V6EX1N72OLv4RpuoPFjFvNzGSPut3B9j/ADpC7QBLldwA6j1Hdfr0NdNq1haanbLHdz/ZoSwP2hF3hffA7Yrm41e3up7O5wJYn2vkEA4PDYPIz/WvzziTAxwtd1I6Rlr/AJr/AIHmcVZKM9OptXzrKIbiNjuYAjH55qxp8u0GNxiOT0/hb/HNY0LkRSW7EqFJMff8Pzq5bTlonTjJIYH3r5STu9dU/kGq2Om0q8eHMbNwwIznpWnbyebOiFiGB4x0NcrBcGKdXYfK5xtA71t6VcAz9yBkjtXm4yk2vapHZRnryM1GkU2BZUyXm+vtUFw6pJtBHyr1/nUUsgSC3QEAlySBVCWb/SNpIKsD0Pr2rzZHQmkWrq4LbWRTjGCfSqAcsI2J7EEE9OaluCyrhiAAM/pVU7gEOMgL/OhLSwSLNw4bagzhVGB36005yCG2hiOv86Zndcy7DnovX9RSPIQ6AgAFQRkZ56U3roTc1IiTZbX++XCmlnXdliQHJCcelV8gl8MA2VyBz0qeA75gvbfxx+tVBppKXQTK0weO4cxtzgLwM9KKhmlBlYElssWGOeM0VVoy1YlKxDAhbLYPWpXH70D+GlhPygYAyOf8amij3liOo61Pmioq+jKzuScKDgnOPWmuBGg3E5Y8HrTljzNyMe1SSRqZAD256Utth7kKRlFMi5B6AGk3AKOxPBqzKFwBjHdSKqyNl24GT6Uk9WTYtxJhFKkFcEj1qMIWTOAcnn605CY1CsuVxjI7U5I/lGwYBH50ddB2CGMKo3gYPBq7hUtxj7/TOPSqRRvMAw3HOfSr8QDA5xzjgfzqktP6/r7g8gMihUJGVwV49Ksw3CeWgYrkgrk9D6VXK7vk4wpxntVW5SQDamAFOcCj3mrf8Edralq8t4Z7ffGBvzk8VlXFmhkwPvEZIAq9aB1DrISOpp8h+7u4IXGe5ok2tRGR9mKYB+bng4qSOEcncTg9jxV+RSsWVwMHrmqu5tjbeDu5x/jTs3pcTVhLaMNPgZI3Yx1qeNTuQ8AZwM+lND7clQckHAFSCTZA7gfMBu2556VUdWgaGvcok0UZYGViW69FHetHTNHN60V7ejbaO25cnmQdsVzOnKkzPPOQ3mHaqdyO5rqRrYRVeQfJBHlMfdT04rrhJQjZb/1/Wpzz95nQXt1BotqkoCpIc7EXrt6YxXFyztcNfXdxl5pXIj9j6VnXuoy6jqNvHcNmOZw6nPT6VUvbpxpEPlF3DXDkEH0bGP0renCajzS0b0X4Gbtshus20s93bGEqVdSXHTbV6zuTZ2y21igjjC7pZc/Mx9Pak1G5U3ZeIZWQ5Vc8FhwwHoabDLDJDibEZbJDDjP+fShxe0dn/X9dw6eZq3mqXOoWWLxnMAIWONTjPbgVvyvcR6LBa27rEiPhiD1PqfWubgaQXUMZjUxIvUfw45qe+uhJbvI7sDhnAX371SikmktCOqZp6tqVpafZo4mE+BxIDkKR1/HrUaXj+fAHwswOVxyMDtn/ADwa5poDOsttJJ94Flz3BAOR9D/WpxLO+jS+aQbmyx5uOrDs4/Ac/Sr5JQje92Dldm/qUQjv5WkyYZP3qMOwx1+oPWpPmuIHRjnKkbs+gyAf5VFHfQ3NhZ3HyPA+0ljwPm4Bz2U/dPocVNYRFL4W7k4fMas3GV/hz7jp+FRK9/e9CovS5mwCNrmVZAuXCsrHo2Pukj1AJGaxLwyabfyQksVbkBj29Af5H6VoyXQwjSKEBchQw+646qT781DfNHeweWR8yjGxj82PY1opcq3ItrdIjujFqkBljMZkA/eqOBIP73+ehyKpXWpXcaJ55LSBcGTOC4HQk+uMA/Sqwje1l327ncvIOO/fI/zmrf2xJc71EbEcDqpPetOdX5X/AF1FZ7lSW5M4Dkguf4hw34+tMSWYOAiA84yehq5HCgOUiP064/Gr9rbxiJ2mU9e/r60JXWv9f19w/QqW8TMhZ0KnHTrxWrYacm1XnVGTG/APPXpV6zt/NESBQIR8xB5Bpt+4hlgkVSARuAHfnkflW0Xya3Ja5tDk/Fvh+D7VI9vGEAGZE7ZPpXJNYm2lXLNtJyGU4aJuxFekXsv2uebB5PGexHbist9OS8iWMKCz/KD7inGtK6vo+39f1+i5LK5V0HxNdafA1rrsX23T/us45ZB0yR3HvW6tq9nH/aHhyX7VYuNz22c5H+z6fSububAwjdK0gjdShkVc7G/vEdwR1FUbSXU/Dd6ZbPAjIDSQA5jkHqPb3FfXZZn86dqeJd0+vb17/wBblwr8ukjq5YrfV7fz7UmKeI5D9Gj9Qe/4VWsb9nl+z3gCXAU7Tj5ZB6qamgmttetn1DRz5Gox8TQHv6gjuPeoJXh1S38mZDHcxH7g4KehBr7enNVUp03f9TqTvqh0yrbBsgfZm+8v9wnuPb+VYXjOa7utYOsXk7XM0oWOaRsZZVUKD78Ac961La7fzjZ3pH2jqj9pBVfU7YG3NuT+5bhM/wAB/u/T0rHMcLTx2HlBrXp3TIqR5lYxUlygZT+8Q/NnuPX8R/KrdtIUDc5BIZcdhWPbF0DwSEh4vl+vtWjZuS6ZAIzgj1Br8jxNB052nv2OeLtGxuyfvrOYBstCN+R3Ht/Olgu3ESSI2GUg7h6/Sk0xxuAH8BaMj2xmq6KYLqaBumcL9PauOpT5vdZSlyu5vC5+0W0TgASKc4HfNRR/NcZ7bCeazoJth+U42nB9/f8AGrsTCS5yDzt715Faj7NvodtOfNqyS6OQegJAxj6U26d2kRUBBG0fkKLggM+3PH8Xvj+VEgzICxA4Odv0rBKxepBaOWZ26AknINLJIAYgcjOD+tJu2RKMDIUnP4064QtKAB8ox2q9L3A04XVizgcs+SOmBU0B8tTyeMtx6CqsJBCNhg2SaswuQjnOQFY4FQk90QRYWSTcoVsjPtRSW2VT5ckY70VTgl1/IT11JGjIXK9c4PtUtmm4MG43Hhqk2DYAPmBPSrVpCiIwc8E5qIrQ2s27lOa2GDtY7gcYFZzlmuNpHCn8q17kBWYg4P3TmqMMGJvm5Udz2ovG/kOzZHP82FHcdB1qOKJwwLDjNTPhZGZRnHFSQsGOHDA8fhRbtsybCeWHY7F4789KneNFCBTwF5psw8pSY+rH/IqK5SRyFwVbHp1pJdLj21Jon3s+1cKo5ParNmMK3HJGSKpQQs65B2+uavqQp+6M4p+zSdmAqhVLexxmmg5Mmf4h6dKJyRIeoDEYGM0qjEbZAHIIzRbXYL3ECg/JxjGTmqU2VOAc4HGeKv4GBx2xiqkxxIc49D9Kb0emxI1DvRuf4ulVmRowwUfKDxU23G47sEt+GKUp97IJLH8KlXWoIqSN5MZJJOOn+FZLagwvE2kZPGDyPpV/Wj5OI9/z45x0rlICz3gd3IQHIPTBrrw9NT94zk7HUZQyS3NtlYgmwLnlG9P8DWbJdMbZgGbDcOM8mp9PcrLcYwwcAFT91h6VDBbI8Erxhtu3ODyysvOD/j3rpjFvV9f6Zi32K7S/ZrtZgOBtCj09QKbq/mQwwkZBjmIZMfwk5BxU2tiN54pthaCVRKuOnI5wfUHNXZJkktYLgBZIwfKfjoOxP8q6YTUVqZSi9zPN1veQSAmIvuweox398fyqeW4hWWOG8wAxyG6jPqDUjRWrXSpuMZ3Dqe454NWbzSluICcL+7cnj0I5/oaaXNZxWlhXtuWdLdlurqJ3EibS8ZHUDHSppkFxb+UQSXXGRwRkVk6VFPY3KEqZISdgI5AyO3+Fa7ebBdjGDCwADZ7HlSfoeDTcdlbT+v61EmZ32i4hhhyQEXA5XGD9RU0WoxLcwTOBER8hY/dZT1Vv6Gn3ccm5ndCFckll6j6jvj1qitsSksU9uWVufl4P1FVB2W/r/mFtC/pzx6Td3FnMu+xlDPECOGib76j0Knkf/Xrd0iUXQWCRi11ZSb0kzncAOPqCp4PsK5y2hmhtjBOrXFqozG235k9CD7f/AFqs2rmExtA/zYGCOpXOV/Ksr8zumWrjNSlxqdwkilracFnUjlTnqPoaqOrDhjuyPlcHnFa+rW4uZfPX7zYkdMdMjkj+tZkQ3hQVy69umazjdJpb/wBf16F2TIgm4kv8w6Zzz+NWI1Xo0a+26rEaIpO0YbuoHWpliXhQQSOQpHWuhNLVktN6DIViAGyPknOewFatnaByFVcZJJyKWwsWmmGeFAyxIyK14bUGZVRs7uvPQU4yS1DkZE0Sx2csiLkAYUD9TWHeuxtYeCV52N7dwfpXTa2WitysDAtIhQnHGQeg965qZZF2p1ReTx0H/wCupcudu39f15D5bIpOoby3VdpbgY6Nnpj0JqSztysxjbgv68YP9CK0tNhhnLwy7QsgKurdB/tf/XHSrctlJCfKuBlgceYP4/Qg96qErNdCGtCAxhw8dyAZXwCwUEbux/H+ea5HW7D+zY2ST5rMElSOtu/t/smu5kQbNxyvy845yPUfSszU4xLuXcpDIeoyH9a6IyalcxcWjzO7MtlPHeac7Q3Gd24fy9xWrDqkWtqtxEPs+pQjLoO/uPUUzWNOa3S4CLiAFCg/uN/dPt6H3xXMSrLBcJc2zGKWM/ePBB969/KM3nl9SzV4PdfqvP8ArzHTqOB2Z8rVrfZIPKuovmGP4W7MPY023uvtKyWt3GBcoMSL/eX1FULW8GoQG5tSI7yI4dPQ/wDxJq5P/p9ul3a/LeQEgqO3qp/pX6JCtCrGNak+aL/Ff5o7E09Uc7rERt9QikY53/Kx/vDsaltnwm45znmrGtBbuw8+NcEfPgjG09xVXTZFlIjbofunH6V+f8SYRUcS6kFpJXMKkVGfkzXsZjHdb1xtYgnPtWpqEO9jcwjeAOV71jWSswK8714xW2k42LyVyu7jvx1r5Xz7iszOuCY/LuYzlDy49Ae/51o2pEvlOvU9Ceo9qpPGyOyYGCSduOMHqB9afZFEnjTdhOx9D/hxWOIjGauzSnJp2NOb5nZWG3H6/So2KjeuSCw4z61NdjfEXRcMGycj2rOmB2FyrcAk46ZryOXodSdyQRsWQDOOOM+9WePOzISeeDjrUFoTLIhbghR+NPQhmwrAHqM9M0pAWV3blVmw2QSasjmPaPu7flI71XJEjMQBvZeB6etSI4+Xn5DGOMdOetDfRi8yW3JK5zg9OKKakoViNp49qKac1omK1+hoPhI1K5wRn6e1N+0kxkHjPQ1caNWCqOo561Xe3yG2YZckjPasW+r/AK/4B0ap6FdHaTOBuB+Xp+tWrVU3MB1AwQaj2rDGQp5I/KorCUtPnBIzn3ounuLVakr252np1OBUYiYAKdwz37/Sr7uF4X7pJpoAVVwRkn7x6UWvrokFik7NtJx8wOB/jUoR3ljeQ5ONqmkmbDBW4weh71XvWdXUISBnpmq2asK9i6yCONNw4xzTZC2VGOo4zUAuVmjwx+YdvUGrJ+Zoy3O3qM9RTjKPwpCFU/KckkNwM+tEhBU9dpGfpUcKgtgMTkE4NKitgKxyygge4qXyXf8AX9dB6vce4XyyRz9OuaqyAhlBJJ6Ej1qccRONuDwBntVO5k2s2eoxgg+3ShPSwn5gksSylSm5euM4+uDVm6ZmRynyRjoD3rLUDPzZz1AovbsW8TMx4xjOfx/Or6pJak30KOqx+f5pVvnAxtrj5pmMpKIRIh5UfzH+Fdrp08N1elZAcYKPzyOMq3uDyK5fVLB0uSVl2zZ4fs3v7GvTw8VBpS6nPUbeiL2jXSCZWBAjkwHBPRv6VpajJcaZKt7bJ5kKn98o7r7/AKisCG68u42Tx5fgeZj5WPYN6c9DXbaPJa3VmhkdlG/YcjlCRyjjt03K3Tt3Nbct/wCt/wDhjGTMW7W3l0ow2zsI0PmwMB1R+x+lZOmXssEjAqkyA7ZY167T3x7da1L6K50e9ktSqvblmMZxwp6snt6/iKqPaJLIlxbbAp6K38Pque4pqor6glpoWfL3zIAvynBjOeGHbB9R0x3q7p90sLtHKzjb8oU/xqT29welUobeSMlWVpIG6DOSPbP9a0EtI5ly+4v645H19aOZybX9f10FZk8y+VOZIWDK2GBBwGHUH29cVqo6PbpIFMkYyjoR1Hf6Ef4VTt7U/ZyhO4dVYjlfVT6jvirGn/aLK4BUAoThv7pqXFqVuUpbE4tiycoJYeNrY5Hofb0qCfTv7h3KOV9fzrfggjnGYC0fqn+HqKl+wOv3sEngkd/f60nU1syuTqcebea3kV4jLGVOSUPerUqZVJ5YFdX43L8pU9xxwfUV0UthJuLKFwM8YrP+yFGZZS4icfMRzhv4T+H8qXup3Rai7GeyM8CvAxk8vjphlU9iKiWNGw/3JB1BHQ/1rSSzcSEKP3i8dOv1qYQSSLscbsdyvIFJLXYpxMmGISEF+oOM981ctLZ0O5IwW5ALVoHT9iqqHJbkgitCz0x8Bju3eg6VrFpbCt3EtbeUxMJTtAX5hmrOm2jTu+1diqOpHWrkOnyNEUOfm65NaSqsUW2E4OOT7e1NJr3pCe1kYOuxhYIo0GefmxWHBAZMOuVlXPTjeD1+hrqr5BLBKfQDnuT3Arnr0NHuYYDKCR9Kl2lJti6WRl6tZyRRxXdoWjmTJ+UYx9B27jFXNM1wXFuu9AJQNksZ6exx6e/Y0+G9hf8Ac3B3BhkZ/iH19aw9Ys5rKcXUbFoz/q5gO3ow/n+tVF9G9EQ9Njokfcri1IVhkvE54z/eWsbUo9qHb+7cNv2Ht649jVOLVGfBxhxwyDofcVd/tGG5gWOUBXXIDOflcf0P86Kcm9US7bGDqTpMJC23c3IBOQ69wa4jVrcxyghi8bcq2eR7Guz1K2Znf7OQWIwYicE+4rlro7ldJFw6tkjv/wDrrqjNbfn9xjy2OeE0tpcpPD8sicH0cehrpbO/XKXtvny2G2ZP89xXO3SjBLN8pOM+lN0u5e0utjkiJzhh2z2NfTZJmjwk/YzfuSf3Po/Tv5DpVHB2OsvUjhmMm0vZ3KjdtPQnoQfesqeCO2uFWJpPJI3KZF2sR2Jq/aSLJE1nJzE6kxnt64/rWUss0l15U7F/JwgJ5wo7D869DiaEZUlUv1/Hr/mvVmtXua1rIftkcpz8x5rcuV2xxlQCuSGHqD2rn4CS4yc4PHvXU7EutMYg8gMeOoYdR+Ir4aKvG3YmWxjzv88cbPsZAu1v7p7Z9u1MuyFbdGu0Nk+ysOo+neotUxsjZhhzEOfxqzYlbm0MTEkgZAHXI6/j3rJpLXp8/wAxxZt2jLcQKx3YdOnXj/6xqjN5kW6NZgFIyQeh+vvTPDs4DSQucYORnsaXUwdzDoRk/jmuGtCzvY6KT6D0keKRYyysG4+lKoBbKLjBNQwABmkccsm0DOMGnQuzTFCcYByfw71yNdDYuCcDYSpBAwffiplBVVKBiVTJPrz0qhFHmcMCQAOn4VoRHy4W3NuwnT/PeoatsDGoC7uoO0jGcnqaKhiRjuAb5s5ORRQ4yeqRk5WOmkQsm5cbgcH3pIiUtpD1cnjNOu5DGGK8EY5NVJJmaIgnHOcdgazbbaXQ67WIGkwpPzHiks5Nr7gNpxUckn7rrjjgUy1ySeD19alRdrslvXQ0NxKAnC4OfrVWS4YOMNnJ6VBNMc7WwR0BpsL7QR3/AIeKclfUTk0i+772jZhznoajYgNyMrjGe30quk24F+idM1LbsHJVn5A64oUW9AuIkamQFGJKdAfftV+AhmO3JAXj1/CqiwhSSpGDxU1nkO4HRuFwavlvt/X9foJNkkZAkKYAG3jFPHz9gMjOPWmSRtHneM7RnK96fEA0MZ54596m19Opew4MrYM2Vzj8TWdcZJYZ5zyexq4xDyZzlc844qrcBUfO77vY9DTbvHVakeRUIAUMRggY/GuZ8S3DABFOMcEeprqpyFiyT8p5HHSuH1SYvcNIf4ATn1rpwsE5psibaQ+0vypg2Msd1EMLk/LKmc7T6H0Nazxf2inn23Dg/vI25dD647j3FczDeSTxZmjjaMdGC8itPRJJGuMq5VQRhh/CfUV6bTV+Y5d9iKaN0uAp2shXBXHBHvW1pT3VrIs1m6mbaVeCUZSdD1U+v+SOa2JLB7lYp0RZQ/38DlSP59j+NW7LSmkY/IPlPU8Vg5tSRqoXReuoI9atYZoU8uYIqusnV1X7pJ7snQ9yp9qx49IMMj7ARk4KE8L/AI/WumjtmhAIUrznp0b1q35PmKvm4DdM/wBKy9q020i/ZWRhW2lbAGLHPoO9bNppBeIMuFbHcVpWtqigcH/GtyzEMSjzVBI+6D/Wn7fUXs32MS20EMN1wyg444zmrFvoakfvDux1OMZ+tb+8XDEnC44AA5P1qWEDG0demDVxxF2J02YH9ktFtZF6nC461p2Gks8Y3/Me5FbESKVG87mHY9qvQRbtvB55wOMUk03ceqVjEGkqzAKvBP3v89aiuNDiYbljPJyB0rrY7cFcGniKPcOCWU5Na2S8mRdnCy6GPm3LhQccdaRNIQEHYwPXdmu3kiV8ggH5s1G9sjvn7uPbjFDhfqNStocjb6SCS/VPcVo2+nYQkpxnnmt0IgVcoPLzj61SvrhYhgkKD/CKlyUXZbg22ZU0YBck7FwRx3/CqDRyPGegA4+mKs6hPvGwttOc59RTZH3N5KH5BgnH86hNykVLQz7uMFYgeQDvOPWsq+tQzuXxjYf16GunvoWUStwJcDjtWFPl4iAoJY4we9bxfLrbUxlqjzS6mJklizhoSSBnqM4xUthrstlKqTYmt2O4xydCPr2Pv+dQ6/bTW12rhGzWXeRF16AEDkZqkr+6/wCthNdTc1PTbaaIX2ju4HUxg/NGfTH+QazIZTIdhC5P30II59qzdMvrrTZjJA+F6YYZBrVuLi31BzIL6NZQu94EUsw9ceood427+n/AFa5SuHliJUxSlR0OOVHt6j2rLu2R+J085c8OPlYf59K1BfWEkSq4nk2nOQduP8arzatpqL5b28zA8nccitYWlurMmSt5nO3dkclo18yJu61RliEYCyAKcfLj0rp3utOkDGItHnseBWXe6fE8jPEx9dhq4VHf3l+H5i5exUs7gyQjyziSP5lJ7EVOro98ZV5EibsZ6Gs9A1pcMSMIRyPWptOcG+eLgL/Ca+glj/bYT2b1tb8Fo/XdfcQ3dcrNS3fAGDyDuz6V2ekuiKQBkMu/A75FcJBu3IGI4Yq3H4V2WitmFCSAY+M9xXgShysq90V9etEYxtGp8phlfZe/4Vj6aHiDYGTHznPNdUrxyWphl6K/yN02knjn8x+VYduFh1N7a4UCQlgsn94ZzyOxqW/e5X1G9rosptW+hu4V/cthZT6Z6HH86saspA3gA+p/GmaYipIBvBAb5lYdOelTXke20dgxIzwfqe9c+IfuWt/XloXSdpGcMKxI5+bJ/KpeWycBSy5DdKVURoSVG1g2WH+e1NLiSFlxz0FeY3c6yYOcsiZwvRqvr/qCrjDBQMnuazombJGMFWwR6mtQkGJ2Y8ZAAPsKhtiY+yi+Xdk56YoqTTs7SXY49utFTdra33ol2fQtXkw2EM/J6+1VsDygM9T2qCZzIBz1xVjaY1QEcAcms47anTe5WuvmIwMc45NNOY1HBG3g4PU0r4Mznt2yaRnYqCDjB55o1tYkazbiRtxT8YXnO44x3/KmKp2s6j5j/nNPhTzGLBiNvfHert2BskwqAEYyR26UKgCM7MFbHUd/alKjaxGORzioWAIUZyoOcios/iBqxbhmDAD07Yq3ChYLgANnOP6VQgTad0vTPY84rR3/ALpDCc4PfjAok7qw0rFt3UxPnGBxz3qO1TeN2AvBwPUVGF+ZlfO0jNSQbYiqD6gegpxi7afIcmhmxVQYGAxyR0IqjcRLkuVJ47nNW7lgJArZOM//AKqqTzKAUweDSd7q+4mtDOuXMdu6lcZBwOtcXrB2Wz4yCSF4HXNdsYxc3Dx7gQqkBgP51zV3ADDEZU+ZSSE9SO9dmEkoSVzGotCjBbLZ2sMJQtI65YA4wa19ChjZ2CDBA+ZT3ogga5iWbAba21yR61q+HEV5pPkCkNzgcmutzlrfqZwSsrHUaCXggEXlh4yclWHQ+o9K6+MWj2ykxAOB97ODn+RrnrNRgBBgjg1uWtt5q4fI9ga4aspSTitDtjTitStNsc4DKE6YNRkRqSW+6O3rWv8A2Ski4IGOxqJtCdyAD34xzSUeaK1B2TKK3LByQOAeBT4ZZXl/eA7ScgZ4rVg8OFXG5sA9DV620SNTtkJznoO1V7OwnJEFrhwAQSD371q28ILDYMZ6H3q9YaZEirsJPsRV9beMHgFTnORW0KUdmzFz7IpxwsW3nBzzjFXA6opyCPcGpGXaCUyPSolTeRuPA7Y6GtY00thXvqI94IwcKW+lU5dSbO0LhvfirU0K9Bwp68dartaIOq84qY0ru7Y0422EgvXZdp6evSiS9CgrGQpbqzHOKhuAYUw20k+ncVlyvHycnf0AAzmnbW1wsnrY0bm9JwkTFif4u1ZF3cEGTklx1Ldqt2vKu7hm28cnFYmp3MauoX+I9/b2ocVbTVslXG72nkQIOQfm9607Z1RmKct191rI0nLyPJGM7QPx9qtxqQzbed3zZq4xtp3FLV2J55HkGQQeTwOprInjzbuzH7uSM960LkmCNCDz94YqK22y2zB8ksuVPqe9aQ6mcrHDeLYTKhYRAAHcB+HNccswaIgKEIG0V6NqwP2MqAMqxAJHtXmV2WiunUk5PPToapRfT8yHZKxj3zsXDg5AIJFVrlzFMskTkH7ysOCpq9fx7cMuR7jt7VSPlzQtHKCrdVPv6VvHls29kZOTRo21+t5gTCNLr+90ST6+h9+/eq96gXf8oz6EfzrDJaM/uyAQcMDWla3okiEdxIo28K+MlQex9RVSocqvHoONS75WUZpWj4xge1TaeTKCzkrF0yTwPpU0qx7/AJlzKP4T90j1B9KhZizAPwOwUcU4yurW1FZp3uLcM5QfLlUByGHUetVbFCt2COM4xW55IKeUQCdu0flk1DPZi3ljJGAWChT1+7VQqRSat5epFnfcJl2bzn7rZrqvD7L9tjicrtlG1ST6g1yl6x86dcclAcfhW9oQMtikzjBifrj8f8ahrRS/r0Kbua80bRlopGUeeChY/wALg45/HH51m3StJF5rDZcRkqf9l14IP681p3+2WBnAJckEr2wRjNZ9vIrXIL4ZZDl8eowCfrjBqVJ8/L1DoKJSlzHHwYJBuPqGrUVY5IJYnJPmnn6Y6isZ0ZDhsHZNn6gitESfu125xnApS20KRUktpYVG48qxAkHIZe1EaqxJQbXzgp6e4q66kxjZkKB8rdj6iq8YBKbR8wPJHUf59a8epGzsjrjK61I4WD3aBeCSMmtadUWG2V+juzn2FZ1tEpkU78NuyQen51fvM+bEvQeXxz6ms01ZhIntZVjDlzgZwD60VAqnYuWA9c0VjVjHmEm+hGseJATzzg+1X5ASpxxgYqNCHm3bSMdv8asSKAXGD83XB6U3ZHQrmcMJwwzn09KhKgyjLE5OMZxxV2aAiP1x6VXij5Z0XIHt0ov1ZLB2KIF9/u4wacrCKPCjJ75psKtJOcrjjuakVPnwSCTxk9DT0SbGh8aO0G7Ock5z2pERUG2YYY8EirhQrEB/Dnj8KQwIw8xjuweM1nbV6hYQwpwnRetTgbUYrgZIOPaoHBjAyM5HXNKjESKARtYd+4rT3U7K71Bl1V53A8beBTEbMwAH3eKLdg6LyeCV9/xpyLtRmxyCefU0naMrBrYhnUeac8Z71nyYw7Nlh6irr/PnedufT0qhccRvgk9s+tK/NvuMh0xf3TuemT1rA1x2bVDICQFXGMeo7Vr30wtNOVdxLOML+Nc/qUheeJy24Ooz9QK7aF2+b+v68zGVrGp4Pulju4be4ZfJlYxMT24+U/mK3tLtGtNTu4pByG/PPIxXC2xIkwDg5Dg+hB7V31heC9+z3BOJCNsmOxH9K6Jq+lxU1Z3OktMYHA46it6xckDaOvY1z1mrZ+Uj/Gt20DBQwrkkn1Ou6N21ZCBuGMdquI5yDWVE5IXnB9TVyGXDjPHbmoilexLdtTRLoyjGcc8U9G6EZ9veqgkAbjAx37VLFIpXnjHf1rSOn3kvY1bZ9uc9On4/WpGk6bfxBqhA24nJ4xwwp7ShVyRyBito3RLSZcMo3HoaGbCg5BI9O9UWkz0OT160qyYxuHX3zXQrXM2iYyknK/l6UM5K4zjntVfeSxKnDZ/OhnaNSQAR3BGaW2qGQ3WRyfmB45Pasl3Idsnao9K055FkUqUG7HJBxWZLHl8k4PX61jKDmtS07bjFd1h/dk8jGeuawXhaS4Znw/XPtzXT+UChAyF6gisC6xE44IH3Tj61u1YmOty9oyKltcKTtIbn6VZBwhU9eAMVSs3MeoSpu/1i5A9DjpUjOQCO4x1P6U3dq7I5VsQ62CEJXoowPpVe1kD2UZB4X5Tx2qa/+azzg/cOc1k6PcZLRNjKncAe4q9XJ3ZL+G5WvY96TxjqwwPYivNtdhbzdyghwc7fX1r0y5IDSgnCk7cjn3FcNrKEyyOyjapyxHp61cWrK/8Awxi3Zs5WduSGHyv17flWZcR7JMk5B6Vo3W070mHyZyGHVSe/0NVxllK8OR054P0960pt6OX9ehnLXYyrxSxDgdeenSqZARgTxkVsT2zhf3QLL6HqKotHxymMdQRXQpL4ehm0RxTYHlSF9nUH0NWLOF3ulVzhc59iKYgJAVlBA6L3re0bT5JyZEyQoClccrRJKKbitQXmXNMtd0hmkj4VcCqOr3GbhActIrBmI7c8AV1NyFs7YxRpulJ4XHAArir5m82UyHHcH2rCK1T0sO+5ZvoR/aLjICGHJPvxWv4OZXikX5trHGDWXqDZkjLsCuMDHXkVc8Hylbq4XcGAyRntWqlddrEmyqulpJGAMoCoP0Oce/ArJjYtdRE5USLx7Ht/WtzUsQ2hlycbt4CnnIrnS5Cy7eqOGU/XkVjPmvfoaRWhtT4lCMQPmXbjHQjgj+tMsDmzcN/DzjPSliImtxh1BULIhJ9eoP49KihcwTTRkfeJbae1EYqTfN/X9f1sGvQtFwYwi8BiGGO1RBzHJvC8jqPQ9KZc8QDadwxjI7ZPFNVy9smSzMMhvX2/SvNrQcm1bU6Y9ySFgztu4Kjgg/rVyTcZgsnzKVBB9MCqlpCD5oDHcEA9AatNwAzHB4X5e1cySuXdkxkHyhkGMUVHKxTnAz0OelFSmlpy/mHvdC9ahBcNu+6RnPvVgDIyufmP61QiDM7Bjhc54rQh4RV6gnrXNzWZ03I3cZK/hTggRTk/eODUssfIIHOfWo5P3aA8lgTmlG27B+ZHDDsyexHy5pltGdzkADHI96sSEi1Vu3WktyVhcEkcYq3rGyF5DlIEeCDndnJpZBmzyDjLdu4oODGAeucGljy0KKV5VsNg9Km1nZD6DZ1yhYHC9d3rVcblIGBg8KfQ1eZd9vIMcAcCoIGUxEsuSpPPvTm43s+hJNafJnkctnHarD/MDnj0wapK/wAyvkANTn3gN8wbb/L0qeV7tjGYBZgeueP8Kz7/ACq7BnaW5NaqRhgzdQPesfXmMSRq/A5xjuauyukncV+pz+qzqZpWAbbEvA96zLR1uLXBwZEOSvtU9+7fYXUj5m5H+FULOGVE3JkFsZ/rXp0orktcwm9bIlXPnByBkdhXV+GCS+3OFODkdq5XIFwu3BXvjvXWeGUy/pnrU1bpJx3Kp2bOztgQwx0HpWzZF8EEkAHg1lW2EILLkEVr2L7gOcemBWDjzHWjXhQ4DbsnPQ1NlmJ+917D9KijIK8D8c805NwPJJI96ErtkNWLMajGdwxnn61YiUjjP596qBxsOccjrUsMnIBIzTVrITZpoQR8pPHP/wCun/KxwxyTzmqKSkAYPWnrKPb29a6IaLUhp9C2I+QVII9KkVFGVwRiqqPgHLHB7jqKnicA7WfOe4rXmIauTLGuwjHWom5IXrgfSphgk54HY0xmRWyV49arTqJIoygKo3Z+lVpio24BDHpxxV93U5BGe4ApmwPDjH1qFd6stsppKWT5s+nFZOqQ5XeqdB83vWpg7ivp+tRyw+bHhicHpitJRfUSaRgmXBjlB+eI4J9PQ/Tsa0LjEkayqMHALL6VTvLOeKRio3KeoFVBeSW+1JUbaMhZAOCv91h/XtWd3Euylqi9I25MA8DnFc1clrO+EkXVDlcHqD2/nWwL2NypDAdiCc8VQ1VAsYY4KkZzitOa9tDFrluULu6EqO0Z5bgj09D+Fcrqpdp2aPIYjkDuR3rXkXdhoSrH2rNuYklIw5WTsV6itkopanNJ32OfdEuCUljMbjjIHH0+lU59KKElJBLF1BQ5ZK6KfTVvVBuNwkXqyqVz781ClvFbSAM6yMvIIfkflT5lF2vb8jJ6nOtazrkh1bn76ng0RlpGxcx7ieMkda6qJ9OyZJ5GEqnG5vl69jjrVk2ltIoMOpRDcMjODg+hz/OnZxjb+v6/ML33OXisochmUIR37mtWC7gtoVEIxjnPc0SafLcyMILlXC87cgY9qpPp7wOyPA80vdFHanKLvzf0/wDhybpaMJdQdlJ+UDPzMxJP4Vi6hPb3W4Tq8FztKh0GVkHqR2Pv3rTuEmxt2jOOMjGK5yeJ0uHkklQDpjriqgo7x0YnfU1tQtWMdmEYMcDn8Km8OQyR3s+RjGAWxwM981BdyRrFbMjOxyBx0NWLKfa8iAlRtPHuCKTau7lpaG/rsscemExnc6KN2eimufuGHyMT1wD+H/6607wvcSTxKBjYgA9eB0rG1KVGSOJAV2/Mx9+lQ3vcpaG3pLeYssTAbQnP0NPIVxD3uI8oGzw69gff3qPRtjq8gAEyx7CD39Pxp9wDGDlNowGAI6g0cy7iv2Ii2VkR8qAec9uf8amiVo4GccEHFR7/AD7eV8hpEAII5Lr059xTIpgYnVcjPRTxzXHVhdm8ZPYu27/vjIoGG7H+VT3RCzgKSCFJIPeqNo4hYkKWjOMdzmh7lTcu6kncTwR0NcjgoydjS9y7Jgr83r60VEG3DG3kUVpFRtqxGuUyuVzgc+tXIyPIUEY+nQVBHjczKdpB6evtUsoZU3DG3qAK83Xov6udnW5MyZYPk5yKJdoG0nIJ/E01pcoFPoDmnx/MCCvOcg0ct9eoIidAsICg7f5GiAfI+OSvOT3qRlzGM9GNLbqSW3A4K8ZrTllslqLQjdf3TMODnOKdH0lC8sDk89sVJCQ1syqfn6AkVC67HSVehxu+tQ21LTQNLEiShsjOBjpUMKFhggAt0Jp6qqygp8yk5Ax2qO6dUO1crnofei7vt/XmAsAQqqsdxBzU7ghnzggkdRVRpSjR4POMdO3ep4ZeGL5IA28fzpOLu5P+v6+4S7EhTap8vOexFY2uus8ccaAEI25xjpxWpOVRS2Tgciudld5Lxdp5fJx6jtW0LkysY+qKkYROT+HSs+V36KflzzjvVzVrkibbg/Lw1ZBlV5BJEzhB8pBP869OjTbjfoc9Rq+hY5idS5yp5BxyK67waxkkdTg7Tnr61wz3eXEbEbRxu7iuv+H7MdTkiY9Yifbg06lN2uwpzV7I75SeAeoq9Yy/PgcD171UCYPJqLcY5twHyjrXCtXsd52cBUoD/Fio5yFwSSP6VW0ucSAYOePWpbphtyTg+tXdxVrbEvcmVi6kHjPrUsM2Bgnn1xVW1y0eWGQeuPSpfKYk8k/StdtejM9HoXUcPkn8KcJgflUiq8S+X1/H3pkhzJwv/wBaqinG66CdmaiSggMetW43HB6j8sVjwuwPf6GrqSYjBBzzj8KtX00E0XnkAXrn1HpVaa4OSAePSqVzcFOCeO1Vftny7eMe9Xa240upqxnIIYDnpS8kccY4yD1qlDKX9fercWRg4JpxTabQnqSPEGj5zn1oiQ7GxjNTwRE8449PSp1tyAOxNWkQ3bQzngB5C881RurBHVtyDBrokhOcNx/WoZbQFSvQH1pyTYlI4W80zbINifj61kX6PGpBxtBx9K9BuLQrJwM56Vj6npwYNtUc9RVJaEt6nml1qE9qzBVjIPYLyfcGsv8At++CuqfLu/uqOa6jXdEmG54E3EfNj3rjr62lRyzB42PVcd6bjfWxk09jJv8AXtQdsStuI4O7PNZ73klwqjzCsn9xep+nr9K0p7N5FG9G+rGq/wDZUgYfut69gpBq7RWljKXdEVrBIxLl969wTz+RqO7kdPupIF9qs3FvMrKZIWZe25uRUXkylSWlkRAMjjpW0U+XTp+X9f1oZddSmsrsSRGUcnHzHAo8274G8rj0JGKspNC2U8x2kOQDjr6Chbi1UgPbylxwSx+Yfh3xV2diblRnkkDC5klmY9Rnis2eI+XI6jC5G4KM7frWze3BjAZ4EiUjKle/uK565vGDHyCVOc7h/nke1SoyvdDvZWZsXYxaW0g5UNggDgVcgKx38kIzkqzBvfINIQs2lxiEBGfDNH1APTj2PFRMnlarGwyCeSo7ccisbe7eRon5nQq4uL2SVCPNRMuo6EAfe/x/Oufu2WaTKLgksTj61fimMN0ZFPIG04OOMd6ppCHuMgqqKN2TwM+lRCUtNen9fkU0kzS0WTcGG4L5gAORmtKWSSZRA43Jg8d1IyDj9KxNKdUSJ84zLjFa0hPmgg4ZW/OqVr8omjKsHeLUEjU/K5wMeh9KlEmJG3diR9feo71GhlVwMIzZyP4WpEy03Jx8+8Z7EVjOMpRSZpF2ZoQSbXyD8oUH8D0pQuZFEagKTyfSqkL7rYqD82ccj9Kt2x+cxsBkLkg1xVISu1/X3Gqa6FtS/liUbST8pzxRTZpGWIKu0nPORRWFov4lr6FK50MAEqEjIXrn1q3NtijXcPlNZtpLtt2wfmPr0FQySt52ZCQowACelcer0Osu3CZU7eh5AqawG5MsTlSMZqo8ioM7uD0pYLjCttHBNUm1ohbmiCIwVkGOcjPalt1ZnG3aeTVOKUzRurEMffpUtg7MGAIBA/yKOZ3EFwrQS4Xv2z0NQ2zNJgS5UE1rXUKXKCRMggDd7H1qsbcsCo69dw9amyb16D9CNY9gKscFe/rVU7WY46DnPvU93zAJX6/ccD19faoEiLKWUnB/i7VbcXq3/X+QitKu6TAOQpDZ7Zqxbq6SbnP3xkqelWYI0ijkLKM4HX+dSySKpTC/Kc546U20txWZk37tjySCFPDd8e9ZgVftJkJ+VeBj0rSuXHlzTbhnPyjPWsm4doLaUEgO/QnsKIpvYT3OZ1uXdcSP2Y1jwuQxOTgcn3rQv/3jPu64x7VlMQSSeua92glycrOOre+gyRklkI2hR2x2rufhXufX3Q8qsDHJ9civPnHmPtDDbmvUPhDZvHcXM8rEB4wFDdwT1rbEcqpP0/Qyo3c0egzny2BqvcRCSLd3HpU14E80AuMAc81YtUQqRnJb0614kGz15NWINIuCrlD26Vt3JDKgOTn3rImtvs5EgIA6k9xU73SNCST93muhLm0Rm2bdioKgFvy9K07eJTgseO3vWHo90jgDdnAzn61rwzbJDk9efrTcHGxne7sX/s6c8ZH04qnLbDdxxzV8Tq8JAbp71VeUMx5+UdM1vHQnUz5iY5AQTgdc09J+AF71UvZ1L47mprEq4U8ZB4qklpd7jvoMnR5ZAOcdqdDaHduxxjpXQW2nRyqGLZ/Hoaum2WJcHGDjin7pPP0MOGIIvQ46g1biRi4CDPqO9aAS3UgNjqeB0NPgNurlV+8B0bg0ejuHN5EtpGCm4fTA71dVcjhe3INJbGBwVU7XxnYeDVnYu3Ibn0NaxtbczepTkTacgcZ6VE534wDnNaRRCAGcZB59arTJHggOpweoolZ2bEmZ88AK5/HFZzRAlgQDj2rUcYcgYZT39KZsycFQD2OKlJ2Kuc5fWSbcEHOc/SsDUtGiuFIkRT9R/Ku9eHcAGH41QurRSQVB45x1p81thbnlOo+HRCoC8qT37VzV/pzQHhSK9pvrNWXBU4+ma5TVtKVoHXHGOtVGrF+RMoM8nuJTECH3bAeeckfhWdeFSpMbO0eMsp6gdj7j3rp9YsCkzhh84P5iufnt2ABjOChJGD0B6itYq73OdqxQjhhA2RRsHPc9x6VDd3f7sFGCspw2ereh/pT7pHKHbIFxywX+YrPnjWRhJgljlZD6ns3+e9Wp8yu3cjlSRG2oGVWhlYybjuUkYw3f8DWeBJO2AuMnG0ipzGMkgBj/AFq1HHuuUbgMxzV6RVxKLehqq/ktA4xuUYIIyD2qe+XN7DKM/MAr89+oaomxLBGSR98j6d6W4JVYJSchiynI4Nc8pKztrqaxWoqSFjcgfeCr26U3IlAii+4Bjnqx7k1KgVfMkDfu5QFb1UY7+2e9RafG+xy2N0f3h3PNRbmu0P4dySyIjskUj5vNxk9j0rbVlOHfOwqQ3sayXjK3qx4B3bmA9zz/AEq7YsWilRyMMc8jlfepkuW8kF77hOpfbHkFwOCejD0NUTGRM7KGVUOMH+H61cvY3SQxPwQOCO/ofpSEmRw+dswUE+jr6/UfrRe3X+rDTtqR2bKzoOqMRkdMVdmbZl+MoSv1FUbfaDwuFznGKv3B325yucLwe45/wrkm2m+Zs1jqhksjNs3hxxgMozn60VaWIGOI7dyle/BB9KKwlV9m+X9V+qLSTRdRgFAXHXPNOOJbj2HQ+9NRQ6Dpv68ilRW84KMEjnjvXnpK+h0oS7wo2g5PYUsTeXb47nnJ7VLIoeMcYPX3xTNnmzBRxjkj1p2XUF3Q5HMcZxkMaksr5kY7gpY8YHU1XuEfcVQ4C8Clt4vKdSSGc9/Q0uW+oNnWabdL5q+Yu0kY5pTJA07rH90H5QKwDNI7KR1HPX9aQXDx7pM8njIOOKGnGPN1ZTa6G24ieSVFAKvyRVKOEL+6zwvQCobacJJmQ7smrRU+eCgypOc+lOMbtLr/AF/SJEVR58idtpwap3RMcRIfnPTPQVZmndJgEUck8nnNVbg5UZUep9atx53f+v67BfoUZFIO11wn3s1ga3NvmIQnaeg9K6TUhHEjNvAXHfrXKXBHlzznjccKD3HrXVRpNWbMpSMW9IjQqTlj29qzHULEMDtnmrs6vJMxIG0KNtM+zNczLDbjMrcKOnSvWprkVmcs3cg0eGE3X2m+B+xxZLf7Z7L+Ndh4L1J55r64VdoLAiJDjYOwrkdRdcJa2x/0SPnr95+5rR8EXS2uuRRuf3FwDE+Tgc9P1p1qftoO3bT+vMzpy5JXO0m1+5hkZ2tnK9nB4/GrGneIZ5GDvGMg9Ub9cVdls4+QAB6+v41lXWmRb90J2Pnkr6159JaKy19Dsk2zoJ/EsDALIW+bpxxVKTXUZvLJAz6965W9s7pQVVt/cqTWa0ki5DB+npW8fkhI9K0zVGV/lYnPQV1mnal53DEkCvF9M1SSA/OHx0+au+0DUBJFvQ8H9Kya11X9f1+OhopXO/S8BBG7J7VRutQMOSG+Xoc1Xh/eKSG/eHmqepWxeMsDg/xDOK1hS5glKxUutZAlEiHBH3gfSnnXRGxkRsEc4Bri9TM8E2cFh2bvWdNqeEAYnAOaag9n95PN2PSY/HDWiKkW5yOpJ4B/rUU/xAm5MjcA/KO5rzB9QDLkEhj6evvSGeSTaBjmm6UdmvzE5dj0lfHUkq5K9SerdantfHasNqrKg6YY5ANecRWzSgb3IAP0rWtLSFCCoGRwSeppxo9yeZM9CXxSxCvE6IQeO/4e1alr4pncYkuU3D2PNed28QZwzYKZx9K2bRo2AWFfu8EmtFh7q7FznZHxLes+Uj8xew2nBpF128Dq726lxz94g/5/Ssi3mG1UAB2917VoRSKUIYkn3oWHtuJ1PI17bXZpWG63cZOCr9voR1rdtbv7QPmG0+naubt549oGfmHrWvp0y8Z6etV7JLRshzuuxsJjIxTHjGwnHzGnqy47U4lXxkUpQuhxZmz25dAcfMOc4rA1W23ISy44z05rrXGBuHT0HSsm+XfG+R1rBu2q2NkeVa9YrJEzLgunP1FcPd24y4UYzyR0INeq6zbqFOOucYArz/U4E84DaduCeDzW6k3sYzjd3OPvFaPOVA5OG7fSsic85UEBhnFdLqaMiECZV44D/desC6UqwLx7c85Xoa0g1s2ZO62KibW3DbtlAyuOje31/nUInztduMc8dqWQrnKt8w5BqEjczsOSRmtIK4rtbHRwxKbF2PO0Z+uR1/CmzJjRbRyWJMjDH4VJJmPRxJjLZXjpxjP9atrbE+FoHIO1bklT0JyOKiStzXYo7pmXKzxXToGKlMLx7itbR1S5WXOA8sAYr7jIOKx45RNcSlxuXdyvT9a3dBiijezmyXgSRonDcEKSCQffBJ/Cs422ZTehFeL5lvBIvEtsQGYH16H8xTDIYndyv3sOOPWrN3B9m1CWJ2/jaFm/MD9QPzqFB50IiUD5OAD6k/dz6envQouavf8Apg3Z2LkrpNH5DYQ4+UnseoxVOIYk2sML7jGD71DuBQl8llOMHrkVdiUTwK27JXof769wff0rOSfxSCLIH3RTlNuD29DVyA7oUDcgjaD3FQyQ7vmzlkwpP8qnA2bcDgnnFclWydzVbEtrkZUueM+9FCrNHeSBMYAHDDgZ5orN3i7D16GotsMK0fXHT+tOhQ+cS2d3WripgDaMELx7moT95ifu45xXl6r1O9WGwxL9pUrkrjn0p8US/asg8gcA8U2E5kG3Ixk46U85OTtIOcj1puSaF5sjki3O+MDrVKZvJG4gbj7VooRtfAPPPWm3UOVGVB9RVKUvtCa7FFLthjgE/WmNKxPAC+woW3d5GWNQcHn/AOvWlaWuyLey5YdaltfMSjcgt43BJbP0rTt5gqZBwQcc9xVIsA+QC3U4x+lPndVfG04cZGPpS30XUaXYmLbpMs3ByfpVMFSwDEhcdatZyowc/Lx/hWRfTtGrYI+XJreMbNWX9fmJlfWbpPLIwOnB/pWBMzTyDeRsbpj07VHf3JklQ5OCOQKdFKofpwoJOO1d6TUVcwauU50LTSlV4zhRSXedJsRIW23NwCoA5Kp3qbT900u9zw2Tn0A64rF1u6N1dFgxZV4GfQV1Uo8zUGYTlbVFRDuBI6DoKms5THfWzg7dsqH/AMeFEMf7hOgLHNPdBHNEMfxDJ9K77q5zdD2m9U+axVlC+5xmqDgHIMkJ+jZH0rR1KEyWsMgXI2AkZ9hXJX+qWFnK0U8TFv4gq5zXjU5Wk4L+tT0pfCpGjcpEAd0qH6GsS+MC52uvr61Wudd0/BMUMjZ7EYrHu9ZeVtsEITtnrzXdCk5O97fL/Mxc7F6WdckoR75rpvBt4WEsQyHU7sHjg/zrhEjubjdvdsduK7bwtbvAUyd0gG0N/eFZ1qagtzSErs76wuCjDJyPrWlKVlTemeOorJsbKedVAG059a3rXR5wgJbiim+YdRJHI6vaKSSVBxmuN1a2GMADB68V6xqejMEztJ461w2r6ZIrE7eDXXF2+Rg+5wsoaJjj9avWsi7l+6SezHpWtcWKJBnZmVvXoBXMXlvPZkuJFZic8jNRU1Wuw4vSyOvsxGwG+KYA905rctLa2bAKXg/7Z5rzjTtbEbhblZYjnhozkflXU2N/HcEFdTfH+8QR+dEI8mhLaep2kGnxtgRQ3JP/AFzPNTppV0F/d2s4HT7uKyLXysZ/tibDAY+fH171qQO0IJXU2ZhlcJORj8ziuiMopXf5/wDAM7v+v+HLEdrdRHDQS5+lWA5Tljj1BNZtzq9rgGTV5JCeCocHn8KoJOJ5cWqysD/FtJrNTu7L+vwLSdtTqYrgv91hz61uaX5nGc+vvzWNoelzttZwSPVhXZWdj5ajjikvisxvTYuQHcAe1WujAj8ajSLavHTtxT2OFwcA1nO1hwQOufr2FZWpDaCOeO9aDSEKR3rN1CX92ysOcVz1eaKSRvDV3OS13ABO3PfFeba5IYrmTrtf94h9x1FekaycRSEn7w7duK848QgFnjY4ZSDn0PrTg/dFNXehz+tBXjOMc8jFc7KhVQEOR710N0xIVZBggdugrFniYMeeh61rd819zCyRnXVqTCWwMgdqpWyYjZ8ZA7ZrfeVY7dgwByOvSqFhH/ozOB99wijuSa1pSutUZyV2jb1OJodOt4iQd8JJHcFSOPyNSygp4eijDHB2yDnpzirNz/pFpNggyW1xgfQgA/4065jX7NdWyc+VDtUnjoc/0pSkmmrb/wDDij08jnbJQ0s/ZhjI7GtzRiY1mjMYPmEZXPGeRj/69ZmhKJreRmGWDmMEnHHUZ/xrThiaGMLKeQ7HHcYOeKlrld290MuaxGLnUZMgB5UEqjPLNtww+vy5H0rJGXidskEjLY7HP+T+NaGoPumt3iJ3BflJ9c5H6/zpLeJftckIx/pG14z2OR0/PI+tKTuuV7BZ7ozwwmheVV/fq37weoPGfzqzagSwuEYr1IPp6Cq9sskFxJIinABz6FT1BqS3IaTMfyrJyuT/AJ71Ek5arf8Arv8A0uoJdzVjYSGBzj94nlSADkEcg/nSFDGu5sMdpBAqKIuXRlIyxDD2Ydv51dJEu1thCsCT7H1qakXPb+uo78rIpm4En3gQoI7jjj+tFOY7IkKckErwM575orglJX97+vwNoqyskdDE2CML05FMZAQzAcntTsHarLwe4qBjgsM8gV5s7N6Hd0HpgSHPBHQ0inLEKcc9KhD/AD4bjOORU5O2eRUHYHPrVK8bdReQhIUyKfrx2p10MJnPG3kZ602MBpOMjPGMUk4JjC5zzg0aKWwdBqRgRq2c89M/pVkSEw7W6/3h3qhPwqIoKMOOtNtpHQfPnaMkk9aUbA2W3TgseDTWUmP5vvKO9SSPvAPQ9T7iq80hxkHqMDI4ptq4lYeCVjPrgfjXP66wRyNzfNW4WBOGIC7cEnoK5rxFIIzGueVPBbrj0rakk5JWIbstTn7wmLIzls8N7UiSslq7g43Dbn61FdFxM8UgxvPQ9M1GSFt3V8/KRxXrRheKuYSlqWJZnggPlEBQgReOnrWBKrO5kOAueea0btyYYiDhSN3NZU53Se3vXbRj1sctWV9C9zsRuBjio53JjL5OSPxqQSYgUnkjtURk+U8cEVo7LWxPme7WrGbw3YSlSWa3Rjj/AHRXn+p6RcXV4wWMg92bsK9J8HIJPCGlkjI+zL3p97ZgkqAAp5BryJTUask11Z6cKftKa+R5RNo+144wp+UfM3pmp4tKjiLOEBOeD6e9drdWZ3YAyCewqjLakE4xn6da2VWUiJUlE5wWrZJ6HINdZ4RsXlkLBeF4FVYrFnPrzXpXhLSRbWisykMeWz61nJ6PyLhC8kbOg6SWjQlee9dbb6YqqMjiodKRVjGM9ea37fCrhgue2a3od5Gda+xhXeko68qSetcRr+gKHOE3DPAr1oIpXkY+lZmoWCzjbtyeua6WuxjF6nz34l0WeNMxKcjn/wCtXD3dk7yEtkMD0PrX0tq2iq+SV578Vwmu+E45N7xoMjngUm4NaoEmjxSSyKFy0ZD54PbFW7WzS44kwRwR712kugSo20rlAcciiLw8G5CY5+lVGXK1ZhKnzbI5AaPa3LhQpXaApIOCG7/0NU4dAjRiJWbIYBl3Yznv/WvR7LwlI0jE5Knkf1rp9D8FI00byoGYccjOR71Srq9mJ4eV73MLwtpNtFEsKbAB12oCxr0zRNKgjUeUmSeu4da2tI8O21rGuyBFI6HbW6tpHHjaB6ACqe2glGKMy3swpB2DI9B0qwYcDgcdwau7fLYlxkdOOoqMkNyp4/pU83VD5bopMABtyKrS/fOOvrV2ZRggYP1qlMSM8jFYTld6FpWKkz8kDI9ayNRmGxhnoOprRugQgI/IVhakf3bEcE8c1jLVGsTn9af5N38OM49q8+1s+a7EH5mfr7V3esnFtNn+Fscd8Vxt9A3nBTjKID+dOLT3FNaHO+UzXTZySB0ArJv0AuQqg7fTNdW0Ijvpcg42cD0NYsyQSX+35kbnnOa2gutjnb1sYOpW0s2ETOAeQK1LbT1tjaqG5h+YH1c1pJp4jm8x/mijUyMy/p+tUbt2RIzn94X3Ee9VGVob/wBbEOPMS2Evy3znkB9xJ7k7sc/WpVO8IwfO+AjGPzqhb/8AIAvmH3mlQA56Dk/zrVtEjltww+XAYnHpjrUpva+gmjI0WLy4ZIguWXlvQluxrQv2AeFJCQDExVvTBxg/40zw3GRc34IADEMc/wAW05H6UuqxyR29i+OqMM/8COaucnyp6k7Mgbc+mh0JLRkZ9Rg8n8jVskLbiXCtEuGzj+8eR7YPNR6LMksT2zrwTvA7DPyn8D6URzTabMsIVZIJ1KSROMo/bB9COPes2lH+v1KV/uJJ+UlMR+d3LsncDv8AXnn8azrJlBUE8A5B9M/0q08glQtbSNtD4HmEF0Yfwn/HuKzA2yZypMbxvgjsDnpiklf4dQVjeh+SWeFBnaTIo9Rjn/GpbRiigrkoc7ge2etVxK0d5HK3yNgNkdMEYNXI0XLKpxlTjnr6UpKK9PUaukTWzKrkMrDjnAzRUEbbTjaWXGQM80Vy8kOr/L/5JDfNfQ6BW3IpAOPQGo926Ukd/wCdJEc249G9Kicnzs54PGB2rxr9/wCux6lxHwVyRg9qmZVISYsR0/KonA3YOMentU8YBtyrYIH+RVPp/X5k2JYUxICOeMYpJYyF4OdxB9BUkXyxKzcH0PrSTgZDdF7+nWhPe60DcqPEXlJztIPUdqEiZNrcEE5NWJARI+45yePy607y8Rr2J65PWiGstNv+HFJIrsp3c8gHqfSqt3IETapG4nOfpV5oxIcDGefoKz3iBcs2SufwFGjdrCa00IJHeWH5SAoOSawtRjEqzSEk9cM3XNbNySw4XaD29aytUK/Zjgc9Fram/e0JaOb1A/u0LL5hxuI6HPqD2qO6+eJRGd5lwcH19aku+jyOflAwD61Rlkf+z4WBOeQPwr2KSdlbuctV2ZHdygpGWGflwB7g1ns25gcfhUtwQYY8np0psKozDcMDuc16C9045NsnZvlCkEZHJqMk+W4znA7Ur/O/yE564PWh1KxueVJ5+tJJ2Q3pofRvgmPb4W0lcDAt0GPwrcmtd6j5ev61W8EW7f8ACOaUrg7ltk4x7V10FiJMcYx614db3q0rq2r1PaoO1OPojj5NHJUnGGP6VTbRyGyVHrmvRzpy7Sc5HQ1Vkshk8YHvWaui7pnE2mlrGyu457ccV1OmSKUVF65qpqpEScACjwfMtzfOhOSgptupLll0FaycjuLKFjGmCSetaixsmM88fnU2nwJgDHOK0Xg/d8CvVpU0onBUqO5lxuy+4+tTLg9Tz3NTNBtzjFQ7thAOc+taR00ZDdxk1srgnbye+aw77SwzD5enFdA0y7Qen9ajYrJkEDipnKGwRuji5tBjZvug8+nakg8PRhySn6V2RhBGVHepYIAD05rJRa0N+fQ5i30BVyQhBPp2rUsdPWD5QMHoK34rdQeenanPAuSRw2e1bqnoZuq3oVEUIABn05psuGIHKtVxlwOOcDvUDowGSPeq3IvqVmj2jJPPSo2+Ukj8c1YkU8nPHbFQ7CD8xODUPTYadytMDtzjJrObClgR71qNnacd+9UpVJJJArJxsUn0Mi6Y7D15NYWpYCHccEMPyzXR3a9c8fzFYV7EXU7v4h+VQmuhpE5zWY0aEEH5TLjnjnNctq0Bjv5ByclV+lddeDfAInOCJSfw7Vh6tFuu2Z8cjJH0ohJ9t2JmBqMAR2lwAyjHFeb32o+V4kK5/dj5evevSvFUyWti7KAcLxnr071443+n6gqqmyZn3B853DPQ+/vXRGPM+VnK58quj0lpQtgGyA8wB+q9qw9YTy2AGRtTJ9iapPqvnXbx8pGmERfbpVjU5DMxcYXgO3pWc1aXKttP1Li09QtlJ0G8x/C64IHP+ea2LBimmmWPbuSNgCR1yBwazLIYs5Vc4zEXHpwRV1y8Hh9VJCu43D1+UZ/WpU37zRMktkWNIKkx3MYwrj5lzkqP649aTVVZbKZSv7y2DOefXkGjSm22QIwEGVYD1znpU06tc31zFIwCXNqEz/tAYrWWjs/07GduqMGyJiuGIBUNGW454IyR/WtN1afy5HAdZhux2Djj9cCqdsjCDTmaP98sZibPqAatWGTD5ROAqjZjoM1MpJ6f1oVFGRteK9kaM5jkPP17ZFOvB5vmSf8ALQ43cdfc+4p0wMdzuVurMA3uD39s1YgjEsjYUYYHeufu8dqaqO146fd+QrWZM+Gt7aYjBMKhh/tAn+lWoJBsMnB2gDHoDVcxEadaj+NR5bk+uSfywabC4Qc8ANg96zmmpWel/wCv60KRYIBbBfyyOVbPUHtRUMhV42K/MPMOABxjFFc/JJ/Ck1/XmVa51mMQrgdO1U7oZkVsnFSW82YcnOCOhNTOhmi/d4Bx1NePfeSPS30ImClN+Rux2p1sw8xc8g8HFNhXd+7bqOn1qWOPDj07Hvmk7tpMES/fj68g8UrPtDk+oqOfg7lJxj8KMMUGMEkcjtTUfP8AQTaJJGDkMvTrj2pkzq67Rnbj8ajZh9nAQDngY7VEhy4VumcZ9apbe6yWWSFWAsJAcnBHeqkvyxoCwGewPanyP8rBQfWqssokjYkEFv4hyce1JNSev/DAytdMu3Ct05JNc5eymcs7NiMZ6da0NSuAPl3ZXPT1rCvJwVPYDqRXbRp2ZnJ6GTqErONi846ei1BE6/ZXjaTdtO7AHQHrUNxJvcknAJ4AohZVORGc9OvWvchDlhax58p3kK6N5ZA7dKQJ5agHlj2zVuGIR/vDycEBT2H9agmUB9wHXgUKV3ZE2srkW4g8nntilkyzMoOScKM+9OKqpLNz7A1a0aJLvVrOELjfNGpB/wB4VSTk07Eu59ZeFrYW+nWURLHy4UX34UV09shBJI5PSsjTFUhFzgLgDHeuitFBxjkGvGjaVRy9f6uewvdgh/lZHOPU1RvkVAevPOa1XYMpBGMenesrUlJiZRg5FU4qzYk3c5K4tpNS1JbWPoxy5H8I7mtPTvDkeh6ussEryRyqVIY5GQe1T6JstZJp3XEjfy9KuCfN7beZ6l8Z9aiSVCMV1f8AX9eY5Sblpsddpx/dr3+tbEa7kGORWHp0mCCemK3LedQu3jivTwrTVjhxF7kMwHQ1l3SHnuO1aV1mRzt5xzVadSM9sjINa1Va7FTVzlry9Nsx38in2WoC4G5Omfypmu2ZMbNnGT+dc5ortDMyu2V3dc15Ur3u9DuUEkd9A+7GD9KuwlgBxyDxWbYEtED19a2IWXO3K4I6V2UtWc03YmU8Hd0NKCdnIGacpAHAyKYSOnb+VdS03Mb3DAbvioHQqMDpUxXbnHeopn6Z/SiSuNPXQrSZUcgcelRvyMY5zVhju6gD0NQttOPX1rOSsUio4BJIOQKqzgFWwMGrsqqpwB17etVLgquAeMde9ZydkWvIyrtW25HWsW4BYuCMZ9e1bt5ls4wM9/SsKc4JGM59axe2hcUc/rCGIicDdyCw/rWNfYE7OOmMYP1rptTw8MijrtI647VxdzJm2j3tzj5scketFPV2Jlscb4+udsGxWxvO0Z9O9efadttY5r9idykrEPU+p9q7rxZJBLcQxSO5ywAQKCWz0+lcTqLw58qBcQo21Qeeh5rqhe7RyNXVyGxlkaYzSHc/LE474robhSF2kjBVE+uB1rA08bjOwxhl2gjsD1rpIEEkwWQARJyzDtgcUq+upVNX1Zo6damaRotqmIw/Nnt9PrTfEMojSJowTCoOM/xKBjirqS/Y7VZNm1WhJAB4IPQj+dZ1/wDLokAckmP92T6gnOazs0/dYXu7suacqIrIgO1QGTPIK44P40k0gLWsjEqikws3bJ5B/QiotDlWbRSjlvMtkxx3jJOCD7Nx9CKht23pcwMSY5CBz0BbBB/PI/Gruu+39f18xFpVAklJKqV3Y3cZfsP51mWJaMQxSAggEc9+eKuaiPtNvbeXxMrYcZzv2j/0LH54rPhmMUZBUFMcKx6YJ5HoazTdk29Cla467VWaUkYzJnIHTv8A5+lS2gZpo1Xlg4C4Prx/jStGXuDIpzEQucdVPuPen6arLKzryEXgj17VpTTXuyRLa3RenUTBmU4wdpU8HIXBxWYhCSESDcSRg+9aCuGKFmyNzFsjrxwazzEJniwx8xmXpSmne7/D8BX6DJ4ZXZdoAQjP40VZLrLdyjllHHH5UUU1Fx+Ffh+ruU/U2Y2ZUiCn68frWhBKuQc47NWbAOcqSV6jFJLNtc7DwK+bd7np3NkRKz5UnGQODzU5KptU4PoawLe6m8wMD9a0f7TD/KYxhRyTTv3HdMnmOWKrng/nSIuxcH7o+YHoRUCX6szLjBAqyjiZGGO/IPuKjkv8guiszgOeTuXGQOlMYsqDbuKtyGx+lKVYRvIowQ3A+nFVxcNbFmbBRvuj0ppNqzQr6jr+cW0K7Tk9D7VlS3Hko4DEOeKdeOZZwdvB+bFY+oSKPNXdjjIzW9OF9CJNlaYm6unRWYonLMRVbxPHHZxW9tE+WZd0jentVnSACFVRncwLH6Vk69P9o1Sc4zg4Ga9OhG9VR6IwqytG5lhATubO3+tTQoZJmPp+VQJlic9T09qmlcQxeWmenUV6krpWOFau7HyurHEZOxOh/pTPtKr94ZFV0kCLlc5ppaNscMPxqeS2hTqXRcQo/wAyAcfnW74QjSXxLpgeMBTcICcd88Vz0QAI2NjrW74XkMXiLSd7E/6THx+NJxcp3QJqx9T6exEnzdc101q2AMk8Vx1nKd46EZ6j0rp7OVWHJ7cGvEhdatHry2NdRkZJ4rI12UrHsTG5jzjt71sW8bSodgOzvVG/szFemWT54MbXU9VHqPWrry0sjOm1zamTE5ji3vyyjjPauYfW862ELH7pP1rptaKRwsQTgc/L6V4h4o1j+zdZiu2J8pJPnHqh4P6fyqFBua1OqNpJux73Y63EIhhuMda0o/EEKoMyADHWvFmv5I1ysu5CNysDwwPTFSQ37ttDOckgCu6j7Q5J04Hu9nrcEjfeGffvVq5vreSIEMOnGK8Ztnlwg+0EljjCnAFM1jWr7S5oDDOrIzFXjkPIHYjH8q3dVuNrp/19x51PFYWdX2cJ6/11PSdcuUkt35wFU96z9O00tZxS7cFuea5TSL668RXCQKCsRI8x+gOOwr1JLcRQIgGFCiuf2Tlecj0Kk1C0UMsFKxqcHGK0IwDhl571DGRgE5x0FTb1TgdPSumnFrQ5pvUsLgrxwaXcuCM5I61B5vGRwc80xmPB6etdCMiYSAcE+1RyEdcA8cZqIsRnAyKQuFwP0pNpFWB3O445A/PFRl+cYpTIMZz14xVaWX5Tnmpe+pSGXD9+4PSqNw4JySWGMinyyHcVzk1QklKk4Bx71i9tTVaDJ85+U8HvWLdsBIQMHjqK0JZ8A8ce9Y13IDvck45NYSunqX6mdqNyqxsehxjJ71w15JsR3PT0Pc1uapcfeGc+o9q5PV5WYbVOP61tR91czMKumhxmqXBF405bLCRQgPr/APWrnZIWALtkLguAe+TW9qhRDEmwSSO2V3djms67hLtcecdz52gjpx1qqb+z/X9dzKSKVsjsh24A4rqYY90kifNhCpb/AGj6fWsWyVQ6Y5U8ACuhuG+wQOxG93cMxPbjgfWokm9HsNXXqWzIlzby2+44tmIAHYd8ewJ/nVW/Rzp8sA+ZtrEY/iAGePwzWfo14INSQOSFlGxgOnzetT3k5tLjKBiEPC98g4P44omrvmX4BG8dOxD4euBY6gm5t1vLEInGOGU55/kavJDGksLRnmMlZkznC54YHuv8qp30CQskkIxGr4U/wlTyPpzkYqRZXUW1wjFZYxy3oen+HFVzc3n/AF/X5CtYtQlpY5FDAEtyemGByrZ/Ss7ViSizKu3dGdydMPn/AD9KtTEhhJHhRMgkMY6K2On0POKh1R1Jt16q0PP+1/8AXFJpt6ajQtk26UPGcCSEfnipzIYEWErskdQz46Zx0B7VW0gKk2JASigSKR3GKe7l2eQcu/z8+vtSulLmF0sW1DMYZIzkbl3Dphu9QyAQOGD9S0ak8Ee4qSwJaUYIxt6k9Kg1xWdIXiO7BIz2H1rVRfLo9yW9StYzLHAGkjYsSQVJ755NFUb/APfSRmNtsezqT3+tFYyoym+ZO3zKU7aNfgd2ieXEQR/3zUSRZfLAn39acjEgjnn3p7vtUE544Ga+fbd9D03sREKoOV2j+YqMzlRgKOmRxTZ5TnuPr3qHO/G4kD1FUkLzHRkl1UYyTW3algQuRwB+NZdoPMn3KPkUfSrkc224CgZA/Wja1xpaFu2Utb7WboxH05rHm5ujE7ncAcZ71rWblkYHGQ5HXkiqWqxk3CSIcOrAg+vsfaizk7klC4iMV86fwqgAP1rl7tGmu0QdGBGc9cV091ITc5XkMgPHYg8iuZ1KQx6okgG0b8YHqa6cLF83KRJ6DNHk8qCVgRlVIxiufkYvLI+eck1uSlbe4ubccEcgVh7eCvTn1r1cMlKTk+tjmq3skRFuSR0PNQyMWfJPH86lmIXIBqADJGTzXbHXU5G3sOx8vA47U0fextzirqxBosqPmHNQlDk4XnpipU020U4O1xYAWfc3A9KsW12YLuCVWKmORX6ejA0zhIiPw+tW/DnhzU/EmqJp+j2zXFzICQOiqPVj2FNPmdybW0PqDTJWnZDEC7MNwCjOQea9E8P6I5jVrsnJwdg6Cqvgnwwmg6PYxSHzbhYESSbuWAAOPauwj2RxcV5SpRjJ63Vz0ZVm4pIXyViTaBxj8qzL9RPGyk4IGCamutSVTt6e+awtb1eK3t22uMkc1pVjDlIpxnc47x3fx2Nqy7sAdTjp9a8Nh0+bxtrbxQbhYQH95J/ePpXR/EzX5tRvP7NsCz3Ehw2Owr0r4V+FodO8PRxmPa7jc5PUn1ow0b3nLbodVSahFRW55nNotxYFba2lYRxjaik5Cit23smhtYwF3hACZT1Ld673U/DyyamihGwzDIA610t14fgbS2hjjXzAMqPXHalzylCfKcWNbdCSju07HkltOIHySBxn8aranajVJUaXnY3OPWuputIhZ2PlbScjp6dj6Go00+WScJFEzO2Au0ZLH6VxU5pqx8lRSTujuPANlGdLtp1RF+UggDgEHnFdm0YZRkZxWbo1p/Z2l2tvgBo0G/Bz83etAThR7V7cNYpM+lXNypvcikXa2Oo60xnC5P60ss4PPVQarSyLtyDwetU4uOxad9yUSDdkYGfWmtJySCRgYqosw3EZPNJJKgXAPFPm2ZVraFoToRk/yphlLEdgecmqZnDH5SMdOaa1xgHf93rTutykizI+Fz371RlkG85PGemaimmY8k4A5qtLMNuO+e9ZuV7XLSsOlfa+Qw5rNnmYsRkBaWe5G/rzVC5cg8E81nJN7lrQLmTC43HFc9rN5siZRgbuKuXtwQPvHOOnvXH65ebjgEgZ5z3rBxcnpuXLRakNzMpIL8g9VzzXL+JNQjhhaQ9GGBjvV28uiVIz14JPYVw+vXbXTMg5RPuj09a21laKOZ6sh8xrvVLRdmNxVwOvA5Ofwp2qLI3zKf8AW5K57KTmp9NgaIx3THG1CnXk45P4YqLxJdiNWS3T59kfbgbgeKtt6Rj0/X/gGV7u7NHS7RFtkkAGVJ8s4+7kdT61HrN6J5rhSu1UwsZPY+p+tWNG3ixgiQ5Y4Yjv05rGuCZZLp+mWPFYya5rX2NIRsri6TE4meSXcBE2Sfw/xqxrVwXt4Zkxkn9etOgJg09RkkvuZvcdKgv0Y2UMQOQwJRvXHI/rV8zk9kKGmpoQziS2hxyvlgMp6EHP8sVBFny54ySygfKT3BNV7Fx9njJGQpweO3/66tA+VLcEkYQIvvj/AOtSk0pXd0hLYXS5A0DmQAnY6evI5GPzNU7hiYWRjyqLIPxGCRUtg6iGYk4JlypHvTWjAjiYnkfJj2zSUlzWvrsLYnspdlxPyc8Lz7Dmp9heLC8FecD071Vmb90+0ndjax98Y/UVc0+TMSEnLqAKE29StEtSyMxDIGG2E/jWbG26xkiYnOcMR71ddmSNWbdnAJHseKq28UjWd15SgkuBz9D/APWrTnTTT/rUztrcpxeVboIHw+Ru55AxxiigRBlAb7y8ZzRUSqK+t/6+Y+ZrRHZxgKNwzz2NMlfkjHfrjoKfKFCqM5bHT1qrvLsOSDjJr5zqmeoxSm8gucgelQPGzttACqD61YlyWGzrjikdioIIwxPp1prREsbHIYwQmQT1OKsWDFmZyOKpyM7FVGM8dBVmGUDCqRjufeh7XGXWBgcOOA/P0NSyRm4t8YAJHX0pkfzgLlcHr/jVjy9kQBA46H196ly0s/vBXOdmBjnRyW2n738j/SsLXLcmZ8JiQc+ldTqUQjlQsPvnPH5f/XrH1Rj9oieYYDbY2zz8w4NddGVmn1M5bWZz9/8AvVS5Xk5wx+orGxl8cjJzXSGDyl1KyYgsgLKPbqK57blvl7DNerhpRenQ5qtyhL15OOaWNQxGDzin3A+YnrSqpBUjO09q7o6rQ5La3LMEm3g5zinAKzEjOT2qeGFZFJwBgcGtXwp4bvvEut2+maTGzyzH5nI4jXux9hXMmnK3U3kmlqO8J+E9T8Va0mmaTF5kmA0kpHyQr/eY/wBK+wPhv4D07wboy2liN074M9y4+aV/X6e1T/D7wXp/hDRI7Gyj/eH5p5j9+RvUmusBCKR+YqZT5lyp6fn/AMAcY29RZwqRBRz7VQup8R9cHFOuJ8LtDc9M1QeNiC7Nx/OlGDbsbKNlqYOpah5Bbzsq/VcjtXlvjnxWtvH5UDbrmU7UQckk12HxS1WDTNFlkbBmP3F7k+lfOVveSS6qL24kO4NlSeQvt9K55JOXLfRHZTfu81tT1/4ceFY/ssmqas6NczfNub8elem+HdWso5ktllUqDtXmvHbTV5J4fs0UgVJhmIE4Abuh/ofpWQNSntrz5GkjmVsYJ5UjrV1FJT5ui0SCnShK/O9WfSmpSwpcrJuTjpir8LpKnmmRAmMszHAAxyT7V89L4j1W4txMsxb92eO4wcVR1rxdqOmfDbxLNcXTN56DTrbPd5shhn2iWQ/XbV04SUtVozKvShCndS2PUfAnxA8J/EvUrq10+G+ivrWIzOJotm+MMFyGUkH7y8HB56cV32m2On6aDJaQLFIV27iSSR9TXzb+z9NH4P8ACL6vMqm61qc7Mj7tvDldw+rtIP8AtmK9jsfGFlfuBI+zJ+UE9frVSpxU3yLU4aeGTXtHH59TsJp/4gcD2NUnvhHnkVmzalEULROpHTg8VnPfJLwWBOOlawT3ZexvtfAnqMHnGaia8DbgG56VgC7OSM/T1pwuAyk8DNOcmt0CSubJuiADkf40xroHByfSsb7X0G4gn9aZJdYC4/OktHuXa5r/AGgFsdvY4pr3G0Z7d81ki4PPOOeCaR5wobnJzk5p3e6CyNF5lOe30qtPOOR3NZ0lwACcgVVNzvz8x/HtSTSVyy28wJyOvaqFxdEZOT16f41WuLrAPNZVxeZXk81Mm4j3F1O7ARyGIbvXHX9wZS3JBzmrup3wZ2XnHU+9c5qFyqQFjwzdMVldJakSbvoVddvfJjEKHBauYjUyyjHLk8E9F9zUtxK93dvIx56AVMQLWMDoxGSfU0e0ur9SOW2xcv5QlmAu0DaU6d+MY9utZE6/aLu0ViSZCN3sq9KdK8kkSgEZHA/Hg5/SrFvELnVMgkAOIxgZwAOT/Oto919xk1Y1LAOl1IzDYQjSsBzgY4FYqttQ5zkrg47mt9SqR3U4AUMcZ6/L2rF0vbLqgSVCU2lto7Y5rBJt27lXtFk1wpjjCEElVCjB9+1RXnz2sSrn5G3R/h1X/PerV5G2HZiwJHBPIrN1V/JihKE7lwePXNCcXJW6j2RLEFS0kbnB4H4ipyCUlPRmjFMv0xbRKvAIWQDsQRSyZ8og9eD+QptxbBXSuMtz5dgm8Nh2z+vNSTq7eYoOQZAV+nFPuF/cQKF52synHXIpYMTRNhc4UH8MVT0fN03JHz7EucsMRvnOewNGn5iyokQEcFm7j1FJdgPpzOB8yEE47A8c/jxUNquU7dOKHJrV/j6f8OLfY2JVR0mO7IK/IR2IqnOgjt4SCyMxOfb+6asRgrBDkjHJ/DHf8KoaqrieNZAVTbt64De1KTS22HbuUFuip3SLyeqkdDRU9sQC4kjEy55yMkGitXXtpr99ibnZygxxdue/tVOTKAdMkYPrir7qGYlR8vpVT5XnTnIH3s181G56b7CIBGA+47jyaU4kb+6D/FRIMnauMnp7U5EZT3UL1FHqDIJUCuPLb1y3QmomOGwThfT19quSL5i7uPTHpTrSBZJTkZGKakrCsSWW6XmNSQOORWvBIBbESt86nH+faqseOEX5AD0U4FJdbsBw+QeDntUa3Kt1IdXUCy37xhDuC9eO4rn9Zj8zTTMR80bCVePvDv8AyrXvH320qS8hhnj2qtOnnWNqGAWORPLIHr2/Gt4Ss7+ZEl9xzuvAwaxDcx5KTRDLeuR0rn3XZIwyNvIrptRxceHo9wzPbKVLD/ZasG7ALI3GGGc16uGelu2hzTX3mVMuX2k4x7VJCu4DgZqSWB5SBEATnj5sfzrsPAvgHXvF92ItIs8xKcSXcvywp68/xH2Feg3daHLazMTRrO4vpktLSFp72ZgkUSjJYn+lfX3wg+HsHgrRFWULNqtwoa5mx3/uj0Ap/wAMvhXpXghBKpN7qzj97dyDn6KP4RXo8cPXA5xWVr3S69TS+iv0Idu1eMH+tUbxyvPGK1JIiF6c1lXtrNIcKKn2b6GlNq92UkIkO4nn0qtrl9Fp9i80jAKoyavC3e3xvQ5x2rzvx34Y8YeLLlYNOW30+wQ58yeQ5f8AAdqmrJwXLFe8/wADePK3zN6I8j8davJruotJIT5KHEa+1cRcQGMlkJ9xX0Pb/BOaSOM6prcUZx8y28PGfYtV+P4FaC6gTajqjsB94Mq/piualQlFtI0eJp9T5rs724nU2yo7HPG08CtSXS9YKi4klHmA7hk5J+vrXoXjv4R6l4MVtZ8OXcmq2MKlp4HjCzxr3YAcOo745HvXI6frMd5ZyZbD/exnqMZ4rrg6WzWp10ZRqRumZmlXWti5MNlZT3UxDOEhQu2MZY7R271m/FGe5uI/C/heCBlvin2ueHbhjPcFRGhHtGsZHp5hr0Pwnq1nHr1pJM3kxOxgd1bayxuCjEH12sa8+8B6N4lPxLl1nUWWV9Dvit9qOqvI8ayoduCwO95BjKqDnIBPANbQUfsu5xZhzJqCW56Nd20kV9baPpNos9rp8SWMEm8KJPLGC3PTc25v+BVl3djrlrfiy/s67FyT5jhRncnsehHbir/iLXNMj1OVdLE6W6kbFlIZsdzx2745+pqtc+LJ3s0tba6kdP4FB4Ueo/nWv7taPe/9I7VQUYLUn0nV9QEjxGNnkJx5RyMH0zWskmqRvvuEKRngqpyQfwrF0u5uJuGbdISNzN0J9RXW2QzEFcnA469TVuMWtDzay5Xe463u7hApdiw9ParwvjtwRiq0yLt+U/8A1qoTSFW2jpWLSk3c5rm2LoFhk9KkN0CcdvrzmuaF4VY5OAO1KNQBZVLDJ6A1Lp9F0NFK50clzwNp9qh+0HGd34VjPdbsYbBHNRvedSTg9KlpbWLV+jNRrhSQeuKrXFycnqPasuW9AINZ93qQXcd2c9qGuZDvY0b28ATO4cVz17qBGcMcfrVO8vWdizHpWNeXQIy5+WsJ1LWY9Sa6vUT52OSCcVzt7dSTlgM4HAFPcyXkh2A7O/tWh9hS2tY1bly3zH3rKTt7zHZLbcZZ6esC7pCGkAGcc4OM1nXKte3W23I+UZKnqfcetbgPlRSMf4gcfXFc8F2xFudoQ5bOCD65pQfPLmv+Zm9EVrdy73ESqdxXKn3Brbts6daGV1H2i4IXBOcL7+5qv4ctRcXbSTEssQLkn+I9h+dT6gRNLhFJcMckcZPrXRJNGaSe5JduY7Hy1AwX+UewH/16g0aMR6lNIMt+63Bsdm4/SrFzlljHVY4DKxHX5iOKk0SInSbxyOXYBG/mKldX1/pBd7Db3AVQwGC3ygfnWJqY3ynaOdwUDrnmty52yXsBGSUBJHb2rIwWKyMh3FieO3rUU7N8/wDX9PuVJW0FvGMwt404dfk5755H86mgYf2h5UnIHy5PTPSkto1eWR2B2/6zHp7fWo4eL7Jz8p3ZNVdKStroSouxo3tvthh2A4jG36DtUMAEa4OQG+XPqK2ZP+PVpWXKMvHr9axr3ItgQeQev0NVKPMtO/8AX9fMSu2JG2FKjkYCkH0zg/0NMt28m5BYLsBOTmrCfOkcoXBZ9pwe+P69ahZQVnZU3FMbl9j0P0qXFJ7/ANegK5oI6mPDEEoSfTr2rPnbeku7sxBDHOD6fTpUMdwImwRu5/SnuyL5hwPLIw3rjsaXK38Wo9FqGmArE0m0Ek4P9KKfGqxxxxuwU7dxx6misq0LzfX8SotI7SHdv/eLgEY696rGDaZCoGT0rQwSoBGR34qCJMBgxJB/GvH5eVXO/wAilDGHdnxggZqcR5jGePXHaho2RTjLZPX/AOtUybcgN8vpUPWzJILaPfJh/XgDoKv2cYEchAGfp1qEx4B7ev0qxZuMFFPzdBx1p8txroRuP3Z5AbvVdXwrDOQeo61duVUgjb7YPrWa2VB54IPbn6Ut0n0YNofKsbRsgXjIGc8j2qhJERp7oDkwzf1qcTFniHIUHPrToFDpeRgZ3cnPr61pHToS9TEnjEd9cwYylxGWXHqRzXK3ClYkyM7flbNdjqzhVsJsjIfYT0wDxk1gT25eaeMKztk4UDJz2A969DCyb6GdRaGv8MPBTeNvEq2khZNOtwJruQcHb2UH1P8AKvs7w7Y2umWEVlYwR29vEoVI0UAACvOfg74V/wCEY8JQxzKPt91ie5b0JH3foBXpVoTwseSO5rsqVryVKO0e3f8A4BjGHu8z6mum0kHPSphJHHhnYVSSKQjJJp/2RQNzct3zVqU+iMmo9WTNewgdC/0FVZJXmfCKEX1705lRGBHWmArkH0obm95DXLHVIkWHactnHqasrEu2qglCjAb9aGvFQffwfTFaxhGBEnKRdKpkZAP1pqYBzyfwrHuNXjiU5bJHvVX+3omJAccfr/hVKtBdQVKTRq6sAYiwwCBxXyZ8TvCf/CP+IpLnTU2adfMzxIowI3/ijHp1yB6GvpW71RrpWSP8a47xhoya5oNzZMQsjDdDIR9yUcqf6H2Nc1ZKfvwOrDt0tGfPdtFFM2WTY5Xkds/StjxHq2pa3Os97dbwCcRRAKgJ5Zgo43E5JPUnrWRueJyLhNkqEqwPBUjg5+lQf2rGkrIbdiM5yGqfbLZnb7TXzRfhthLEjM3zrxmr1nYJCFZ4wQD+VZltrsEZKrbNuznJIOaJddmmkGy2+XPrzXX7S+i3OWrUm9TrLR4oQWBzn/PFaC6ghACsR2riINREjAMGiY/3uh+hq0GlPKHI9qWstEczf8x151EHkHI6Hmq8l8rcZ9Tgc1z6zOMBuPpSh8kHJHekrp2fQnQ1ZJu3H1qAyKWByC69CeoqkZG6Ag+xppuMfKWxk9MU1OVrvoNI0Wu9pxyMDGailvew/PNZjzA9/pg1AzkHnJqZVGnZ9S+helvDj39fes6a4JOe5qORiGJ5yBWXd3wGUi+Zj1rCdV9DRRuSXl0sQyWJ5+6OtUI45L2Ub8hM9KW2tjM+6Tkk9617WERvGvAGdvPasnNNtyLtbRElpapAVwMAe3ei+SMFAJBw2TkcZPrVpHKDIJ68Co5WaRs5UknkMo5FRKo+vT/ISiZ15EzRQgAkANuzzkGsMwtNKExgY2kelb98GKHyFI9SO1Uo4pHljDKVkZgMkZ5pw6RXoS1pcvabb/Z9NwA2Hfg1Dc4e4dYwBDDGCGx1bOOa1tcuIdOsY4YwDISBjHO0f/XzWXECR5CDYUG+UnGBnsffFb1EnKVtl/X4GME1qyCQOLaQbDk7UTPGQOo/PmtARLaaRaxxNuBO/gdecUhgkm82ZBtEjKIsn/VoM44981JfRbQIo8usICkA/dH/AOs0a9tf8/6/4cE9TPEZe7n2gESKIwfQ9aiugpEjAY4yRjGSed39KvSopXyt+12OMjoo9ahnLSTt5SbiF2k9h6n6YqqSvHVfn6ik+qK2msotppOuRtY47Y5/mKy4w4uWTHzZwT7CtqW2FtptnD90TSM77epUdDWbBhDLOSHUAgHPLEnAomraBFrc2redGs/LfAWTlee4PAH1qrNGjzBZF25GOvfrg1TvJi8kca7dsQEaDHp3rXSOSaGGSMK8mf3m3ru7nHvVtK3Kv+HJSZALIpG3zK1uzKyPu/ixjB9MVQvi1puMbESNuHuBmtV5BEzKEDI4O6Psx6/pWTrwBSK4jbeioMkehHf39fzrDW5RlhuvOMkE1fHzypEQc7jkew61kKxW5A4O3qK2CrLMjp958Dnse9bzSjG4k7jbptxw2cg9qKkvbWV5wsIJbbk4FFOlCMop/wBfiRKSTszvkfCqACPaol6OOPWpJIxHLgDmot+yRtw5xzx27V83DR3PV9RzbcRgjGTkGmS7VcADPPHNI/zKCB8uckD0pwUlTgYI6H2pPVXDVD4n3cDhcdfWml/LkJUfjimowAYHgtxjsKTY4PJyM9PWpSsDZaEplhyn3hziqk+CchcAnHFN5U55U5z1xk+lPXEoHTf3GeaFZbgyrMMAlGyVGc/Wn2LkBzgZYdajKsS4PT0z0qaxAUMT98njPpWl9CLMx9VXfpvGSUk3fka7H4R+Fv7U8RNq13H/AKHaHIBHEkhHH5daxLHS5tZmXTrcEyzTEA4+6M8n6Cvf/D+k2+jaPbafYKFihXbnuT3P1rsoydOLk9+n+fy/P0IceZ8vQ2YpN8yRqcZPNdbp8aRooA6evrXK6dag3AbP3a6e3chfWu7BpRv3ZniXfRF4uBxj8RUMsvX+dNEhPXpUUldz2uclrEMzgckjPaqNzeonU4/pUeovJHuIBPHWuM1fUJFc/NgHtXJWrKmdVGh7Q37rWFTJVxx+lZN1r4VflJJ9Sa4241UecyySAN2GetU7nUmfJKSKgGMleK5/aytsdn1ZR3NrUddeRzVW0vnlm3M5C1hSXKSMQu/J4xtPWqUWotdzCG1IKKf3jjofYU7Xs0ikmro9W025Qx8HP9avzBHTAx0rhdMvjCqpltvQV1FpdholJOM12xldWRwVYtO54/8AE/SRba+bpQFivBvPtIOG/MYNcD9mVWbkc17X8S7QXWkNIATJAwlUjr6Efl/KvI5IcOPl5zmuaUldwZvCWiZVigw/Qda044MDAAz1FQRqGAUfeIzj0q5a/dySTg8e1dNNaamdR32JPsonB8xRkUW0csLAA5QcjnpV1HHHH1FPXyw+AeK0lFXuun9f1cxW1ixDbCRASBk8/WkeyYEkdMZINWonHA2596tDBXJJPtmk3pYm1jGa14Oagki+XpwPWteYgZJAz1xjisu7ZVBLEAeueKlySbWwRKLKBncCRVW7uIrfJkY8jj3NVNR1YDKQcnuxrEdmlk3OxJPNckpXuonRGD6k95eyXJ2qCqH0plvG2cgAc+lOjty2MEjtWpa223BOMe/as3tqbXSCCLeQACcD86vxREoQUHPfPSnRvGjbVBc/7IqzGJX6Kqqp6tWXK2rMjcjWEKpJDYHep7exdvnW3KDghn9PatSyWDYzFlYjkY6Ut7eRpG7YO9hwAetXOKSvYlanPapdJBtWMc/7XrWbotxJea1BHKxEAfLbRgYHuaj1QPI5LptzwQeBVnSbbZbXMxyMr5akccnr+lXTqWlzS6EyjpZFGWc6rr9/ebHaMNlARwFHAx9f61padZeWm2YkyzEh888t159hV6zszFAGz5cTtjleij+dRaxMLOBYlAMrdfXnsfw61upuCsYWTI4ZRPrC2kXzQQKHO7jgcZP44xUEcgmv5NhxvkLg57L3/SrGlBWs/OVFDy5QnHJVep/UVTsNqQ6jcMfkWPyoR0JLHGfpjPNaOPM7sIuysVLucfZvNAVWldlbHTC9/wAc1Y0+GXyGUDlmXqexzWXcgnTbHIJbzJE9cqGGa6PSV22cszn5lbag98Y/kaILTUmTKupRALbglQUXcO+Fz0rBkUFIyxwoPm4IwPb9a2bmXzGV3A29Se21eg/Gsq+ZTGFwqTSoHHPy47fSp5nFNLS5Vr6MqRk+aRIBvb5s/wA8VrwSNFdxMrgKWGfesS0kIkUTgtH1wByPcVt+WgjR3IJ3AAg9RSldNP8Ar/g+g90XL4LeTYhIF0rF9v8AfX296wL2T7PLNuGY0AUgj8s1qsygERDBC55HP4Vk37/abNmb5pYdqPnuM8E/hWlLRsl3RnGL/SUZeBJ93PpXWQWZubln28Id59zjGP0rnNIhNzfuDwUXcD/d9q7reunaQqqv76YYye3HSs8Q29v63sUt7ma9yto25SBLJ15+6PSioLlA2WYA5bt645orWDhyrmWvqRd9PyOrvRINrouc81CXB2krxj8jVnzMxhWHOetMARoiQp3Drmvnbxbuj1NSBh+7cKeMHBFPidtoLYqOV/3nXr7cCgSjBTOWB4NRfTzFbXUYdwlbsAM4/nV+EqykDr1561SkJblWHIx7U2OUoSgOexzx1qk7vTUSLcq/uiVAIx0PSs+Z0KsFXawP8NakJBgxuGOnNVbpCpwAN2Kck5K9g2KMEzBQH/eDr05qYbzDvKHcThdvJP4d6UQrEoMh255yo6CvQ/AXhcXDx6pexkQqc2sbjBJ/vn+lbUKftLt6Jb/1/X4ESlZWNf4a+Gf7IsBeXyYv5xyD/wAswegFdvGfmx3/AJ1G+FUAnJ/rToASQfzq3aUtdFsiorlRsWK8jIGcVtww8ADqawYpNkiAZzXT2Y3RgmvTwttjjrtrUaYyAAOppjoCCCOauMuT14phQdxmuxK2xzcxQa0LjhsD2rn/ABB4Q/tC3f7LOsNx1UsMrmuqkXBG3igMPX2qJQjNWaNIVZRd4s+e/FngDxGmo211HprXQSRWb7MwYHB+oNXbyy1G2tolbTbxRu+YeUT+de9ADn8jTtmRjc2KydFyVjdYySd2fPWnawbSMmVGjkJLHepUj25FcjcTR2OtyeQy/ZrsmZcdAx5Zfz5H1r6ruLOG4GJ445AeodAc1yXiL4f+HNZXZeaXErj5lkgzGyn1BFZSw8r8y6G9PGRas4nj9nKThx1zW/ZXQwozTPEvg248MxefbztdaYDhmZf3kWem7HVff86xbaRkcjdnPeiLa0XQc3CpqjY8QzxSWUkchBRkbP5V5FcIQwDAjtkDv612+sTyyERFuMZNcjeoQzcHFQ1eV3uc82o2SKYjLYYEE9c5qaMcccMe1c54luJbOxZ7eRkkzhWXjFYtl4p1SIfPJHMP+mi8/mK3pxktY7C9otpHo8WQwOAxxjGKnKZCjGDXFW3i+X5fNtE9PkYir3/CVw8E2suSOmQRWk6vSQKL6HYwMFwWbGKseeFXgj1rhZfFWT+7tuf9ps1TudZvLoYaTYh/hTgVjOq4bFqmnudXqeswwEqGDyf3Qf51zl9ey3ZOX2p/dFUo8sQOTk81bgjJAyMg81xylzOz3N4pLVFURZxuBx9KtQW+GA4yTV2O2JGcYFW4YQvI55pNq2g79irFEAB03ZwBWjbWW4j7QAc/w54FSW0QJ3tnK8JU9zKLaMb2G49scmm/dSbsRvoQSyx2yFfl/CqSTTXkwWPcEHGF6n8abIpkl8y4GCcDYO1a9rAtrarI6gMw+TPBA/ve9EEpNN/1/wAEmTtsTQRssQQEeSo+b39hTbt4rNWkB3sBlQR1NMe4eKASSbiScAY7e1ZN27tKMsd7n5R6fhXROpo+hCiiGNZb24D3DsEDcR/xGtlVQNHHKSsCfM4HU+wqpZRMhbyhtBGWbrxnn8asKm9SoPOcsT/KojayaW/qS3rZj7vUDMWSIYgjAx/n6Vhawk921vDAVDSkBz35OAfpgVoXJ2l0QEBRz75q5plssTG+uB84hWCJD3AHLf0rpjZ/L/MylpsQXax2tvNDbH93bRqqt3z3P49ax7iRRpS7dxSa4XjoQFQkj8zV++YLbiORsmdzvb0H+cVh6vI0R0qAD5GSWR1/2nbaP0FNPmlZ/wBXC2hPaxpNpFhctgCGScY7EN0/lV5pXXR7aKQKJZ8ykgYwPuiq1hGv9kQ2yNuKMGwf7wyCf1qfXZ1glgmPzbIFQIOnBJyB71q5Jp206EWd9SlcNGPNiYk4HCd/T8q5+6la6uo4wNqhQiMT19qfDcPHLNK2WkxtHs3XJrOmEm6GfYc5ztH8LA8ilSWvvajbX2S1bv5Sxl93XH0ramIKxISSFAI4qmYykZdlDPvY49uoP61bWRfssMo7R5GPXpj9ayktX3+8pSTK9zK4ZGB/dKTux1z2NVBchXBG1ixALY4br1qzrLFbWNwSqO2cAY7VnwRlxEnUrNhcDGcjpRCP9f1/wwN/M6zwzp6Qz3ExBMEjjbnrgfwmp9bmLXDDIDKd57jHYYrR0+B7HRpInIG0jYx6FjzwawjJ5t1IzncZQST6BflxSmrL7hRI4b1RAM8hSV4GcE8/1orPiUu5eNgofnPTpxj+VFNqD1d/6+RPPy6HoNxmNXCnIPeqqSZVhk59KW0uiX8ib5sd/Sl2AbgOSelfPJu9l6/1oerchKuyDGAQM561K1sHi3KQJFIz9KISQhBwR6+ppVcFZEDYPpnqaUUnuLdEv2copYHcMZyKjMakmRhznB461Ms+IFGeo5FM3xFGxuG7tTvrzdA0sIx8uIgOTuPFLNjChecjnB5zUSSx7yhGNnfrit/wr4dl17UDGMizTBlYdh6D61tTp8ztFkSdkX/AfhR9ZvFvbv5dPhYcH/lqR2+gr1xFUEBMBFG1QPSn2trFa2cdvbqscSDCqBjApWAXgDpxiuuSSSjBaL+r/MyT6sgcZOAOf0qSBOSRk46+9Cphef19KkjGCMdTWckaLuXbVPMcHoB0retZXCgEVkWUXQk+9btvDhFx0rvwtNpXRz1pImEmOTnmmNL74pki4yMmqF5I0K55z7DNdjnvcwUE9i8zbu/I6c0wuBn6Vy9z4ghjYqz4I6jPSoY/Edu5H7wfTNZrEU2jT6rU7HXLNt7jn1qT7Vt4P0rkTrceQRIp54xUjaqpXcHHA5rRVItLUzdGSeqOrNwD6fh3phmRvvcf1rkzrSrgFvwpv9tqvIYHI49qaqLcFSaNjxM8R02WGVQyOjKyn0I5r51t5JFk8sEkKxUeuM4r0/xN4hVbGU7s7lOBnmvNtJjU4Ln/AGs+tYRiqtSTe2h0R9yFhZQSrFvvDjHesa+t8glVNbF0+0M2T83IGayJbhppCkK5GPmbHArnjKzdtVdmE9WcB41YLbFc4BOAfeuSiQE45+tdn47t/KtbdGOZGkyOOT61zFvAzEDHFdFNuEXd9SlHmasiS2iJXJ+lWhEcdOnQ1ZtbY8DnFX0s2IwF6DOa53UO2MUlqZKw4Ixx7irUMLcED2rWi01s54xV6DTQMHAz2FZuTeo3YpW9sTgMvINacNoFwSMHqAKtxWexc45J7dKuQ2/HAzVKDa11M2+5USAdOAp7VIYPkGDknt7Ve8gYBIxnrUNz80ywxffHLNj7o9KIprXqNroJGmxAUXLZwT6CsyQPcXAKfN1AyfvHtWheZWPyYRyVO8k9BSWdviHKEZzgHb096mzb1F5IksrVFmIG2RYx80jDoe4onIeWSWf7qYG09celWH/dQFMAbeevU1TjtWupP3mTHnv/ABe9UoK1xbFFjLd3ZkjbKLkZPQewq7p2kvcFSFJbdt5PWuhttIKWLy7NsYAIAXqTXUfYodL8PqxCg53I3U5HbB5z3qJ1VTba1f8AmZTltFHDeILZLGCPDjcSVXHcdenUVSQAW2JD87qN4x0HXFN1u+WO6M853XTOBCmchB6t71DDKX+Vn3vID83ct71th4ylq9zOVlZEMlv9rkWEfKrHfIw7L7/hUV/qf2jUHEZxBANq46YFGrTizimjjfM0gVSRzj2rn5XWGzbceWYs75/hHOM1q+yf9f1/Vw06k17em7S1jwFMjfKvYYNVNUkEnilkc/u0KKDngYXg/mTUWiss94blw3+r3FT2HYD3NZerTGO7IH+taQs5zyvPSqjDla+/+n3E5aHTaOTLOYixADE7m6gDnn64qv4husvuBLhivzZ6DGcfkabpswe4nTBIZCfpwc/zqG+SMCUyfOQ7YGf7igc/hihcyWxLd2YxMi2su4/Pgtx05/8ArUWQDqyk/NlQSex7H8siiVjvkBOWI+bHYUWanzEVQS75ix6Hqv8AKt4/DoL1NtYj/Z0kgBV0Kqynr6GmW8RkspEDBgiBiM+hwamnKraOinAKA5PfHII9+opnh8mYH5QXkVo8j3b+XNc9pNuO6/r+vUpOyTItRRpNOtAmCC2NpHUY6/hWx4W05FuRcXALKSCqnqjYwDVi3s82MCuAWTDZx0HQ1p2kQDpCFOA4kGP4sjinGdnb7gsnsN1rdHa2w6s5YqpPBA4P6VTtrEXSy3VuG2TxhEXPQen14p+q7pjc4fe8K+VEPbjd+Nbnh2NBDbIpLL5ynI9uv4Un7y7f1/wBPyOHWyba8ZhdlVzhRwee/wClFev3vhcbi0TKG3sDkY46/wBaK55uTY1NPW/4HCeWyySE8HGcinxtmRD2+tWHbErDqD3xVRHG/Cg46ZIrxU2lc9J9iYNztbgH9TSpy/PAHGcVVk4UnJyvH1pxcqQ+fvCqSvp1Em0ydVMcjRMeOoIHH1oCKCrJkgnp60nmP9m3rt3qcHtxT7bdJIsSJukdsIq9ye1WoXSS3ZJe0XTnv7mO2t033DtgHHQep+le3+HNKh0bTltoABjlm7s3rWR4N8PLo9j506g30wBlYdU/2R9K6Rn27Qo4HBNdUIci5E/UiUtCcHC9eTTEJPPUilRf4iTn+lSqgDD8q1aVrMzTGuNwAH/6qckYDLnoO1PHGCOv8qlTBBJxRy7FJmhYMGPNbEBGDz9M1z1q4VsAnJrWt51Iz0I9a9Kg/dTOetEtzHLfKP8A61QSQq/+s/H2qRZlz1pcgn61q43Mk7HGeKfh+NXzLp+otaXHXDpuU/lyK8z1vwV450pGeCzjvkQ532cgYn/gBwa+glkC/wAQ9Kk3gAY796weFpt3OmGNrQVr39T5LXxy2nXf2LxFa3Ol3gOMXMbIG/E10drr6Sx7obkOpBPDZFfQmr6Zp+s2j22qWVre2zDBjuIhIv61434v+BemOHu/Bc76Vdfe+yPIzW8nsO6H3GR7VlPDuPvR/r+vmbQxvMrTRgrrLO3Lnb71K9++0N5hP49a4KGG5srue0v4pobuByksLnlGH+evQ1tQ3G2Lc52xgZOfSpSVvIJzXQ2Z4/t0UiTv+62/Oc4wPrWO2taRp4aJLoyn7p2jIrmNavLrUZpEilkWA4AjBwDiqsGn7YxlfzHT3rinNzuqb08jCTu9Tso2TVo0a3DbH4UFeW9q0pNFuLWHMkQVO5TkD61D4EuUggtmKg+UxQjGcc9f16V7RZW9tqViF2qdw/n/AEruw9JSjdHFXruDR8x/ESxxpcUm0kpKvzegPFcdZRZOQMV7p8W/Dw07Qr/qYtu5DjoQw4rx/T7c4HH4Vm3vHqduHkpR5i3Z23K5Hbiti2tMnjt+tNs4eBkY6dRWxbx546j+tRGC0bsvyOtaohS0XYR3qdLYbQ3GcdauJF04+hqysI3D5eKu8WJ3RThgzzt/KpFg2gHbxj0q8IAvI4Y09k5yQT/Ws+fW62HYyrgFf97oB6e9VoYfJiaRjkk5+prTMfnTFsDAOMVW1EDesYB2qcnHrS5ley3HbqZMkLO4ULncQH9T7VoSosahFxwAWb09BS2cJ3rkHcW7dqsC1lncQQoXldgNqjOSe1Nyt7u5D094orCbyUHb+7zwMff9q67RPDErziNlAX5S/U7R2+lbOleHV0hFhl2PeXEYDcfLCOpwfXjBrs7W2iso1lIwCpJzwTxjgjvSc43aWxxVcQ38JzXiKygt7SWNEykcsaBh83JHPI5Fct8RdVElrp1oPkUqWUZzjsWz19a6nxO5FonmsdoZp5HPX17da8k8RX7XDXF3cKd4BAIP3EP3cf571hFOSf3kQS3ORmlefV42x8pfEZbsK2LdgFEoI3F8KvfAHX+dYGlxs7vcPjIyRk8LnpWq0YjEEf2hWYEcLkn867YysrmzWplaxcCOYruLZO5senYVh65cfuUtUPUAY9M8kVbvHV75pPmJUAkAccnge9UIY/Nv3nC+YsXCg9M9s100oWXN0+75Gc5dEXIplsoCijkbVYjru9vpWBcyGRHmbmQt83v71e1J2QwRSkEZ3ED+dZkJDFkLZV2xz2rSgklzb3InvZnS+H5TuLg7m8hyc+vAH86fcOAFXcHLtMhJHJJpnh20kjjmbK70TaM+uf8AAVHqihWhVMlEDsD6knnP41lOSc9yobFWzyXgZlDOVK4PGQD6/SrdzCkJSaPd5L4KMezDkA+4xTrBSLYxsu8RuXA7j/JrSvoBLYPEWAjmG5Wx9yQcqT9RkVMqjUn/AF/X9alcuhnvcLsSVR833wPYjmrvhSN0k3BRsScHd/sn/IrGtYZSBGyEbSQfzrrfD1vGS5OEjUBiCegWmpWb5f66g/hR0MVupl89+E2Bto9MkmlsV810c4AkkDL/ALI/yKszwr/Z25DscxOgBOCCDn+lV7WRjDIq4LbMg9ulEY3TuDbTMe7i86e4IPDTBsj0IIP61s6Kx2WysVC+WEyOoPr9aoyQtMxc43Iyh+3A6/rWhpEatcONudswUZ7Bhj+YpKNqd/8AhvUly949U0kx3GnoGuoo5BjljkHjn8aKs+H/AA7FdW6yJw0i78egorgdRXs2K0TxVsq4yTj0HaoJMGUNnG72xVc3ZiIDqSCOM84FWYSJEDoMbj371wKL2R6b8ySSIjHGdxyKfHby7XCYMZbODT4lOSNpAHQjmnXWoW1ikk12qxxoudrMRk10UMPLESUIrVmc5qC5m9B00SW0Aa5eOOJh95jx+dd78NPDkBRNVmQMMZtwxz/wIf0rx/w5HP458WWtoFIst/mTk5KrGOw+vSvqPToEjgSKFFjjUbVUDAUDoBXqVsFHCJJSu3939foc9Ou6t21ZIdLycckU5Ew/fB61MylQcDNRudnPQ9wTXJZdFc033JA4AFM3hSOTuB5+tVZpggJ65yOD1qrcXoCqc8+ue1S5ajRfkny3NV7m+ZY8qc4rDutQCsTuwPeqD6oMnkkHrR7zS8i0up08upHO5WKkAEYrRtNS5LO+QfeuB/tBeUycdQaaNceJtrMN3bHGfpXbSlrYJpOJ6pHqCHaCwx1q2t2pPLEZ/SvI18TsijuV96t2vjJJcgthhwM10KqtjmlQe6PVxcjj5hu9qkF1wQX6V5vD4kQryRz71ZTxChXAI45/Cq577mfs2jvlu1UsCRj3pVuUctuIwBnNcDN4gXZgMCT1rPk8S4JQSZOOcHofSh1LK9h+zuY3xR0ldS1+O/tQoZIvLm9WwcqffAJritQ0+dBgp+7AzXqNrC13Y/a3AHmN19R61Um01HLb1HP44rzJOSTg9uvzIlV10PKotPDMGKjoM/Wrs1kEiAI5713EuiwqW+Qrz2rP1DTlXlQOM5Nc0pa3SLUkzjtIulsbxkkBWKYhS4/hI6GvW/B+s/ZCIJ2GOduf1B9j+hryjUbBkl+ZD1x9PpXQ6TdvcW+GP72MYY4++PX612Uans7WMq1NVFqer+ONJXxX4J1C2twHmkiYxAdSw5A+vFfMmn2bxuY5Y2jkQ7XRhgoR1BHrXv3gnXWtZ1gkJ8snHJ6Gm/EnwSt+Tr+iR75ipNzFGvMmP4gP7w710ytUXOt+pjh6nsJezlszyG1twAMDGe1aMUJyuRipreIouMFW6cjGKurEPLIwfoK5nJ7I9ePchijXPbPTrVgR446Cp0hGMuB7cU/ZlN3PA6VmnfSxbIQBt2gc9dxqKY7Yy3oO9Wgm4cH5T7802WDewXPB61Em99jRWW5WhiMMSbwdxG4/zqhLA0jg4685Hatu4AfcwBA69Og7UkNo0kqxoMs/p2o5rvQybtuZtrblQDGN8jsFXHbNdr4Q0oWFxDcuvmOsjfPjqwHFReHNKMrLdMuVyUjHqehb/Cu1tLTyxBGNvy/MV6fN/k1n7Vp2irM4q9S+nQiht1N6ksgIfPJGR1/pVu6RVjOXHC7d3+eK1RaBsui4B7DgjH6Vm6zEkds8rKcs2wAHG73rSVNxhyHEp8zuee+LXeYrbRr8kzjfjghExnH1JFeT+L4wLWYRsQJJiQPb0/SvbNZ06TEM8cavKAyNETjep5OD2OQD714/4ykkhjtRLAUZeRuIYMcn8utZqTTa/r+v8zqpa7HJ2MHkwyRbD5jKGI7jH/66asgW8JzwqsCRyeRjgVI0ht3yQRIScg89fWqtsdkjN1IBOB1OK3pPujonFpD9F0tZtNnudTuBb2anIOcPk989h7Ut1JYpFJ/Z0Jjt/wCEEY3e9UdR1CS/vI4HcR28ROyBfuk/3jVO8lY2zNkCBRtQHglu9ds1dcq6/wBXMYq0tTGu2824L4PpyewqAW/7sOAeOSKtWMfnO27IbBOMdK0re1zKqL95/l2nqff3ro9pyNRItzO5r6SMaBvVSbooVRe7jHJHuB2otbJLi1jadwVZfmAPIyetFyoE0MEWf3ChlxwQfX2NXraQSXG9PmBXcynjI9R+uRXNztq9v66lONiCOxMTRnZl0yrgdHHqP51Qu41S4Ns7jaxKI2exGVz+orfuZ0jSNx8xT5sgfwnqD9OormrxvPnSILueN8f8BzkcVDleVkXbQ0rO1+yaTH9qT/SWcooJ5ArX0KABngPzhoH692I4qjfwtezQxRMwmjiIRcZ8zaMY/wB4dvUcda0pG2Wdw8Y2thNp9MMv+BrTW77f1+Jm+xvakw/syxljHSQ5A754NUFDJqYh4+48bDt0NaGqKg06OJRlwRyPoSPzwPyqqP32uK0i/eiDZHY85/PgVai3deY27ajLomFI2UD55V3Ke/AwT+Zq7oxWGe5Y5G2QKvPr/wDWrLF0EW1aTDMXIOejADBB/StIzJ9h86JWJ/1hzxjPGD9BTfwEpLmPXPD+oLBoiXAzJuby8LxjG7/61Fc1oUEt9pccFvIwCkvtA5HY/qf5UV42Io81RvlZcXCKs2eZW1lZXUQ8+68puwxzn29a6Pw14Pl1i6EWmOG2r88042Iv496zGvtB8ObbCazfUNUQLJMCgOzp8pJ+7xXp3gTxDpHijSNU/wCEU08Wk0IInW8nELNGV5DDldpIxkY6dq9vC5M1H2tTVL+t+1+xlWxujjT/AK+RDD8MrnTLF72UWmtWu0l1s3ZZI8d1BOG/T6VR1/QfB2r6UqXvhy3toSVeGePesx38bzk5KZPXnBr0zRb+xk0wXEyTpYBP9cGAAUL8w9doPQ1wnjvStOsvE2ma7f6vFp9rcxCOXTvK3TMOm6JQcANlSVIHTPWvVjCnQ9xKyf8AXzPPcqlZ6nN/CrwfL4Yu9W+0Mskhl8mF0PDRL0b8cg16/bAJEmeBiud0pDHFucgnAwcYP1I7fStnz/lAzgda8CvUlVqOR7FKPLBIsyMOc456GqFzMqqSQQe49Ke0ykBTx34rGv7nG4Z6dDWPLfUu4l1drwvUeprNuZ8k4PPYelZ13d5yOnPHtWdLfL1ZgCOCDTVO+jY721RLqE0m0sD8w96x5L5lIDtkeo7VPc3ykHBDe2OlYF425jsOFrenRvdWJdS25tJcxOgIlAPYVVvZHdApII9QaxN8idsg9vSp4FDsPkPX1roUFFEuRbsLTUb+8W20+KS7uG6Rxj5gPU+1dtZ/DW+dEn1W5WzlLDMUHztt75PTNdd8G9L0618Nf2nE4lurpmSRsf6vacbB/P3rq7nO/cwAfGR7D0qKz9n7sd/yOKeJm5WTsjyXXvA2r2JefRZP7RshyEBCzqPp0b8OfauRTWXilaG4LRzJw0UoKOv4HmvdxIVfy3XGTknPas7WtJsdWt2j1O0huGPALKCye4PUVx+2lFNblwryXxankkeqGbgMVP1rR0Owm1GdSd/2cN+8lx8qjP6110XgbRLZ1cW8nJztMpZa3oYBboYYdqxDBVVHCj2reVZLYt1nLYt+TF9kSOBQIkTaB7elUDBxsB5A4PerlgNruowAeRg5H0xTrmM5Py/MMnrXPJXV+5zXszGkhPzDpjBrKvYydwx19K3ZQGAbBAI6VmXaHjCkD+RrllF8xtF6HMXlqJMg9evrVYWZgiLRHDdj3roJbfkEAZBqpcxA4Xv3qJaLRm0XcoBp48PDj/aX1ruvB3ih4pEt7jOGxwTx+f8AWuOYCOQHA2k4b/GrCqYSWyD9KuliHTfOmTUgp6M67x94QSQS63pKcnMlzCoOW/2wPX1FcDGCCOm0jNen+EvEqMscNy+RgKc9fx96x/HPhyLS7hL6wGLO4fmPtG59PY88V3VFGova0np1Hha0oP2VT5HIGLknnJoCgnGcHpzVzYCR2pwi4AI56VzuS3R6JSEbH+Edegp6IeeOTwK0raxlup1jto2kPAO0cD6mut0Xw3HZ2Rv7xTLPuXYmeAc1fs205SVomFXERhotWcGulXc84hEbq7MEAPb3PtXRXVkLKwkjtwVdsp5gHJJ4rbeDN4ZVPyqOHz3JPP5irMdoLi6ssZ27wxz6dP6Vzq0tF1/zOedZytzdC3Y6MltHDC5VvITaNowBgc4P1/KtGxsk8tBkkY/i5P8A+ur4gwFUr1YsQfx//VVmGAKo28ECuynh1KblY4XJspTjajgcsB9OcYrG1hGuNRs7WPIEa+a/PSug1Aqqhycbec+mP8msuxjLgzSjEs24hvRCeB+VKpG0uQFormNfWq/uI15G1gM88/5zXzn48ulbUgihXFhI0Oeu5j1+oFfQPxL1Y+HtFae2Aa8lHk20Y5yx4zjvgc186a/YSW8gtiCZyvmvvPKjrz7nOTXFONqjfb+vyOzCrS76nLyBidxyy92zzVC6nKOegXB5HrWwiL0XOM5/xrIuots23+AHIrppJJHS1zOxRgX5CekjnGPQetVLuXz5VjXIiT5QD39zVy6bghAA7nj2FMtbR38rywTIzbeemf8APFdkFb35bGMlbRF7TLJmiVmXBfOMd1HUkelbkGmBLhZHwFSMlgex7EVBBGWbfAwXCgxAjpt7fzrZdGmsvJUfvZAc7eSFArKrK8roSSWhylzPIt+Z4SuVfHXh+x/DGasrcJc2stxZgLIjDcmc/L3OKo6lGkTMyDaijjjox6//AKqzInkgRWhb7rnIB7Ecj6GqjaUboq/K7tG7cTEBQDwR6/rVLRx9q1SEE55+fPfv/SljY3KI8fD/AHAD79qs+GIGiv5gf9aqEKD05oppaoc3pc2722JUYJVkwuM8ncw5+ta91+/06bPzTScyED73zfeHv0/GqWqoIraFlG7e6HB/D+dW7GTzbZCu3dvdeB05BrpnG2+y/r5GF9bmhq0uyxkkjK8COQ5H3SrD/H9aZcp9ldCvXzNuc/wEAgD8Sai1MBoNTtA+PMj3J7cDJ/QflT9TLSQWsmCu1huPYZXAP5/zrGnoro0lruQtbfJ5bbWQP5vvsbhsVYspN13fFMNbybSqd1IBHPtjvT7BRLZTSSHafLMfTsecj8ayvC0ry3c0UpKzLtjYjqPnOD/X3rJ3W47dUe0/DaxjXSDNOu/f8qjfg4FFdH4bih0+0SW6t42tpI1Aj5Kq+M5H15orOUqV/fdmckm27pHyjq1td67YDxJaWr/bLoiKbyH+R2XguwJ4JG3gccZFW9ea98EW+i6ro1w+nay6tBcxROJI5AVzuwfXoVOR3Fd546054LuG3jguY47a3+zFoIN1uuCRuBH3uwxjIri/HOkTjwbpmrXcYKQ3Rto5mBzNGy5784yvHoa+ykpSi+T3U38tdLej7efkcNOonNX1Me98beJ9b0iHS7/U2/s9AEWOJRHkdlJHUc9K6jwBd3ms61aDVLgzz2WI/nJLbR93JPUY4HpXnaahut5EWKJEwFHrx/X3rr/hROw1ieeXaWKBQfbPSuPFUo228/nr/X/DHXRclLU+kbMgxDd0PX8afLcYjP8AeXg57VQtpQ1uODgjkA9BVDUrh4kZ8Z7n3HrXz04NM9JMvyXgUk5/CsTWLwyL5kI3Mo+YDuP/AK1ZFxqXON+VPQisu41CRGyGGegatI0XLcmUrDbzUcqdpGKzpbwPt3HLd6qX0u5ywXGTk4HFU/NBJz164rSNO25DlqX3uCeQwz0PvUDNzzkVCjfMMMefSp1DM3bjjNaOy9CVqORCxBAye2Ki1PWR4fSO5wHkDAhMgFl74zVpZFj8pWaNWlcRx72A3Oei5Pqa4rxLdXt1q0ek3ukzxahAT5kLxN5ijuAO4x3FXRh7We+i/r8Cas+VW7n1v8OTYXXg6wvtHl32d3mcZULtY9QQO4IrYucOzMRwBgr6Vznwb0f+x/hppNmZxMXBnUoQQgc7goPtXSXStE52kEP8mTxzmuTFJObUdv6/I4Y+Zj3P3mZW+Q9M9sU2Bix65GOMVoXke8PhQT09qgtLYwsS20kdT6VwON5JXNObQZcAIIx/D3FQTja+6M4Y8Y7GprskSrjnuOKr3B3R8hVyM5WtXL3dCktrj7d8OAxHT8a1kjEsfPJwCOOtcw0wYj5h/XIrasbnhMEDFVS10fqTNdULd2OZCxAKtnJ96yruxIVgAa61NkqgYxkHOKbPZqyKHXP071UqCnqRGbW5wE1q+7G3GPUdary6fIXB2ckdq7L7EHmCqhyD6VZezi847VCsmF6Z+tYvCRSua+3exwV9pUgjyQcEdagtraVo/K2knHGOuK9Zj0uC4iAI5xjJ71mnRI7fUoiqDYTk80pYKSkl0ZSxF0zz2OyuLSQOyHA7EcGvSLSNde8NT2czAPIm0D+6w+6R+lat1pUNxbFdqhiPSs7w7bNZzyxKgCZzwO/rXRRoSo1HT3TInV50pbNHmFvbStO0ARjOG2bAMnIOMV2Oh+Cpp9supN5UZ58sH5j7E12tnplrbXM91HAguJm3SPjkmtAYxXTSw0aa97Vm1TFzqaLQz4rC3sbVktoljVV/hGM1k3rhLDdn5Io9+Om581tavJ5VjI2RwM/hXC+OdTWPR7aziYCa7I4zzgf4msMZUte2+3zZlSheSRdjmW6LSRoPLkYr6A4HH65rT0+Fd6cAEGPPP15+uTg025tFsdOslVMCJEDhe3Y1LbM0c8uUXbtOD/tKcn/GuVQ5anLLoym7rQ3E+fa3qBmplPGQOtcfeeO9E0u4kt9Qu/JnjJDxsh3Dnj8+Ks6V450DVJFS01GDex+4zbT+Rruo4im47kuElrY0NdJmWK2U7XmcDI6hB97/AD71L8u9FChdq8AdvQVAksN95k8LgM6BYznHyk8H8cVkeNPEUfhrTLm5l/e3EcJdEA5B5A3e2a560lTvUl1/r7/8xRTm+VHmHxX1+I+K50tx5txp0SwRgcjznO5zj2XAz9a4rW9MeytQtxmTULrE0zE5Kjsv4nt6CprJtur2mtaof3ZUy+Y3JmYt+8wO5ySPoK07lvtE15fztCgjQiNpBjcxOARn0XpXnttPXfW/+R6CSVktkeYyx+VJL3YZX2JrFvwkYfbyUHJrqdRQSzKIFP2cMQJH/wCWh9RWMpj27/syhGGx8kkj6/jW1KL5tTa9jn4YJJXjnxwBnPp6g1sWEaqZlADlvnRc4574/nUVqv2a7kg8oyROfX0rTt7dYs+aUYxsGj29/Sux1Lx3t/Xb+tjCzvqFnAY4xPOoyf8AVxr1DdKVLhhqSQ7igxtLqOvqRV++lWxUSyBTIylEx1z3JFc1Cz21m13MeST5WTyR3NTNcyt2/r/gFQXUr+IzsmEKf6sfMMc5NZti2Gk3bsJzuHXp6VfvA1w6NwSefxqs8RjutgOO2fU04TvFRBxuW7dDC+8bT5gJXHI9yP8APFauiApeyK/QrwT6VR09jHdRxqoeFu2OVJ9PTmtrT18q5jhDAtJuQEj9M1cbc6sKb0aZc1UmXzArP+7UMBj/AGRikscwrGVYbwwJ+uCPwPFNu3IjkdQo+TJ98cCjQwzCRpMMzYDZ+uf8a6JtSvYxSs0aXEuvXKMPklgXB9wdp/pUs4a402e0UESrG0ajPBZcY/XGKZaSJ5cN0ekikBu+0t0/PFGiyltXYzfMC+4OerN0x/KuSDSv8jaXclsZ0UxQxkbowFf3JGd351p+FNE+0+JpdsTLHIFc+nPIGf8Ae6VyVq3ka7cQXBwS7LxwSc5GPw7V6n4ILzySWcDoJ5SMMODg9dv19KiUuW8uvzFL4T2Tw+sdxEhXm2SPYrFcqX/i4+v5c0Vr6KsMFhFFENiBQRx6j/HP45or0KUfcVzzJaswPhXet4o8AaXqerwwSXc8f71lTAcqcbj7nHNfN37W2s3cfxCttJjKLp1rZxzRwAfLvctuYj1wAPwoor0MRJxxbinZcz/UpQiotpHkV1bReXayKu0yAlgOldJ4MBt9fRI2OCcH34zRRX0OYQipVEltb8jHDSbtd/1c980e4ke0wxBxxUl8T5JwSMen0oor4mr8SPW+yzg9Wcx3GU43YJHbpVWSRioyc0UVcW+ZhPZFKdiUPOMVULfOhwOeP0oorSs7Rfp/mZLcnSNTt/Kp41Gcc8LmiisJfD9/6my/yPMfEmo3WoyXrTyELbHMaJwo5Ar6w8LXs2u+FNKvNQKveiyjcXAUCQHZnrRRWeKS/s/5r8mc71qO5e+H0zJPqkEeFihMc8ajopk5cD/ZJ5x6k12d6d/2fP8AE5zj2oornw7bw8H6foYVl+8ZFcj94qds1A7EW+7jdgHNFFFfRaGUNzLvCTL1PfpUdzwEx/EOaKKUfhfqbdUZNxxOw9Oc96uafM3kKeCdxX8KKKqm3Z/11NJrRHUWLsrbVY4XkfiDWqDnggcDNFFd8NjgmtV8itbE/aVySc5zmrDRLw+Pm5ooqFrG7Ke6L9j0APPHemXKh7tAw/GiitnsvUS2LgOIzjtSQqAhYDk8miitUPsPH9acpJoopGq3MvxIcaRctgZC/wBa4PUYY28c6azKD5WmiRAeisGGD+poorysT/G+78pG0Nn8/wBD0J8Sw/OB0/pmqGPLt3ZchvMHP0wP5HFFFOv8bM4bHz749Pn+MdTaQAkylT74AArltoMnQDr09fX9KKK8qi7wTZ6C2Rv6H4n1fR3hFneP5ZIPlyHevpgA9ByelaHifUrrWLXRbe+kLJqd8TdEH5nCfdXPYDPSiiujdxv5fmgskrr+tGZXiMefNdQMStvp1yIreNeFVTwQfXNRaKD4g1nTrTUXZrbcE8tTgYyf8MUUVVDWKv5FSKupRJKbrKhVilZUVRgKF6Vzd7Cn9qzIFAV0yQPWiis6bfJE1ZQuR5VvDs4Ytgt39Ku6FGk1zLJIoLQLiMdhniiiu+CTvf8ArQz6GZrDNd+IooJmJjYIpA9KoanK0l9KjY8uH5UUDgAUUVLe4l0I7UBfMI6om4fWluol8yIkZJCsfruxRRTXxf13BsvWeI4JJFA3gbwx9d2K2Jv3epwhehlPb1XmiitYdPX/ADM5PVla5dwlom4lTFg5+hqbSJGW2aUcMCP/AEGiipk7U5teX6D+0jT0mNZNJgjYfKRIP0Y/0FZd7NIumae6sVZmV2I4yT1oorGfxfNfoaQ1saWs20f/AAkEEgyHmTLkHuBnP1yK7TwfI0eq2Tp8rAsnHcYoopJ3buRJHvFrLJJYqwkaNsg5TjqMkfSiiiqqNpnmvc//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For removing anterior foreign bodies, having the child blow the nose with the opposite nostril occluded is frequently successful.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17879=[""].join("\n");
var outline_f17_29_17879=null;
var title_f17_29_17880="M-mode echo periparum CM II";
var content_f17_29_17880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Recovered peripartum cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    M-mode echocardiogram obtained two weeks after delivery shows clinical recovery from the cardiomyopathy. Left ventricular dimensions are normal and left ventricular dysfunction has resolved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17880=[""].join("\n");
var outline_f17_29_17880=null;
var title_f17_29_17881="Pelvic shapes";
var content_f17_29_17881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50612%7EOBGYN%2F63123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50612%7EOBGYN%2F63123&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Four basic female pelvic types",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Diameters of the fetal head at term",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 382px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.177.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17881=[""].join("\n");
var outline_f17_29_17881=null;
var title_f17_29_17882="Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis";
var content_f17_29_17882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Milton H Nirken, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Whitney A High, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17882/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Moise L Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/29/17882/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/29/17882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe idiosyncratic reactions, most commonly triggered by medications, which are characterized by fever and mucocutaneous lesions leading to necrosis and sloughing of the epidermis. SJS and TEN are distinguished chiefly by severity and percentage of body surface involved. In this review, the term",
"    <span class=\"nowrap\">",
"     \"SJS/TEN\"",
"    </span>",
"    is used to refer collectively to SJS, TEN, and",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    overlap syndrome.",
"   </p>",
"   <p>",
"    The clinical manifestations, pathogenesis, evaluation, and diagnosis of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    will be presented in this topic review. The treatment, prognosis, and long-term complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Stevens-Johnson syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SJS is the less severe condition, in which skin sloughing is limited to less than 10 percent of the body surface [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1\">",
"     1",
"    </a>",
"    ]. It is characterized by a prodrome of malaise and fever, followed by the rapid onset of erythematous or purpuric macules and plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The skin lesions progress to epidermal necrosis and sloughing (",
"    <a class=\"graphic graphic_picture graphicRef67632 graphicRef76141 graphicRef73805 \" href=\"UTD.htm?28/10/28842\">",
"     picture 1A-C",
"    </a>",
"    ). Mucosal membranes are affected in 92 to 100 percent of patients, usually at two or more distinct sites (ocular, oral, and genital) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Toxic epidermal necrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic epidermal necrolysis (TEN), or Lyell's syndrome, involves sloughing of greater than 30 percent of the body surface area (",
"    <a class=\"graphic graphic_picture graphicRef68458 graphicRef82150 graphicRef59418 graphicRef66134 \" href=\"UTD.htm?33/20/34122\">",
"     picture 2A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1\">",
"     1",
"    </a>",
"    ]. TEN also begins with a prodrome of fever and malaise, although temperatures are typically higher than those seen with SJS, often exceeding 39 degrees Celsius. Mucous membranes are involved in nearly all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/4\">",
"     4",
"    </a>",
"    ]. The skin lesions are widely distributed erythematous macules and patches, although about 50 percent of cases begin with diffuse erythema [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. In the early stages, skin pain may be prominent and out of proportion to clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7\">",
"     7",
"    </a>",
"    ]. The skin lesions progress to full-thickness epidermal necrosis leads. The ultimate appearance of the skin has been likened to that of extensive thermal",
"    <span class=\"nowrap\">",
"     injury&nbsp;[",
"     <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/5\">",
"      5",
"     </a>",
"     ].",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     SJS/TEN overlap syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SJS/TEN",
"    overlap syndrome describes patients with involvement of greater than 10 percent, but less than 30 percent of body surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a lack of consensus regarding whether SJS and TEN represent different severities of the same condition or separate disorders, primarily because the pathogenesis of these disorders is not well-understood. Likewise, there are differing opinions about the degree to which SJS overlaps with severe erythema multiforme (EM), a condition with similar presentation. The most widely employed criteria, which are presented herein, propose a continuum between TEN and SJS, and distinguish SJS from severe EM (",
"    <a class=\"graphic graphic_table graphicRef77983 \" href=\"UTD.htm?14/1/14364\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,3,8\">",
"     1,3,8",
"    </a>",
"    ]. The nosologic controversies surrounding these disorders are discussed below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Nosologic controversies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various estimates of the incidence of SJS,",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    overlap, and TEN are reported in the literature, and the imprecise distinctions among these disorders has impeded more definite figures. SJS is the more common disorder, outnumbering TEN by as much as three cases to one [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/9\">",
"     9",
"    </a>",
"    ]. Estimates of incidence for all three disorders range from two to seven cases per million people per year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. Incidence may be highest in the spring months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SJS and TEN can occur in patients of any age. The mean age of patients with SJS has varied from 25 to 47 years, depending upon the series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/14,16,17\">",
"     14,16,17",
"    </a>",
"    ]. Patients affected by TEN tend to be slightly older, with a mean reported age between 46 and 63 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Women account for over 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are the leading trigger of SJS and TEN in both adults and children, although in children, infections are responsible for a relatively higher percentage of cases of SJS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     In adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;In adults, medications cause 30 to 50 percent of cases of SJS and up to 80 percent of cases of TEN [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,7,8,18,19\">",
"     1,7,8,18,19",
"    </a>",
"    ]. Infections are the next most common trigger of adult SJS (up to 15 percent). In contrast, it is unusual for infections to trigger TEN in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/4,20,21\">",
"     4,20,21",
"    </a>",
"    ]. Rare causes of SJS and TEN include vaccinations, systemic diseases, chemical exposure, herbal medicines, and foods [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/8,22-24\">",
"     8,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following groups of agents are most commonly implicated (",
"    <a class=\"graphic graphic_table graphicRef59655 \" href=\"UTD.htm?34/33/35356\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/14,25-27\">",
"     14,25-27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anti-gout agents (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antibiotics (sulfonamides &gt;&gt; penicillins &gt; cephalosporins)",
"     </li>",
"     <li>",
"      Antipsychotics and anti-epileptics (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      , dilantin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Analgesics and non-steroidal anti-inflammatory agents (especially",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"       piroxicam",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A case control study published in the 1990s quantified the relative risk of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    corresponding with common medications (",
"    <a class=\"graphic graphic_table graphicRef54152 \" href=\"UTD.htm?33/23/34171\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/28\">",
"     28",
"    </a>",
"    ]. A 2007 multinational study from Europe and Israel indicated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    was the most common cause of SJS and TEN in these areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/29\">",
"     29",
"    </a>",
"    ]. Newer drugs that have been associated with SJS and TEN include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many other types of agents have been implicated in smaller numbers of cases. These are discussed in other topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     In children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications are the leading cause of SJS and TEN in children, as in adults. However, infections, particularly Mycoplasma pneumonia and herpes viruses, are associated with a greater proportion of pediatric cases of SJS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The medications most often implicated in pediatric",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    are sulfonamide antimicrobials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , valproic acid, and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"      acetaminophen",
"     </a>",
"     /paracetamol",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/32\">",
"     32",
"    </a>",
"    ]. The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    has also been associated [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HISTORY AND CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug exposure commonly precedes the onset of symptoms by one to three weeks (average 14 days) in medication-related cases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34\">",
"     34",
"    </a>",
"    ]. Reexposure may result in onset of symptoms in as little as 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prodrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SJS and TEN typically have a prodrome of fever and influenza-like symptoms one to three days before the development of mucocutaneous lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/36\">",
"     36",
"    </a>",
"    ]. Fever is usually higher with TEN, and often exceeds 39 degrees Celsius [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34\">",
"     34",
"    </a>",
"    ]. Skin tenderness, photophobia, and conjunctival itching or burning may be early symptoms in both conditions.",
"   </p>",
"   <p>",
"    The following signs and symptoms, when present early in the course of a drug reaction or illness, should alert clinicians to the possibility of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Confluent erythema (erythroderma)",
"     </li>",
"     <li>",
"      Facial edema or central facial involvement",
"     </li>",
"     <li>",
"      Skin pain",
"     </li>",
"     <li>",
"      Palpable purpura",
"     </li>",
"     <li>",
"      Skin necrosis",
"     </li>",
"     <li>",
"      Blisters",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epidermal detachment",
"     </li>",
"     <li>",
"      Mucous membrane erosions and crusting",
"     </li>",
"     <li>",
"      Swelling of tongue",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin lesions typically begin as ill-defined erythematous macules with purpuric centers, although about 50 percent of cases of TEN begin with diffuse erythema (",
"    <a class=\"graphic graphic_picture graphicRef67632 graphicRef68458 graphicRef82150 graphicRef59418 graphicRef66134 graphicRef76141 graphicRef73805 \" href=\"UTD.htm?43/29/44506\">",
"     picture 1A-C, 2A-D",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,5,6\">",
"     1,5,6",
"    </a>",
"    ]. In SJS, the lesions are often quite targetoid, while in TEN, the targets may be more atypical and less well-demarcated. A burning sensation or other paresthesias may be noted. In the early stages, skin pain can be prominent and out of proportion to clinical findings, particularly in TEN [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7,34\">",
"     7,34",
"    </a>",
"    ]. Lesions are symmetrically distributed, and start upon the face and thorax before spreading to other areas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7\">",
"     7",
"    </a>",
"    ]. The scalp is typically spared, and palms and soles are less often involved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vesicles and bullae then form and the skin begins to slough within days. Nikolsky sign (ie, the ability to extend the area of superficial sloughing by gentle lateral pressure on the surface of the skin at an apparently uninvolved site) may be positive. Sloughing progresses rapidly for two to three days and then usually stabilizes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/39\">",
"     39",
"    </a>",
"    ]. Fulminant cases of TEN have been described, in which nearly 100 percent of the epidermis sloughed over a matter of hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucous membranes are involved in more than 90 percent of cases of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/3\">",
"     3",
"    </a>",
"    ]. Typically, at least two mucus membranes are affected, although this may not always include the oral mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/36,40\">",
"     36,40",
"    </a>",
"    ]. Painful crusts and erosions may occur upon any mucosal surface (",
"    <a class=\"graphic graphic_picture graphicRef68682 \" href=\"UTD.htm?41/55/42866\">",
"     picture 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34,36\">",
"     34,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ophthalmologic - Conjunctival lesions have been reported in 85 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34,41,42\">",
"       34,41,42",
"      </a>",
"      ]. Excessive tearing sometimes occurs from obstruction of the tear punctae [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/36\">",
"       36",
"      </a>",
"      ]. Ocular involvement may range from simple hyperemia and congestion of vessels to scarring with the development of synechiae between the eyelids and conjunctiva [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7,41\">",
"       7,41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Urogenital - Urethritis may result in dysuria or even urinary retention [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary - Pulmonary complications of TEN may include dyspnea, hypoxia, bronchial hypersecretion, tracheobronchitis, pulmonary edema, bacterial pneumonitis, and bronchiolitis obliterans [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematologic abnormalities, particularly anemia and lymphopenia, are common in TEN [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7\">",
"     7",
"    </a>",
"    ]. Eosinophilia is unusual, despite the strong association of TEN with drug ingestion. Neutropenia is noted in about one-third of patients, and is correlated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7,45\">",
"     7,45",
"    </a>",
"    ]. Glucocorticoids can cause demarginalization and mobilization of neutrophils into the circulation, and this must be considered in patients who received these agents prior to testing, as this may obscure neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=see_link&amp;anchor=H17#H17\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild elevations in serum aminotransferase levels (two to three times normal) are present in about one-half of patients with TEN, while overt hepatitis occurs in approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;The time course of",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    from prodrome to hospital discharge in the absence of significant complications, is typically two to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Reepithelialization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reepithelialization may begin after several days, and typically requires two to three weeks; corresponding to the usual duration of hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/46\">",
"     46",
"    </a>",
"    ]. Skin that remained attached during the acute process may peel gradually and nails may be shed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for SJS and TEN include HIV infection, genetic factors, concomitant viral infections, underlying immunologic diseases, and possibly physical factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HIV infection have been reported to be at three times increased risk for",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"    The reasons for this susceptibility are not fully understood, although exposure to multiple medications (including sulfonamide antibiotics), \"slow acetylation\" status, immune dysregulation, and the presence of concomitant infections may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 40-fold increased risk for",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    specifically has been reported in HIV-infected patients, as compared to the risk among the general population taking this same medication [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/50\">",
"     50",
"    </a>",
"    ]. Toxic hydroxylamine metabolites and depleted systemic glutathione reserves have been implicated in this toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors associated with an increased risk of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain HLA-types (",
"      <a class=\"graphic graphic_table graphicRef76186 \" href=\"UTD.htm?5/58/6059\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/52-60\">",
"       52-60",
"      </a>",
"      ]. Patients with HLA-B*1502 are at sufficiently increased risk for",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      due to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      and other aromatic anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) that the United States Food and Drug Administration has suggested screening patients of Asian and South Asian ancestry (in whom the prevalence of this allele is significant&mdash;approximately 7 to 10 percent) if use of carbamazepine is under consideration [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/57\">",
"       57",
"      </a>",
"      ]. Genome-wide studies have also found an association between the HLA-A*3101 allele and carbamazepine-induced SJS-TEN in Japanese persons and in persons of European descent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Screening of such patients before initiation of carbamazepine is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"       \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lower N-acetylation capacity (\"slow acetylators\"), which may be congenital or acquired (eg, with HIV infection): Patients with this condition may have prolonged exposure to immunogenic or toxic drug metabolites [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymorphisms in the IL4 receptor gene, which are biologically linked to Th2 cytokine-driven inflammatory mediators [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignancy may increase the risk of SJS and TEN, although data are conflicting as to whether malignancy truly increases the risk, or is simply associated with increased exposure to causative medications [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/7,62,63\">",
"       7,62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Higher doses and more rapid introduction of medications may increase the risk of SJS or TEN. As examples,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      doses below 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      were associated with a lower risk of",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      than higher doses [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/29\">",
"       29",
"      </a>",
"      ]. Similarly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      was associated with high rates of severe skin reactions when it was initially introduced [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/64\">",
"       64",
"      </a>",
"      ]. Recommendations were subsequently made for gradual titration when beginning therapy, and more recent studies suggest much lower rates of",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coincidental viral infections or other coingestants [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with systemic lupus erythematosus appear to experience higher rates of SJS and TEN [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Physical stimuli, such as ultraviolet light or radiation therapy, may be co-factors in some cases [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/62,68,69\">",
"       62,68,69",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic mechanisms that induce skin damage in",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    are incompletely understood. The shortened interval between a recurrent exposure and the onset of symptoms is consistent with an immunologic process [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Granulysin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A promising line of investigation has implicated granulysin, a cytolytic protein produced and secreted by cytotoxic T lymphocytes and natural killer (NK cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/70\">",
"     70",
"    </a>",
"    ]. Cells from five patients with SJS or TEN were analyzed with gene expression profiling. Granulysin was identified as the most highly expressed cytotoxic molecule. Both fluid and cells from",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    patient blisters demonstrated cytotoxicity when incubated with keratinocytes, and depletion of granulysin reduced the effect. Control",
"    <span class=\"nowrap\">",
"     fluid/cells",
"    </span>",
"    from patients with burns showed no such activity. The levels of granulysin in blister fluid correlated with the severity of disease. In addition, injection of granulysin from patient blisters into mouse skin caused dose-dependent blistering and necrosis.",
"   </p>",
"   <p>",
"    The mechanism through which cytotoxic T lymphocytes and natural killer cells are stimulated to release granulysin is unknown. The results of one study suggest that interaction between the",
"    <span class=\"nowrap\">",
"     CD94/NKG2C",
"    </span>",
"    receptor on these cells and HLA-E, an MHC class Ib molecule expressed by keratinocytes in patients with SJS or TEN, may promote degranulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for reactive drug metabolites has been supported by the finding that many patients with SJS and TEN demonstrate altered metabolic capabilities, such as slow N-acetylation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/47,48,72\">",
"     47,48,72",
"    </a>",
"    ]. This may result in prolonged exposure to toxic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunogenic metabolites in these individuals. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Genetic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Other hypothesized mechanisms for",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    have involved mixed drug-induced and immunologically-mediated phenomenon. Keratinocytes normally express the death receptor, CD95 (fas). When fas interacts with its ligand (fas ligand), the affected cell undergoes apoptosis, a highly-controlled process that eliminates unwanted cells without creating an inflammatory reaction. Mass triggering of apoptosis among keratinocytes may explain the pauci-inflammatory nature of the epidermal necrosis observed in",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"    Serum levels of soluble fas ligand were reported to be elevated in 5 of 7 patients with early drug reactions who subsequently developed",
"    <span class=\"nowrap\">",
"     SJS/TEN,",
"    </span>",
"    even before skin detachment or mucosal lesions appeared [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/73\">",
"     73",
"    </a>",
"    ]. In contrast, soluble fas ligand levels were normal in a group of 32 control patients with less severe drug reactions. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Histology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Perforin, TNF-a, and granzyme B, which are involved in distinct non-apoptotic cell death pathways, are also found in the high concentrations in the peripheral mononuclear cells and blister fluid of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/74\">",
"     74",
"    </a>",
"    ]. However, elevations in these mediators are not specific to",
"    <span class=\"nowrap\">",
"     SJS/TEN.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     NOSOLOGIC CONTROVERSIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The categorization, or nosology, of SJS, TEN, and severe EM, is an area of ongoing controversy that will only be resolved once the pathophysiology of these disorders has been revealed. An understanding of the controversy requires a brief historical review.",
"   </p>",
"   <p>",
"    Erythema multiforme, the least severe of the disorders, was described by von Hebra in 1866 as acral (peripheral), targetoid, edematous papules",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plaques without mucosal involvement (",
"    <a class=\"graphic graphic_picture graphicRef74095 \" href=\"UTD.htm?40/61/41951\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/75\">",
"     75",
"    </a>",
"    ]. It is associated with infections, particularly herpes simplex virus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stevens-Johnson syndrome was subsequently described as a pediatric affliction by Stevens and Johnson in 1922 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/2\">",
"     2",
"    </a>",
"    ]. These authors reported on two cases consisting of a \"generalized eruption with continued fever, inflamed buccal mucosa, and severe purulent conjunctivitis.\" The cases were distinguished from EM (von Hebra) by the \"character of the lesions&hellip;the prolonged high fever and the terminal heavy crusting.\"",
"   </p>",
"   <p>",
"    Two categories of EM were later suggested: erythema multiforme minor (von Hebra), and a severe form, erythema multiforme major (EM major), which encompassed SJS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/77\">",
"     77",
"    </a>",
"    ]. Subsequently, SJS came to be used synonymously with EM major, a view which is still held by many dermatologists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/6,78\">",
"     6,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, this categorization did not address cases with predominantly acral, targetoid eruptions, characteristic of EM minor (von Hebra), but with mucosal involvement more characteristic of EM major. To encompass this variant, it was proposed that EM major and SJS be considered distinct conditions with the term EM being restricted to acral, targetoid lesions, either with or without mucosal involvement, and the term SJS applied to mucous membrane involvement and widespread vesicles arising upon erythematous skin, without classic targetoid lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. Distinguishing the two conditions is also consistent with observations about etiology, as there is a strong association between herpes virus infections and EM, while SJS is more often associated with exogenous agents (eg, drugs) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/19\">",
"     19",
"    </a>",
"    ]. While differing slightly in definitional characteristics of the diseases, studies of the expression of IL-13 and other cytokines lends further support to the notion that SJS and TEN are diseases akin to one another, but distinct from classic erythema multiforme [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/79,80\">",
"     79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TEN was first described in 1948, with a small series appearing a decade later [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/5\">",
"     5",
"    </a>",
"    ]. TEN was distinguished by an acute, diffuse, erythematous rash followed by widespread full-thickness epidermal sloughing, and was initially believed to be distinct from SJS.",
"   </p>",
"   <p>",
"    It was later proposed that SJS and TEN were varying degrees of the same process, differing only in the extent of involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/37,81\">",
"     37,81",
"    </a>",
"    ]. However, this unifying concept has not been universally accepted. Some have cited subtle histologic differences between SJS and TEN [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, one report demonstrated that serum from TEN patients was directly cytotoxic to cultured keratinocytes, while serum from SJS patients was toxic only in the presence of lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/82\">",
"     82",
"    </a>",
"    ]. This observation supported the original hypothesis that the conditions were different, with a toxic metabolite triggering TEN and an immunologic cellular response mediating SJS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe EM (EM major) and SJS are viewed by many experts as separate entities, based on etiologic and clinical distinctions. In contrast, the concept that SJS and TEN exist along a continuum of a single disease process appears well-supported by the majority of evidence and is accepted by most, although not all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;SJS, TEN, and",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    overlap are clinical diagnoses supported by compatible histologic findings. There are no universally-accepted diagnostic criteria, and histology findings are neither specific nor diagnostic. Despite these limitations, the diagnosis of SJS or TEN would be appropriate in a patient with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A suggestive history of antecedent drug exposure or illness",
"     </li>",
"     <li>",
"      A prodrome of acute-onset febrile illness and malaise",
"     </li>",
"     <li>",
"      Erythematous macules, targetoid lesions, or diffuse erythema progressing to vesicles and bullae",
"     </li>",
"     <li>",
"      Necrosis and sloughing of the epidermis (of varying degrees)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy is useful in excluding or including many of the conditions in the differential diagnosis. An appropriate sample may be obtained using a large (&gt;4 mm) punch biopsy or by deep shave biopsy (\"saucerization\") technique.",
"   </p>",
"   <p>",
"    The earliest histologic finding in SJS is a perivascular mononuclear inflammatory infiltrate comprised primarily of T-lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. This infiltrate is not diagnostic, and it may be seen in a wide variety of conditions, including a simple drug-induced exanthem. A sparse infiltrate of lymphocytes develops at the dermoepidermal junction, with lymphocytes clustered around dying basal keratinocytes (\"satellitosis\") [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/9\">",
"     9",
"    </a>",
"    ]. As the lesions progress, frank subepidermal vesiculation develops, with full thickness epidermal necrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fully developed SJS is distinguished by full thickness epidermal detachment with splitting above the basement membrane, minimal inflammatory infiltrate, and normal immunofluorescence.",
"     </li>",
"     <li>",
"      The histopathology of TEN is similar. In addition, abnormalities of the underlying sweat ducts have been described in TEN, including lymphocytic infiltration, basal cell hyperplasia, and necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate cultures should be performed on blood, wounds, and mucosal lesions to evaluate for the presence of staphylococcal species, in particular. In children, serologies for Mycoplasma pneumoniae infection should also be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=see_link&amp;anchor=H15#H15\">",
"     \"Mycoplasma pneumoniae infection in children\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Investigational tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small pilot study has suggested that measurement of serum granulysin (a cytotoxic molecule present in the blister fluid of patients with SJS or TEN) might assist with early diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/86\">",
"     86",
"    </a>",
"    ]. Serum granulysin levels were found to be elevated in four out of five patients with SJS or TEN two to four days prior to the onset of skin erosions. However, the proportion of patients with elevated granulysin levels decreased rapidly with disease progression. Further studies are necessary to determine whether serum granulysin levels will be a useful early diagnostic test for SJS and TEN. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of",
"    <span class=\"nowrap\">",
"     SJS/TEN",
"    </span>",
"    includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythema multiforme (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Nosologic controversies'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Erythroderma and other erythematous drug eruptions",
"     </li>",
"     <li>",
"      Acute generalized exanthematous pustulosis (AGEP) and other pustular drug eruptions",
"     </li>",
"     <li>",
"      Phototoxic eruptions",
"     </li>",
"     <li>",
"      Toxic shock syndrome (TSS)",
"     </li>",
"     <li>",
"      Staphylococcal scalded skin syndrome (SSSS) (in children)",
"     </li>",
"     <li>",
"      Paraneoplastic pemphigus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythroderma and erythematous drug eruptions - Erythematous drug reactions are commonplace. The generalized and symmetric maculopapular erythema of a drug eruption can mimic early",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      However, erythematous drug eruptions lack mucosal involvement as well as the ill-defined but prominent skin pain of TEN. Treatment of erythematous drug reactions includes withdrawal of possible causative agents and supportive measures (eg, antihistamines for pruritus). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"       \"Drug eruptions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pustular drug eruptions - Pustular drug reactions, including acute generalized exanthematous pustulosis (AGEP), may also be severe and mimic early",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/87\">",
"       87",
"      </a>",
"      ]. AGEP is an eruption consisting of non-follicularly centered pustules that often begin on the neck and intertriginous areas. Most commonly, AGEP is caused by beta-lactam antibiotics, occurring within a few days of ingestion. The lesions are not associated with pain, and mucosal involvement is rare. The pustules of AGEP may coalesce and slough, but this occurs during resolution of the disorder, and is not present during the evolving phase of the disease. Treatment of pustular drug reactions includes withdrawal and supportive measures.",
"     </li>",
"     <li>",
"      Phototoxic eruptions - Phototoxic eruptions are caused by direct interaction of a chemical with sunlight to yield a byproduct toxic to the skin. The most common phototoxic reactions to be confused with",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      are those that are due to oral ingestants. As an example, fluoroquinolones may yield a phototoxic reaction, which can lead to widespread epidermal sloughing. Important clues to the presence of a phototoxic eruption include recent sun exposure, known phototoxic qualities of certain medications, and locations of the lesions on sun-exposed areas. When sloughing is marked, the patient with a severe phototoxic reaction is managed in a burn unit, much like a patient with",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=see_link\">",
"       \"Drug eruptions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Toxic shock syndrome - Toxic shock syndrome (TSS) is classically caused by Staphylococcus aureus, although a similar disorder can be caused by toxin-elaborating strains of Group A streptococci. Compared to",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      TSS presents with more prominent involvement of multiple organ systems.",
"      <br/>",
"      <br/>",
"      TSS is caused by elaboration of specific bacterial toxin(s) from staphylococci or streptococci that act as superantigens, non-specifically activating large numbers of T lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/88\">",
"       88",
"      </a>",
"      ]. These disorders are described briefly here and presented in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"       \"Staphylococcal toxic shock syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      TSS develops acutely in healthy individuals, particularly young women, typically (but not always) within days of menstruation or a surgical procedure.",
"      <br/>",
"      <br/>",
"      Cutaneous manifestations may include a diffuse, red, macular rash resembling sunburn that may involve the palms and soles (",
"      <a class=\"graphic graphic_picture graphicRef82561 graphicRef61786 graphicRef77600 graphicRef54896 \" href=\"UTD.htm?40/7/41081\">",
"       picture 5A-D",
"      </a>",
"      ). This eruption may be subtle or fleeting. Petechiae, vesicles, and bullae may develop in severe cases. Desquamation occurs one to two weeks after the onset of illness and chiefly affects the palms and soles. Mucosal involvement in TSS includes hyperemia of the vaginal and oropharyngeal mucosa and conjunctival-scleral suffusion and hemorrhage (",
"      <a class=\"graphic graphic_picture graphicRef66457 \" href=\"UTD.htm?36/46/37615\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/89\">",
"       89",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Systemic signs and symptoms include fever, nonpitting edema of the face and hands, diarrhea and vomiting, myalgias, hypotension, mental status changes, and multi-organ failure. Early laboratory findings include elevations of creatinine phosphokinase, elevated transaminases, and elevated creatinine. The diagnosis of TSS is based upon clinical presentation, utilizing the CDC case definition (",
"      <a class=\"graphic graphic_table graphicRef54778 \" href=\"UTD.htm?35/1/35868\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staphylococcal scalded skin syndrome - Staphylococcal scalded skin syndrome (SSSS), also known as Ritter disease, is caused by epidermolytic toxins produced by certain strains of Staphylococci [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/90\">",
"       90",
"      </a>",
"      ]. This toxin is distributed systemically and results in dissolution of keratinocyte attachments in only the upper layer of the epidermis (stratum granulosum). SSSS usually affects newborns and children [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/91\">",
"       91",
"      </a>",
"      ]. Adults are less commonly affected because improved renal function allows for clearance of the toxins from the body, although adults with renal failure are more susceptible [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/92\">",
"       92",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=see_link\">",
"       \"Vesiculobullous and pustular lesions in the newborn\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      SSSS presents with fever, irritability, and a generalized, erythematous, micromacular to maculopapular rash (",
"      <a class=\"graphic graphic_picture graphicRef72261 graphicRef50249 \" href=\"UTD.htm?43/22/44390\">",
"       picture 7A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/90-92\">",
"       90-92",
"      </a>",
"      ]. The exfoliative phase is heralded by perioral exudation and crusting with large radial fissures, likened to an \"unhappy clown,\" appearing around the mouth. However, mucosal membranes are not involved. There is usually no history of drug exposure.",
"      <br/>",
"      <br/>",
"      SSSS is distinguished clinically from",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      chiefly by its epidemiology and sparing of mucous membranes. The diagnosis is supported by histologic examination, which reveals sloughing of only the upper layers of the epidermis. Frozen section examination of sloughing epidermis can often distinguish SSSS from TEN as histology in TEN will reveal a subepidermal split with full thickness epidermal necrosis, while only partial thickness epidermal sloughing and minimal keratinocyte necrosis will be noted in SSSS [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/93,94\">",
"       93,94",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Treatment of SSSS involves eradication using intravenous antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?17/29/17882/abstract/90\">",
"       90",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paraneoplastic pemphigus &mdash; Paraneoplastic pemphigus (PNP) is a rare disorder that can represent the initial presentation of a malignancy or occur in a patient with a known neoplastic process, such as non-Hodgkin lymphoma in adults or Castleman's disease in children. Patients may develop severe mucocutaneous disease with ocular and oral blisters and skin lesions that resemble erythema multiforme, bullous pemphigoid, or lichen planus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"       \"Paraneoplastic pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SJS, TEN, and",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      overlap syndrome represent disorders of uncertain etiology that are characterized by desquamative lesions of the skin and mucous membranes. Cases with less than 10 percent epidermal involvement are classified as SJS; those with 30 percent or more involvement are classified as TEN; cases with between 10 and 30 percent involvement are considered overlap",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TEN is almost invariably drug-induced, while SJS is associated with infections, as well as drug administration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiologies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SJS and TEN begin with a prodrome of fever and influenza-like symptoms one to three days before the development of mucocutaneous and skin lesions. Characteristic vesicular and bullous skin lesions then appear and progress over several days, followed by sloughing. There may be multiorgan involvement. In the absence of complications, the disorder generally resolves sufficiently that the patient can be discharged from the hospital in two to four weeks. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'History and clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for SJS and TEN include HIV infection, genetic factors, concomitant viral infections, underlying immunologic diseases, and possibly physical factors. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SJS or TEN is clinical. Histologic findings on skin biopsy are supportive, but not independently diagnostic. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis includes erythema multiforme, other types of severe medication reactions, severe reactions to bacterial toxins (eg, toxic shock syndrome, staphylococcal scalded skin syndrome), and Kawasaki disease. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/1\">",
"      Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/2\">",
"      Stevens, AM, Johnson, FC. A new eruptive fever associated with stomatitis and ophthalmia: a report of two cases in children. Am J Dis Child 1922; 24:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/3\">",
"      Letko E, Papaliodis DN, Papaliodis GN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature. Ann Allergy Asthma Immunol 2005; 94:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/4\">",
"      Rasmussen JE. Toxic epidermal necrolysis. A review of 75 cases in children. Arch Dermatol 1975; 111:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/5\">",
"      LYELL A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68:355.",
"     </a>",
"    </li>",
"    <li>",
"     Fritsch, PO, Ruiz-Maldonado, R. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. In: Fitzpatrick's dermatology in general medicine (6e), Freedberg, IM, et al (Eds), McGraw-Hill Inc., New York 2003. p.544.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/7\">",
"      Roujeau JC, Chosidow O, Saiag P, Guillaume JC. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/8\">",
"      Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/9\">",
"      Rzany B, Hering O, Mockenhaupt M, et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/10\">",
"      Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996; 49:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/11\">",
"      Strom BL, Carson JL, Halpern AC, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991; 10:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/12\">",
"      Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/13\">",
"      Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990; 126:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/14\">",
"      Sch&ouml;pf E, St&uuml;hmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol 1991; 127:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/15\">",
"      Wanat KA, Anadkat MJ, Klekotka PA. Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. J Am Acad Dermatol 2009; 60:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/16\">",
"      Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology 1995; 102:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/17\">",
"      Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994; 73:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/18\">",
"      Roujeau JC. What is going on in erythema multiforme? Dermatology 1994; 188:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/19\">",
"      Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/20\">",
"      Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 1979; 100:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/21\">",
"      de Groot R, Oranje AP, Vuzevski VD, Mettau JW. Toxic epidermal necrolysis probably due to Klebsiella pneumoniae sepsis. Dermatologica 1984; 169:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/22\">",
"      Chowdhury AD, Oda M, Markus AF, et al. Herbal medicine induced Stevens-Johnson syndrome: a case report. Int J Paediatr Dent 2004; 14:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/23\">",
"      Nethercott JR, Choi BC. Erythema multiforme (Stevens-Johnson syndrome)--chart review of 123 hospitalized patients. Dermatologica 1985; 171:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/24\">",
"      Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/25\">",
"      Mockenhaupt M, Kelly JP, Kaufman D, et al. The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with nonsteroidal antiinflammatory drugs: a multinational perspective. J Rheumatol 2003; 30:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/26\">",
"      Devi K, George S, Criton S, et al. Carbamazepine--the commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: a study of 7 years. Indian J Dermatol Venereol Leprol 2005; 71:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/27\">",
"      Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/28\">",
"      Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/29\">",
"      Halevy S, Ghislain PD, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/30\">",
"      L&eacute;aut&eacute;-Labr&egrave;ze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson syndrome. Arch Dis Child 2000; 83:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/31\">",
"      Wetter DA, Camilleri MJ. Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. Mayo Clin Proc 2010; 85:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/32\">",
"      Levi N, Bastuji-Garin S, Mockenhaupt M, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics 2009; 123:e297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/33\">",
"      Dore J, Salisbury RE. Morbidity and mortality of mucocutaneous diseases in the pediatric population at a tertiary care center. J Burn Care Res 2007; 28:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/34\">",
"      Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/35\">",
"      Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006; 55:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/36\">",
"      Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/37\">",
"      Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985; 13:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/38\">",
"      Revuz J, Roujeau JC, Guillaume JC, et al. Treatment of toxic epidermal necrolysis. Cr&eacute;teil's experience. Arch Dermatol 1987; 123:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/39\">",
"      Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal necrolysis. A step forward in treatment. JAMA 1987; 257:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/40\">",
"      Roupe G, Ahlm&eacute;n M, Fagerberg B, Suurk&uuml;la M. Toxic epidermal necrolysis with extensive mucosal erosions of the gastrointestinal and respiratory tracts. Int Arch Allergy Appl Immunol 1986; 80:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/41\">",
"      Sheridan RL, Schulz JT, Ryan CM, et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002; 109:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/42\">",
"      Morales ME, Purdue GF, Verity SM, et al. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. Am J Ophthalmol 2010; 150:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/43\">",
"      Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/44\">",
"      Kim MJ, Lee KY. Bronchiolitis obliterans in children with Stevens-Johnson syndrome: follow-up with high resolution CT. Pediatr Radiol 1996; 26:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/45\">",
"      Westly ED, Wechsler HL. Toxic epidermal necrolysis. Granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/46\">",
"      Jordan MH, Lewis MS, Jeng JG, Rees JM. Treatment of toxic epidermal necrolysis by burn units: another market or another threat? J Burn Care Rehabil 1991; 12:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/47\">",
"      Dietrich A, Kawakubo Y, Rzany B, et al. Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/48\">",
"      Wolkenstein P, Carri&egrave;re V, Charue D, et al. A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/49\">",
"      Slatore CG, Tilles SA. Sulfonamide hypersensitivity. Immunol Allergy Clin North Am 2004; 24:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/50\">",
"      Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereol 2003; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/51\">",
"      Gruchalla RS. 10. Drug allergy. J Allergy Clin Immunol 2003; 111:S548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/52\">",
"      Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol 1987; 123:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/53\">",
"      Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/54\">",
"      Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/55\">",
"      Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/56\">",
"      Shirato S, Kagaya F, Suzuki Y, Joukou S. Stevens-Johnson syndrome induced by methazolamide treatment. Arch Ophthalmol 1997; 115:550.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#carbamazepine (Accessed on December 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/58\">",
"      Chen P, Lin JJ, Lu CS, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/59\">",
"      McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/60\">",
"      Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/61\">",
"      Ueta M, Sotozono C, Inatomi T, et al. Association of IL4R polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/62\">",
"      Sommers KR, Kong KM, Bui DT, et al. Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine. Anticancer Drugs 2003; 14:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/63\">",
"      Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome in oncologic patients. Eur Rev Med Pharmacol Sci 2007; 11:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/64\">",
"      Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998; 39 Suppl 7:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/65\">",
"      Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/66\">",
"      Chosidow O, Bourgault L, Roujeau JC. Drug rashes. What are the targets of cell-mediated cytotoxicity? Arch Dermatol 1994; 130:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/67\">",
"      Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev 2006; 5:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/68\">",
"      Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/69\">",
"      Duncan KO, Tigelaar RE, Bolognia JL. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. J Am Acad Dermatol 1999; 40:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/70\">",
"      Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 2008; 14:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/71\">",
"      Morel E, Escamochero S, Caba&ntilde;as R, et al. CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Allergy Clin Immunol 2010; 125:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/72\">",
"      Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/73\">",
"      Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/74\">",
"      Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 2002; 109:155.",
"     </a>",
"    </li>",
"    <li>",
"     von Hebra, F. Atlas der Hautkrankheiten. Vienna: Kaiserliche Akademie der Wissenchaften Wien, 1866.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/76\">",
"      Forman R, Koren G, Shear NH. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf 2002; 25:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/77\">",
"      THOMAS BA. The so-called Stevens-Johnson syndrome. Br Med J 1950; 1:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/78\">",
"      Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/79\">",
"      Caproni M, Torchia D, Schincaglia E, et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/80\">",
"      Quaglino P, Caproni M, Osella-Abate S, et al. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/ toxic epidermal necrolysis but not in those with erythema multiforme. Br J Dermatol 2008; 158:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/81\">",
"      Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122:837.",
"     </a>",
"    </li>",
"    <li>",
"     Bennion, S, Fitzpatrick, JE. Serum from patients with toxic epidermal necrosis is directly toxic to cultured keratinocytes. (Poster). American Academy of Dermatology 45th Annual Meeting, New Orleans, Louisiana December 6-11th, 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/83\">",
"      Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988; 95:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/84\">",
"      Villada G, Roujeau JC, Cl&eacute;rici T, et al. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992; 128:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/85\">",
"      Akosa AB, Elhag AM. Toxic epidermal necrolysis. A study of the sweat glands. J Cutan Pathol 1995; 22:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/86\">",
"      Abe R, Yoshioka N, Murata J, et al. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 2009; 151:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/87\">",
"      Pomahac B, Lim J, Liu A. A case report of generalized pustulosis with systemic manifestations requiring burn intensive care unit admission. J Burn Care Res 2008; 29:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/88\">",
"      Chuang YY, Huang YC, Lin TY. Toxic shock syndrome in children: epidemiology, pathogenesis, and management. Paediatr Drugs 2005; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/89\">",
"      Chesney PJ, Davis JP, Purdy WK, et al. Clinical manifestations of toxic shock syndrome. JAMA 1981; 246:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/90\">",
"      Patel GK, Finlay AY. Staphylococcal scalded skin syndrome: diagnosis and management. Am J Clin Dermatol 2003; 4:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/91\">",
"      Dobson CM, King CM. Adult staphylococcal scalded skin syndrome: histological pitfalls and new diagnostic perspectives. Br J Dermatol 2003; 148:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/92\">",
"      Cribier B, Piemont Y, Grosshans E. Staphylococcal scalded skin syndrome in adults. A clinical review illustrated with a new case. J Am Acad Dermatol 1994; 30:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/93\">",
"      Honig PJ, Gaisin A, Buck BE. Frozen section differentiation of drug-induced and staphylococcal-induced toxic epidermal necrolysis. J Pediatr 1978; 92:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/29/17882/abstract/94\">",
"      Amon RB, Dimond RL. Toxic epidermal necrolysis. Rapid differentiation between staphylococcal- and drug-induced disease. Arch Dermatol 1975; 111:1433.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2091 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17882=[""].join("\n");
var outline_f17_29_17882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Toxic epidermal necrolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SJS/TEN overlap syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      In adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      In children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HISTORY AND CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prodrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Skin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Reepithelialization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Granulysin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      NOSOLOGIC CONTROVERSIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Investigational tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/2091\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2091|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/48/25345\" title=\"picture 1A\">",
"      Cutaneous changes of Stevens Johnson Syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/25/27030\" title=\"picture 1B\">",
"      Cutaneous findings of Stevens Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/7/30836\" title=\"picture 1C\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/1/39953\" title=\"picture 2A\">",
"      Toxic epidermal necrolysis - back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/18/35106\" title=\"picture 2B\">",
"      Toxic epidermal necrolysis - bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/27/13747\" title=\"picture 2C\">",
"      Toxic epidermal necrolysis - abdomen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/63/18419\" title=\"picture 2D\">",
"      Toxic epidermal necrolysis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/55/42866\" title=\"picture 3\">",
"      Stevens-Johnson syndrome - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/61/41951\" title=\"picture 4\">",
"      Erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/4/29761\" title=\"picture 5A\">",
"      Macular erythema in toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/45/23249\" title=\"picture 5B\">",
"      Toxic shock syndrome - macular erythema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/23/31103\" title=\"picture 5C\">",
"      Rash in Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/45/2768\" title=\"picture 5D\">",
"      Toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37615\" title=\"picture 6\">",
"      Conjunctival suffusion in Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/52/13121\" title=\"picture 7A\">",
"      Staphylococcal scalded skin syndrome - trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44273\" title=\"picture 7B\">",
"      Staphylococcal scalded skin syndrome - face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/2091|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/1/14364\" title=\"table 1\">",
"      Classification EM SJS TEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/33/35356\" title=\"table 2\">",
"      Drugs assoc w SJS TEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/23/34171\" title=\"table 3\">",
"      SJSTEN risk specific meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/58/6059\" title=\"table 4\">",
"      SJSTEN risk HLA type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/1/35868\" title=\"table 5\">",
"      Clinical criteria for Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6713?source=related_link\">",
"      Mycoplasma pneumoniae infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/31/15864?source=related_link\">",
"      Vesiculobullous and pustular lesions in the newborn",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_29_17883="Morbidity rate after failed forceps vacuum";
var content_f17_29_17883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69438&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rate of neonatal morbidity after cesarean delivery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Morbidity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Labor with attempts at operative birth*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Labor with no attempts at operative birth*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subdural or cerebral hemorrhage",
"       </td>",
"       <td>",
"        25.7",
"       </td>",
"       <td>",
"        6.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Facial nerve injury",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Convulsions",
"       </td>",
"       <td>",
"        68.8",
"       </td>",
"       <td>",
"        19.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CNS depression",
"       </td>",
"       <td>",
"        17.1",
"       </td>",
"       <td>",
"        9.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mechanical ventilation",
"       </td>",
"       <td>",
"        156.1",
"       </td>",
"       <td>",
"        101.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Number of cases per 10,000 infants.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: data in Towner D, Castro MA, Eby-Wilkens E, et al. N Engl J Med 1999; 341:1709.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17883=[""].join("\n");
var outline_f17_29_17883=null;
var title_f17_29_17884="Adverse reactions to patch testing";
var content_f17_29_17884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F72682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F72682&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adverse reaction to patch testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Active sensitization",
"       </td>",
"       <td>",
"        A negative reaction is followed by a late positive reaction after 10 to 20 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Angry back\" or \"excites skin syndrome\"",
"       </td>",
"       <td>",
"        A few strong positive reactions cause a chain of multiple reactions to other patch tests that would otherwise be negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flare of dermatitis",
"       </td>",
"       <td>",
"        Usually not a serious event and helps to validate the positive reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adhesive tape reaction",
"       </td>",
"       <td>",
"        Rare with the current acrylate based adhesive tapes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Koebner phenomenon",
"       </td>",
"       <td>",
"        Can be seen in patients with active psoriasis and lichen planus",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Persistence positive reaction",
"       </td>",
"       <td>",
"        Encountered more often with gold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pigmentary alteration",
"       </td>",
"       <td>",
"        This includes post inflammatory hyper- and hypo-pigmentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pressure effect",
"       </td>",
"       <td>",
"        Imprint caused by pressure from the chamber or when testing a solid material",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bacterial and viral infections",
"       </td>",
"       <td>",
"        Higher risk (bacterial) when testing to plant substances",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrosis/scar/keloid",
"       </td>",
"       <td>",
"        Risk of testing to unknown caustic substances that burn a hole in the skin",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidal reaction",
"       </td>",
"       <td>",
"        Has been described with metals including palladium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Milia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anaphylactoid",
"       </td>",
"       <td>",
"        Extremely rare but potential risk with bacitracin, neomycin, and contact urticaria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Weiss G, Shemer A, Trau H. The Koebner phenomenon; review of the literature. JEADV 2002; 16:241.",
"       </li>",
"       <li>",
"        Thijs L, Deraedt K, Goosens A. Granuloma possibly induced by palladium after ear piercing. Dermatitis 2008; 19:E26.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17884=[""].join("\n");
var outline_f17_29_17884=null;
var title_f17_29_17885="Treatment urge incontinence in women";
var content_f17_29_17885=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76810&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of behavioral and pharmacologic treatments for urge and mixed urinary incontinence in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Target population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Efficacy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Behavioral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pelvic floor muscle exercises",
"       </td>",
"       <td>",
"        Women",
"       </td>",
"       <td>",
"        Up to 80 percent decrease in episodes; motivated patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bladder retraining",
"       </td>",
"       <td>",
"        Cognitively intact",
"       </td>",
"       <td>",
"        &ge;35 percent decrease in UI episodes; pt perception of cure at 6 mos RR 1.69 [1.21-2.34]",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prompted voiding",
"       </td>",
"       <td>",
"        Dependent, cognitively impaired",
"       </td>",
"       <td>",
"        Average reduction 0.8-1.8 in UI episodes daytime; cure rare, caregiver dependent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Habit training",
"       </td>",
"       <td>",
"        Voiding record available",
"       </td>",
"       <td>",
"        Highly dependent on caregiver compliance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scheduled (timed) voiding",
"       </td>",
"       <td>",
"        Unable to toilet independently",
"       </td>",
"       <td>",
"        30 to 80 percent decrease in daytime episodes but study quality fair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Pharmacologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All antimuscarinics",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        WMD in daily UI episodes 0.6 (95 percent CI 0.4-0.8); dry mouth RR 2.56 (95 percent CI 2.24-2.92)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxybutynin",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        ER: 71 percent mean reduction weekly UI episodes, cure rate 23 percent, dry mouth 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tolterodine",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        ER: 69 percent mean reduction weekly UI episodes, cure rate 17 percent, dry mouth 22 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trospium",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        20 mg bid: 59 percent mean reduction daily urge UI episodes (versus 44 percent with placebo), cure rate 21 percent, dry mouth 22 percent, constipation 10 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Darifenacin",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        7.5 mg or 15 mg daily: 68 percent and 73 percent, respectively, median reduction in weekly UI episodes (versus 56 percent with placebo). Dry mouth 19 percent and 31 percent respectively, constipation 14 percent (both doses)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solifenacin",
"       </td>",
"       <td>",
"        Unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        5 mg or 10 mg daily: 61 percent and 52 percent, respectively, mean reduction daily UI episodes (versus 28 percent with placebo), dry mouth 8 percent and 23 percent, constipation 4 percent and 9 percent, respectively",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrogens",
"       </td>",
"       <td>",
"        Postmenopausal women unresponsive to behavioral treatment alone",
"       </td>",
"       <td>",
"        Topical of some benefit",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     WMD: weighed mean difference; ER: extended release, NA: not available; RR: relative risk.",
"    </div>",
"    <div class=\"reference\">",
"     Second International Consulation on Incontinence. Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publication Ltd, Plymouth, UK 2002; Fonda D, DuBeau C, Harari D, et al. Incontinence in the Frail Elderly. In: Third International Consulation on Incontinence. Abrams P, Cardozo L, Khoury S, Wein A (Eds), Health Publication Ltd,&nbsp;Plymouth, UK 2005; Cochrane Library (Accessed December 2004); Diokno A, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial. Mayo Clin Proc 2003; 78:687; Zinner N, Gittelman, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004; 171:2311; Cardoza L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172:1919; Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004; 45:420; Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynecol Scan 2004; 83:892.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17885=[""].join("\n");
var outline_f17_29_17885=null;
var title_f17_29_17886="CO2 dissociation curves";
var content_f17_29_17886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CO2 dissociation curves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 485px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The top figure (A) shows the CO2 dissociation curves for blood of different O2 saturations. Note that oxygenated blood carries less CO2 for the same PCO2. The bottom figure (B) shows the \"physiological\" curve between arterial (a) and mixed venous (v) blood.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from West, JB (Ed), Respiratory Physiology, 5th ed, Williams &amp;Wilkins, Baltimore, MD 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17886=[""].join("\n");
var outline_f17_29_17886=null;
var title_f17_29_17887="Gram stain abscess 11";
var content_f17_29_17887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain abscess 11",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 365px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_29_17887=[""].join("\n");
var outline_f17_29_17887=null;
